



The ThinkEquity Conference

Mandarin Oriental • New York



2023





Security, Speed and Accuracy for Capital Markets Transactions

Industry leading solutions delivered with peace of mind.

- IPO / SPAC / de-SPAC Transactions
- Equity & Debt Offerings
- Mergers & Acquisitions
- Annual Meeting & Proxy Statements
- SEC EDGAR and iXBRL Filings

For more information on Toppan Merrill services and solutions contact Michael Frohlich at **201.410.6500** or **MichaelFrohlich@ToppanMerrill.com**.

Advancing business. Expanding possible.



TOPPAN
TOPPAN MERRILL

We're all connected.

At Loeb & Loeb, we connect deep industry insight with cutting-edge transactional experience to represent domestic and foreign companies, both public and private, in a range of legal and business matters.

As pioneers in counseling on regulations related to the use of new technologies and developing media channels, we have a unique depth of experience advising companies in



the digital and information services sectors as they access the capital markets. We also have decades of experience representing innovators in the life sciences industries and energy companies, along with their financial intermediaries, in the full spectrum of capital raising and corporate finance transactions.

Connect with us and experience the difference.

LOEB & LOEB LLP

LOS ANGELES
NEW YORK
CHICAGO
NASHVILLE

WASHINGTON, DC
SAN FRANCISCO
BEIJING
HONG KONG

loeb.com

GRASSI

ADVISORS & ACCOUNTANTS

**Our Experience and Passion
Drive Audit Quality and Results.**

Grassi's SEC & Capital Markets team delivers hands-on, cost-effective solutions to help your business achieve its IPO and meet all SEC and PCAOB requirements.

STRENGTH IN CERTAINTY

Lou Pizzileo, CPA
Partner, SEC & Capital Markets Services Leader
lpizzileo@grassicpas.com | 516.209.7314

grassicpas.com/ipo

Blank Rome is proud to sponsor the **2023 ThinkEquity Conference**

Increased competition and the regulatory changes that typically go along with it make capital-raising efforts a significant challenge. Businesses with an eye toward growth need a new path, and we can help pave the way. Our corporate and securities attorneys represent issuers, underwriters, placement agents, and funds in public and private offerings of equity, debt, and asset-backed securities, including initial public offerings, follow-on offerings, at-the-market offerings, registered direct offerings, SPACs, PIPEs, 144A transactions, and tender offers. With more than 75 years of experience, we understand the legal and capital markets issues and the complex regulatory framework that is critical to success.

For more information, please contact:

Leslie Marlow

Partner, Corporate
212.885.5358

leslie.marlow@blankrome.com

Brad L. Shiffman

Partner, Corporate
212.885.5442

brad.shiffman@blankrome.com

BLANKROME
blankrome.com

Chicago • Cincinnati • Dallas • Fort Lauderdale • Houston • Los Angeles • New York • Orange County
Philadelphia • Pittsburgh • Princeton • Shanghai • Tampa • Washington • Wilmington

Data, technology
and expertise that
**connect you
to opportunity**

nyse.com

NYSE
AN ICE EXCHANGE

The road to the capital markets begins with us.

Sullivan & Worcester is a
proud Platinum Sponsor of the
2023 ThinkEquity Conference.



Sullivan
SULLIVAN & WORCESTER

sullivanlaw.com

BOSTON LONDON NEW YORK TEL AVIV WASHINGTON, DC

ATTORNEY ADVERTISING



NASDAQ
WELCOMES
RED CHIP
COMPANIES, INC.

RedChip

REDCHIP

**Discovering Tomorrow's
Blue Chips Today™**

Investor Relations | Media

Contact Us
1-800-REDCHIP
RedChip.com



Not all Law Firms are the Same

What separates Sheppard Mullin is not what we do, but how we do it. Progressive not conservative, problem solvers not just legal practitioners. Our clients understand and value this difference.

How can we help you?

SheppardMullin
www.sheppardmullin.com



The ThinkEquity Conference

OCTOBER 19, 2023
MANDARIN ORIENTAL | NEW YORK

To our valued clients and all conference participants:

Welcome to The ThinkEquity Conference at the Mandarin Oriental Hotel in New York. On behalf of everyone at ThinkEquity, we would like to extend a heartfelt thank you to all of our presenting companies, sponsors and investors for their support in making this event a premier showcase of emerging growth companies from all over the world. The 2023 conference features over 75 public and private companies across many sectors and over 600 one-on-one meetings. The presenting company management teams will be offering their insight on their companies and industries as a whole and are more than happy to answer questions on their respective businesses.

This conference book contains information about ThinkEquity and our conference sponsors. We also have detailed descriptions of each of our presenting companies, listed alphabetically.

We hope that you will find this an extremely productive day. We are excited to have you participate in the conference and look forward to a memorable event. If there is any way we can make your experience even more productive, please let us know.

Thank You,
The ThinkEquity Team



The ThinkEquity Conference

ThinkEquity Contacts

Ramnarain “Joseph” Jaigobind CEO	rj@think-equity.com (646) 968-9356
<u>Investment Banking</u>	
Eric Lord Head of Investment Banking	el@think-equity.com (646) 968-9360
Kevin Mangan Managing Director, Head of Equity Syndicate	km@think-equity.com (646) 968-9371
Andrew Scott Managing Director	as@think-equity.com (646) 968-9375
Frank Argenziano Senior Managing Director	fa@think-equity.com (212) 716-9706
Uzie Ovits Managing Director, Israel Investment Banking	uo@think-equity.com
Tara Sharif, Ph.D. Managing Director	ts@think-equity.com (646) 968-9364
<u>Institutional Sales</u>	
Chirag Choudhary Head of Equity Capital Markets	cc@think-equity.com (646) 968-9368
Scott Rothbaum Head of Institutional Sales	sr@think-equity.com (212) 716-9707
<u>Equity Research</u>	
Ashok Kumar Head of Equity Research	ak@think-equity.com
<u>Debt Capital Markets</u>	
Jeff Singer Head of Debt Capital Markets	js@think-equity.com (646) 968-9362
<u>Global Corporate Advisory</u>	
Karim Rammal Managing Director Global Corporate Advisory	kr@think-equity.com (646) 688-7772
<u>Trading</u>	
Phil Quartuccio Head of Global Trading	pq@think-equity.com (646) 968-9361
David Hentschel Head of Institutional Trading	dh@think-equity.com (646) 968-9374
<u>Corporate & Executive Services</u>	
Craig Skop Managing Director	cs@think-equity.com (646) 968-9369



The ThinkEquity Conference

Disclaimer

Investment products are made available through ThinkEquity LLC, member NYSE, FINRA (www.finra.org) & SIPC (www.sipc.org).

These documents are for informational purposes only. The information does not constitute a solicitation or an offer to buy or sell any security.

This information is confidential and intended solely for the use of ThinkEquity LLC and the client or prospective client to whom it has been delivered. It is not to be reproduced or distributed to any person except to the client's professional advisor.

Before making an investment decision, you should carefully read the applicable offering memorandum or prospectus which contains important disclosures regarding risks, fees, and expenses. Any third party information used in this document has been obtained from various published and unpublished sources considered to be reliable. However, ThinkEquity cannot guarantee its accuracy or completeness and thus, does not accept liability for any direct or consequential losses arising from its use.

Past performance is no guarantee of future results. The investment return and principal value of an investment can fluctuate with changes in market conditions.



The ThinkEquity Conference

October 19, 2023

MANDARIN ORIENTAL · NEW YORK

2023 ThinkEquity Conference Presenting Companies




The ThinkEquity Conference
 October 19, 2023
 MANDARIN ORIENTAL · NEW YORK

2023 ThinkEquity Conference Sponsoring Companies



DENTONS

Global Venture Technology

Dentons Global Venture Technology
 a boutique on a global
 law firm platform

Innovation.
 Acceleration.
 Disruption.

Venture**Beyond.**

dentons**venturebeyond.com**

© 2023 Dentons. Dentons is a global legal practice providing client services worldwide through its member firms and affiliates. Please see dentons.com for Legal Notices.

GT MEANS Go-To

Greenberg Traurig's Capital Market's Practice is comprised of more than 100 attorneys from the firm's global Corporate and Public Finance groups who handle U.S. and cross-border transactions, IPOs, high yield and investment grade debt offerings, Rule 144A and Regulation S offerings for foreign private issuers, registered direct offerings, ATMs, public and private equity line transactions, PIPEs, as well as securities offerings involving SPACs and REITs.

Our lawyers offer clients the combined benefits of local presence and global resources to provide the legal and market experience needed to manage and close the most complex transactions, as well as provide practical counsel on clients' day-to-day operations.



Marvin S. Rosen
New York
rosenm@gtlaw.com



Alan I. Annex
Miami
Alan.Annex@gtlaw.com



David Huberman
Tel Aviv
David.Huberman@gtlaw.com

GREENBERG TRAURIG, P.A. | ATTORNEYS AT LAW | 2650 ATTORNEYS | 47 LOCATIONS WORLDWIDE* | GTLAW.COM

ONE VANDERBILT AVENUE | NEW YORK, NY 10017 | 212.801.9200

333 S.E. 2ND AVENUE | SUITE 4500 | MIAMI, FL 33131 | 305.579.0500

ONE AZRIELI CENTER | ROUND TOWER, 30TH FLOOR | 132 MENACHEM BEGIN
TEL AVIV, 6701101, ISRAEL | +972 (0) 3.636.6000

Greenberg Traurig is a service mark and trade name of Greenberg Traurig, LLP and Greenberg Traurig, P.A. ©2023 Greenberg Traurig, P.A. Attorneys at Law. All rights reserved. Attorney Advertising. *These numbers are subject to fluctuation. 38976

WORLDWIDE LOCATIONS

United States, Europe
and the Middle East,
Asia, Latin America

Ever wonder where
the people with all the
answers get all the
answers?

Ask MARCUM



marcumllp.com

MARCUM
ACCOUNTANTS ▲ ADVISORS

Meeting You at the Cutting Edge

With an unparalleled corporate practice at the nexus of the public and private sectors, we provide legal solutions to complex business challenges and ensure that you thrive in this highly regulated economy.

How can we help you?
[Venable.com/Corporate](https://www.venable.com/corporate)

VENABLE^{LLP}

CA | DC | DE | FL | IL | MD | NY | VA

William N. Haddad, Esq.
151 W. 42nd Street, New York, NY | Attorney advertising.



LEGAL GUIDANCE FOR INDUSTRY NEEDS

Sichenzia Ross Ference Carmel LLP delivers an unmatched concentration of expertise in corporate and securities law and commercial and securities litigation in the domestic and global markets. Our attorneys work with client companies in diverse industries ranging from biotechnology to natural energy, healthcare and telecommunications.

Visit www.srfc.law to learn more.

OUR EXPERTISE:

- Initial and Secondary Public Offerings
- PIPE Transactions
- Reverse Mergers
- Mergers & Acquisitions
- Restricted Stock & SEC Filings
- Securities Litigation and Arbitration
- SPAC & De-SPAC Transactions
- Private Equity Funds, Hedge Funds, Pre-IPO Funds and SPVs
- SEC and FINRA Enforcement Defense



[WWW.SRFC.LAW](http://www.srfc.law)

Focus on your company's financial future

Proud Sponsor of ThinkEquity Conference 2023

newsfile

ThinkEquity

Member of NYSE - FINRA - SIPC

Why have **hundreds of companies** switched to Newsfile for newswire services?

To experience superior customer service, reach and value.

Our team of specialists are ready 24/7 to showcase your discoveries to a global investment community of investors, analysts and institutions. Ensure compliance with all stock exchanges by reaching major broker terminals, financial databases, aggregators, media and more.

Stock Exchange Distribution

Newsfile has direct feeds and integration with all North American stock exchanges. Includes OTCIQ integration and direct feeds into Nasdaq, NYSE and NEO.

Extensive Distribution Lists

Reach key influencers, analysts, financial databases, media, broker terminals and more.

Multimedia Capability

Make your release stand out! Embed a picture, map, or chart at no extra cost.

Email and Fax Distribution

Deliver to your email and fax lists. Easily manage your lists on our portal and add subscription capability to your website.

Social Media

Includes subject specific hashtags to your release to help reach key influencers. Automatically have your story posted to your corporate twitter feed.

IR Website Posting

Integrate RSS feeds to automatically populate the news section of your corporate website.

Tracking and Reporting

Access detailed news release statistics.

SEDAR and EDGAR Filing

Leverage Canada's largest and most experienced SEDAR/EDGAR filing agency.



SEC & FINANCIAL REPORTING
OUTSOURCED ACCOUNTING SERVICES
MERGER & ACQUISITIONS
SPAC TRANSACTION SERVICES
CFO CONSULTING SERVICES FOR PRIVATE COMPANIES
TAX COMPLIANCE & PLANNING

845.613.3394 | CFOSQUAD.COM

New York, NY Woodmere, NY Springfield, NJ Monsey, NY Davao City, Philippines

www.newsfilecorp.com



Smart decisions today. Lasting value tomorrow.™

At Crowe, we help our clients embrace volatility in today's business environment. We work with them to make smart decisions amid complexity and uncertainty, which drives lasting value – sometimes in unexpected ways.

With deep experience across a range of industries and a focus on the unique requirements of your business, we can help you uncover hidden opportunities.

To learn more, visit crowe.com.

Contact:

Andrew Spivack
+1 646 231 7216
andrew.spivack@crowe.com

AUDIT / TAX / ADVISORY / CONSULTING

Visit www.crowe.com/disclosure for more information about Crowe LLP, its subsidiaries, and Crowe Global. © 2023 Crowe LLP.

Audit2499-006T

The ThinkEquity Conference

October 19, 2023

MANDARIN ORIENTAL · NEW YORK

2023 ThinkEquity Conference Presenting Companies






Alarum Technologies Ltd. - עב פורג יט"מ (TASE:ALAR) | Public Company
30 Haarba'a Street | Tel Aviv-Yafo, Tel Aviv 6473926 | Israel | 972 9 866 6110 | www.alarum.io

Alarum Technologies Ltd. provides cybersecurity and privacy solutions to consumers and enterprises in Israel, the United States, the Middle East, the United Kingdom, the British Virgin Islands, the Asia Pacific, and internationally. The company operates through three segments: Enterprise Cybersecurity, Enterprise Internet Access, and Consumer Internet Access. It offers iShield, a cybersecurity cloud software that pro... As of Date: 4/29/2023

Key Statistics

	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FYE 12/31/2023	2024FYE 12/31/2024
Total Revenue		4,886	10,281	18,779	24,164	25,700
Total Revenues, 1 Year Growth (%)		48.78	110.42	82.66	28.68	6.36
Gross Profit Margin (%)		48.85	49.96	53.93	67.6	71
EBITDA Margin (%)		(164.27)	(139.69)	(65.22)	13.27	16.84
EBIT Margin (%)		(168.38)	(143.77)	(68.45)	(32.94)	7.34
Net Income Margin (%)		(160.56)	(127.66)	(70.03)	(32.38)	7.49
Diluted EPS Excl. Extra Items		(0.73)	(0.48)	(0.42)	NA	NA
Diluted EPS Before Extra, 1 Year Growth (%)		(98.22)	(34.07)	(13.26)	NA	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Holder	Common Stock	of Total Shares Outstanding	Market Value(mm)
Yotam Benattia	2,638,490.00	4.52	1.0
Roni Lev	2,638,490.00	4.52	1.0
Renaissance Technologies LLC	142,610.00	0.24	0.1
Harel Insurance Investments & Financial Services Ltd.	121,678.00	0.21	0.0
Shachar Daniel	110,710.00	0.19	0.0

Market Data TASE:ALAR \$0.39 2.76% \$0.01

Last (Delayed)	0.39	Avg Daily Volume	50,139
VWAP (Delayed)	0.39	Avg 3M Daily Volume	241,921
Open	0.38	Shares Out. (9/20/2023)	58,412,171
Previous Close	0.38	Float (%)	90.61
Day High/Low	0.394815 / 0.387283	Inst. Ownership (%)	1.27
52 wk High/Low	0.45144 / 0.147796	Shares Sold Short	NA
Beta 3Y	0.71	Short Int/ShOut (%)	NA
Market Cap. (\$M)	22.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	22.2		



Status: Operating

Primary Industry (CIQ/GICS): Systems Software

Topic Tags: Encryption, Network Security, Cloud Data Services, Cloud Services, Cloud Service

Officers & Directors

Chairman of the Board	Chen Katz
Co-Founder, CEO & Director	Shachar Daniel
Co-Founder and VP of Product Strategy,...	Eitan Bremier

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	0.39
Ordinary Shares Outstanding (actual)	58,412,171

Market Capitalization	22,622
Cash & Short Term Investments	3,813
Total Debt	3,377
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	22,201
Total Common Equity	6,124
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	3,377
Total Capital	9,501

Stock Chart



Multiples	2022 FY	2023 FY E
Period Ended	12/30/2022	12/30/2023
Price/ EPS (x)	NM	NA
TEV/ Total Revenue (x)	1.19	0.92
TEV/ EBITDA (x)	NM	6.92
Price/ Book (x)	0.95	NA



Alliance Entertainment Holding Corporation (OTCPK:AENT) | Public Company
8201 Peters Road | Suite 1000 | Plantation, FL 33324 | USA | (954) 255-4000 | www.aent.com

Alliance Entertainment Holding Corporation operates as a wholesaler, distributor, and e-commerce provider for the entertainment industry worldwide. The company offers gaming products, vinyl records, digital video discs and blu-rays, compact discs, and consumer products and collectibles. It also provides third party logistics products and services. The company distributes its physical media, entertainment products, ha... As of Date: 9/5/2023

Key Statistics

	Last 5 Yr Trend	2020 FY 6/30/2020	2021 FY 6/30/2021	2022 FY 6/30/2022	2023FYE 6/30/2023	2024FYE 6/30/2024
Total Revenue		775,596	1,323,567	1,417,377	1,150,000	1,110,000
Total Revenues, 1 Year Growth (%)		3.89	70.65	7.09	NA	(3.48)
Gross Profit Margin (%)		15.36	13.8	12.87	9	12
EBITDA Margin (%)		4.28	5.16	4.23	NA	NA
EBIT Margin (%)		2.25	4.3	3.65	(2.87)	1.99
Net Income Margin (%)		0.69	2.58	2.02	(2.96)	0.62
Diluted EPS Excl. Extra Items		5.96	37.98	31.8	(0.67)	0.14
Diluted EPS Before Extra, 1 Year Growth (%)		NM	NM	(16.26)	NA	NA


Estimates



Multiples

	2022 FY	2023 FY E
Period Ended	06/29/2022	06/29/2023
Price/ EPS (x)	0.04	NM
TEV/ Total Revenue (x)	0.15	0.18
TEV/ EBITDA (x)	3.08	NA
Price/ Book (x)	0.16	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Holder	Common Stock	of Total Shares Outstanding	Market Value(mm)
Bruce Ogilvie Jr.	23,833,300.00	47.19	28.4
Jeffrey Walker	22,936,078.00	45.42	27.3
Hudson Bay Capital Management LP	750,000.00	1.49	0.9
W. Thomas Donaldson III	572,727.00	1.13	0.7
Heights Capital Management, Inc.	507,155.00	1.00	0.6

Market Data OTCPK:AENT \$1.14 (4.20%) (\$0.05)

Last (Delayed)	1.14	Avg Daily Volume	689
VWAP (Delayed)	1.16	Avg 3M Daily Volume	30,487
Open	1.24	Shares Out. (6/29/2023)	50,502,170
Previous Close	1.19	Float (%)	5.40
Day High/Low	1.24 / 1.14	Inst. Ownership (%)	3.41
52 wk High/Low	12.24 / 0.93	Shares Sold Short	9,335
Beta 3Y	NA	Short Int/ShOut (%)	0.02
Market Cap. (\$M)	62.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	206.1		



Status: Operating

Primary Industry (CIQ/GICS): Distributors

Officers & Directors

Executive Chairman of the Board	Bruce Ogilvie Jr.
CEO & Director	Jeffrey Walker
CFO & Director	John Kutch

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	1.19
Ordinary Shares Outstanding (actual)	50,502,170

Market Capitalization	60,098
Cash & Short Term Investments	1,034
Total Debt	144,476
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	203,540
Total Common Equity	83,959
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	144,476
Total Capital	228,435

Stock Chart





Annovis Bio, Inc. (NYSE:ANVS) | Public Company

1055 Westlakes Drive | Suite 300 | Berwyn, PA 19312 | USA | (610) 727-3913 | www.annovisbio.com

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which... As of Date: 4/6/2023

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FY E 12/31/2023	2024FY E 12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(0.87)	(1.9)	(3.1)	NA	NA
Diluted EPS Before Extra, 1 Year Growth (%)		(75.19)	118.35	63.35	NA	NA

Estimates	Multiples	2022 FY	2023 FYE
Period Ended		12/30/2022	12/30/2023
Price/ EPS (x)		NM	NA
TEV/ Total Revenue (x)		NA	NA
TEV/ EBITDA (x)		NA	NA
Price/ Book (x)		2.56	NA

Revenue by Business and Geographic Segments
No data available

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Michael M. B. Hoffman	1,475,760.00	16.38	13.1
Maria L. Maccicchini	1,057,489.00	11.73	9.4
Aigh Capital Management LLC	419,070.00	4.65	3.7
Vanguard Group Inc.	252,030.00	2.80	2.2
BlackRock Inc.	97,293.00	1.08	0.9

Market Data NYSE:ANVS \$8.71 (2.14%) (\$0.19)			
Last (Delayed)	8.71	Avg Daily Volume	15,217
VWAP (Delayed)	8.75	Avg 3M Daily Volume	27,825
Open	9.00	Shares Out. (8/14/2023)	9,012,273
Previous Close	8.90	Float (%)	70.46
Day High/Low	9.11 / 8.61	Inst. Ownership (%)	13.65
52 wk High/Low	23.8881 / 8.7201	Shares Sold Short	347,997
Beta 3Y	1.37	Short Int/ShOut (%)	3.86
Market Cap. (\$M)	79.5	Div. Yield (%)	NA
Total Enterprise Value (\$M)	63.7		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Cardiovascular, Chronic Diseases, Neurology, Pain Management, Stroke, Dementia, Neurodegenerative

Officers & Directors	
Chairman of the Board	Michael M. B. Hoffman
Founder, CEO, President & Executive Di...	Maria L. Maccicchini
Chief Financial Officer	Henry Hagopian III

Debt Maturity
No data available

Capitalization	
Reported Currency Code	USD
Closing Price	8.90
Ordinary Shares Outstanding (actual)	9,012,273
Market Capitalization	80,164
Cash & Short Term Investments	15,725
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	64,440
Total Common Equity	20,743
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	20,743




Asset Entities Inc. (NASDAQCM:ASST) | Public Company

100 Crescent Court | 7th Floor | Dallas, TX 75201 | USA | (214) 459-3117 | www.assetentities.com

Asset Entities Inc., a technology company, provides social media marketing and content delivery services across Discord, TikTok, and other social media platforms. It also designs, develops, and manages servers for communities on Discord. The company was founded in 2020 and is based in Dallas, Texas. Asset Entities Inc. is a subsidiary of Asset Entities Holdings, Llc. As of Date: 9/17/2023

	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022
Total Revenue		209	830	343
Total Revenues, 1 Year Growth (%)		NA	297.77	(58.64)
Gross Profit Margin (%)		99.08	80.68	54.76
EBITDA Margin (%)		NA	NA	NA
EBIT Margin (%)		3.76	1.79	(188.06)
Net Income Margin (%)		3.76	1.79	(188.06)
Diluted EPS Excl. Extra Items		NA	0	(0.06)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	NA	NM



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Holder	Common Stock	% of Total Shares Outstanding	Market Value(mm)
Asset Entities Holdings Llc	8,385,276.00	60.94	3.7
Arshia Sarkhani	500,000.00	3.63	0.2
Kyle Fairbanks	500,000.00	3.63	0.2
Robyn Baker	292,680.00	2.13	0.1
Carla Woodcock	292,680.00	2.13	0.1

Market Data NASDAQCM:ASST \$0.38 (14.73%) (\$0.06)			
Last (Delayed)	0.38	Avg Daily Volume	47,381
VWAP (Delayed)	0.39	Avg 3M Daily Volume	77,079
Open	0.42	Shares Out. (10/3/2023)	5,375,724
Previous Close	0.44	Float (%)	15.14
Day High/Low	0.4478 / 0.37	Inst. Ownership (%)	0.94
52 wk High/Low	6.98 / 0.428	Shares Sold Short	19,861
Beta 3Y	NA	Short Int/ShOut (%)	0.37
Market Cap. (\$M)	5.5	Div. Yield (%)	NA
Total Enterprise Value (\$M)	0.5		



Status: Operating Subsidiary
Primary Industry (CIQ/GICS): Advertising
Topic Tags: Social Media Marketing, Media Marketing

Officers & Directors	
Executive Chairman & General Counsel	Michael Gaubert
Co-Founder, CEO, President & Director	Arshia Sarkhani
Co-Founder & Chief Marketing Officer	Jackson Fairbanks

Debt Maturity
No data available

Capitalization	
Reported Currency Code	USD
Closing Price	0.44
Ordinary Shares Outstanding (actual)	13,761,000
Market Capitalization	6,055
Cash & Short Term Investments	5,016
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	1,039
Total Common Equity	4,906
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	4,906



Multiples		2022 FY
Period Ended		12/30/2022
Price/ EPS (x)		NM
TEV/ Total Revenue (x)		17.25
TEV/ EBITDA (x)		NA
Price/ Book (x)		31.43




Azitra, Inc. (NYSEAM:AZTR) | Public Company

21 Business Park Drive | Branford, CT 06405 | USA | (203) 646-6446 | azitrainc.com

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of *S. epidermidis* for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of *S. epidermidis* for treating the papulopustular rash experien... As of Date: 7/5/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY
	Trend	12/31/2020	12/31/2021	12/31/2022
Total Revenue		425	110	284
Total Revenues, 1 Year Growth (%)		NA	(74.12)	158.18
Gross Profit Margin (%)		100	100	100
EBITDA Margin (%)		NM	NM	NM
EBIT Margin (%)		NM	NM	NM
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(6.57)	(11.2)	(12.74)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	70.34	13.81

Revenue by Business and Geographic Segments



Multiples 2022 FY

Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	194.90
TEV/ EBITDA (x)	NM
Price/ Book (x)	NM

Top Holders

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Bios Equity Partners LP	6,652,361.00	54.99	9.6
Bayer AG	1,307,401.00	10.81	1.9
Connecticut Innovations Inc.	647,739.00	5.35	0.9
KDT Ventures	291,911.00	2.41	0.4
Andrew Cain McClary	269,245.00	2.23	0.4

Market Data NYSEAM:AZTR \$1.45

0.70% \$0.01

Last (Delayed)	1.45	Avg Daily Volume	1,331
VWAP (Delayed)	1.48	Avg 3M Daily Volume	14,054
Open	1.45	Shares Out. (8/14/2023)	12,097,643
Previous Close	1.44	Float (%)	24.12
Day High/Low	1.54 / 1.45	Inst. Ownership (%)	3.20
52 wk High/Low	5.18 / 1.31	Shares Sold Short	3,284
Beta 3Y	NA	Short Int/ShOut (%)	0.03
Market Cap. (\$M)	18.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	13.3		



Status: Operating


Primary Industry (CIQ/GICS): Biotechnology

Topic Tags: Chronic Diseases, Dermatology, Oncology, Health Diagnostics, Cancer, Ichthyosis Vulgaris, Cancer Pa...

Officers & Directors

President, CEO & Director	Francisco D. Salva
Co-Founder, COO & Director	Travis M. Whitfill
CFO, Treasurer & Secretary	Norman Staskey

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	1.44
Ordinary Shares Outstanding (actual)	12,097,643
Market Capitalization	17,421
Cash & Short Term Investments	6,290
Total Debt	992
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	12,122
Total Common Equity	7,236
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	992

Stock Chart




Beamr Imaging Ltd. (NASDAQCM:BMR) | Public Company

10 HaManofim Street | Herzliya, Tel Aviv 4672561 | Israel | 888 520 8735 | www.beamr.com

Beamr Imaging Ltd. provides video encoding, transcoding, and optimization solutions in the United States, Israel, and internationally. The company offers a suite of video compression software encoder solutions, including Beamr 4, Beamr 4X content adaptive, Beamr 5, and Beamr 5X content adaptive encoders; Beamr JPEGmini photo optimization software solutions for reducing joint photographic experts group file sizes; and... As of Date: 8/23/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY
	Trend	12/31/2020	12/31/2021	12/31/2022
Total Revenue		3,176	3,300	2,863
Total Revenues, 1 Year Growth (%)		(22.39)	3.9	(13.24)
Gross Profit Margin (%)		97.04	97.27	96.58
EBITDA Margin (%)		(31.11)	(10.94)	(35.03)
EBIT Margin (%)		(52.49)	(16.79)	(36.01)
Net Income Margin (%)		(77.42)	(28.85)	(43.59)
Diluted EPS Excl. Extra Items		(0.96)	(0.37)	(0.48)
Diluted EPS Before Extra, 1 Year Growth (%)		(37.67)	(61.34)	31.09

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Holder	Common Stock	% Equivalent Held	of Total Shares Outstanding	Market Value(mm)
Sharon Carmel	3,693,190.00		28.67	6.6
Innovation Endeavors Israel	2,272,150.00		17.64	4.1
Verizon Ventures	1,073,731.00		8.33	1.9
Disruptive	1,056,290.00		8.20	1.9
Innovation Endeavors LLC	1,042,445.00		8.09	1.9

Market Data NASDAQCM:BMR \$1.78

(1.11%) (\$0.02)

Last (Delayed)	1.78	Avg Daily Volume	3,777
VWAP (Delayed)	1.73	Avg 3M Daily Volume	100,622
Open	1.73	Shares Out. (8/1/2023)	12,882,896
Previous Close	1.80	Float (%)	26.73
Day High/Low	1.78 / 1.63	Inst. Ownership (%)	0.20
52 wk High/Low	8.04 / 1.15	Shares Sold Short	15,754
Beta 3Y	NA	Short Int/ShOut (%)	0.12
Market Cap. (\$M)	21.0	Div. Yield (%)	NA
Total Enterprise Value (\$M)	15.4		



Status: Operating

Primary Industry (CIQ/GICS): Application Software

Topic Tags: Encoding Hardware, Streaming Media, Video Streaming, Video Encoding, Encoding, Streaming Platform, ...

Officers & Directors

Founder, Chairman & CEO	Sharon Carmel
Co-Founder	Ido Dan
Co-Founder	Mark Fisher

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	1.80
Ordinary Shares Outstanding (actual)	12,882,896
Market Capitalization	23,189
Cash & Short Term Investments	6,224
Total Debt	606
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	17,571
Total Common Equity	9,967
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	606
Total Capital	10,573

Stock Chart



Multiples 2022 FY

Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	8.14
TEV/ EBITDA (x)	NM
Price/ Book (x)	NM



Bexion Pharmaceuticals, Inc. | Private Company

632 Russell Street | Covington, KY 41011 | USA

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops biologic immunotherapy for the treatment of solid tumor cancers and chemotherapy-induced peripheral neuropathy. It offers BXQ-350, a compound to treat cancer. The company was incorporated in 2006 and is based in Covington, Kentucky.

Headquarters	632 Russell St. Covington, KY 41011 USA	Phone	(859) 446-7386
---------------------	-----------------------------------------	--------------	----------------

Corporate Data

Status	Operating
Primary Industry (CIQ/GICS)	Pharmaceuticals
Topic Tags	Chronic Diseases, Immunology, Neurology, Oncology, Cancer, Immunotherapy, Neuropathy
Categories ¹	Biopharma, Life Science, Pharmaceutical
Date of Incorporation	06/07/2006
SIC Code	2834
NACE Code	21.20 - Manufacture of pharmaceutical preparations
NAICS Code	325412 - Pharmaceutical Preparation Manufacturing
U.S. Number Of Employees 2022	24
U.S. Number Of Employees 2021	22
U.S. Latest Employee Growth %	9.09

Officers & Directors

Chairman of the Board	Charles Richard "Chuck" Scheper
President, CEO & Director	Richard "Scott" Shively
Co-Founder & Chief Scientific Officer	Ray Takigiku

Latest Activity

Key Developments

Bexion Pharmaceuticals, Inc. Presents at BioFuture 2023, Oct- 04-2023	Company Conference Presentation	10/4/2023
Demy-Colton Inc., BioFuture 2023, Oct 04, 2023 through Oct 06,	Conference	10/4/2023




BK Technologies Corporation (NYSEAM:BKTI) | Public Company

7100 Technology Drive | West Melbourne, FL 32904 | USA | (321) 984-1414 | www.bktechnologies.com

BK Technologies Corporation, through its subsidiary, BK Technologies, Inc., engages in design, manufacture, and markets wireless communications products in the United States and internationally. The company offers two-way land mobile radios (LMR) and related components. It offers KNG Series and BKR Series radios operate in both the P25 digital and analog modes which are used primarily in government, public safety, an... *As of Date: 9/17/2023*

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022
	Total Revenue		44,139	45,364
Total Revenues, 1 Year Growth (%)		10.07	2.78	12.32
Gross Profit Margin (%)		40.85	35.85	19.82
EBITDA Margin (%)		5.3	0.44	(17.19)
EBIT Margin (%)		2.25	(2.64)	(19.98)
Net Income Margin (%)		0.44	(3.75)	(22.83)
Diluted EPS Excl. Extra Items		0.08	(0.57)	(3.45)
Diluted EPS Before Extra, 1 Year Growth (%)		NM	NM	NM

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders			
Holder	Common Stock	of Total Shares Outstanding	Market Value(mm)
Fundamental Global Investors LLC	606,735.00	17.82	7.4
Aigh Capital Management LLC	330,896.00	9.72	4.0
Donald F. U. Goebert	252,902.00	7.43	3.1
Atria Wealth Solutions Inc.	197,330.00	5.80	2.4
Joseph Hugh Moglia	169,163.00	4.97	2.1


Market Data NYSEAM:BKTI \$12.50 2.54% \$0.31			
Last (Delayed)	12.50	Avg Daily Volume	5,056
VWAP (Delayed)	12.07	Avg 3M Daily Volume	15,488
Open	11.90	Shares Out. (8/10/2023)	3,404,218
Previous Close	12.19	Float (%)	58.36
Day High/Low	12.5 / 11.8	Inst. Ownership (%)	22.67
52 wk High/Low	19.9 / 8.79	Shares Sold Short	756
Beta 3Y	0.80	Short Int/ShOut (%)	0.02
Market Cap. (\$M)	41.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	47.3		



Status: Operating

Primary Industry (CIQ/GICS): Communications Equipment

Officers & Directors	
Chairman of the Board	Daniel Kyle Cerminara
CEO & Director	John M. Suzuki
President	Timothy A. Vitou



Capitalization	
Reported Currency Code	USD
Closing Price	12.19
Ordinary Shares Outstanding (actual)	3,404,218
Market Capitalization	41,497
Cash & Short Term Investments	2,688
Total Debt	8,665
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	47,474
Total Common Equity	17,826
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	8,665
Total Capital	26,491



Multiples 2022 FY	
Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	0.95
TEV/ EBITDA (x)	NM
Price/ Book (x)	2.06



BSF Enterprise Plc (LSE:BSFA) | Public Company

31 Old Burlington Street | Ground Floor | London W1S 3AS | United Kingdom | www.bsferprise.com

BSF Enterprise Plc does not have significant operations. It intends to acquire the businesses within biotechnology, innovative marketing, and e-commerce sectors. The company was incorporated in 2018 and is based in London, United Kingdom. As of Date: 8/23/2023



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY
	Trend	9/30/2020	9/30/2021	9/30/2022
Total Revenue		NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA
EBITDA Margin (%)		NA	NA	NA
EBIT Margin (%)		NA	NA	NA
Net Income Margin (%)		NA	NA	NA
Diluted EPS Excl. Extra Items		(0.01)	(0)	(0.03)
Diluted EPS Before Extra, 1 Year Growth (%)		(68.55)	(37.85)	NM

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
ASF Group Ltd.	16,610,944.00	16.07	1.8
Jarvis Securities PLC	14,756,975.00	14.28	1.6
Che J. Connon	12,927,977.00	12.51	1.4
Newcastle University Holding Ltd	6,915,624.00	6.69	0.8
Min Yang	5,779,850.00	5.59	0.6

Market Data LSE:BSFA \$0.11 (2.70%) \$0.00			
Last (Delayed)	0.11	Avg Daily Volume	303,765
VWAP (Delayed)	0.11	Avg 3M Daily Volume	652,819
Open	0.11	Shares Out. (9/26/2023)	103,336,937
Previous Close	0.11	Float (%)	51.81
Day High/Low	0.112452 / 0.108591	Inst. Ownership (%)	27.14
52 wk High/Low	0.288127 / 0.060328	Shares Sold Short	NA
Beta 3Y	(0.12)	Short Int/ShOut (%)	NA
Market Cap. (\$M)	11.5	Div. Yield (%)	NA
Total Enterprise Value (\$M)	11.3		

Officers & Directors	
Chairman of the Board	Min "Mary" Yang
CEO, MD & Executive	Che J. Connon
Director	
Chief Financial Officer	Graham Duncan
Capitalization	
Reported Currency Code	GBP
Closing Price	0.11
Ordinary Shares Outstanding (actual)	103,336,937
Market Capitalization	11,533
Cash & Short Term Investments	431
Total Debt	241
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	11,348
Total Common Equity	6,980
Total Preferred Equity	NA
Total Debt	241
Total Capital	7,221



Multiples	
Period Ended	09/29/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	NA
TEV/ EBITDA (x)	NM
Price/ Book (x)	2.14



CEL-SCI Corporation (NYSEAM:CVM) | Public Company

8229 Boone Boulevard | Suite 802 | Vienna, VA 22182 | USA | (703) 506-9460 | cel-sci.com

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma ... As of Date: 5/9/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
	Trend	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Total Revenue		559	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		20.73	NA	NA	NA	NA
Gross Profit Margin (%)		NM	NA	NA	NA	NA
EBITDA Margin (%)		NM	NA	NA	NA	NA
EBIT Margin (%)		NM	NA	NA	NA	NA
Net Income Margin (%)		NM	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(0.82)	(0.93)	(0.87)	(0.74)	(0.57)
Diluted EPS Before Extra, 1 Year Growth (%)		16	12.77	(6.11)	(14.94)	(22.97)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FYE
EPS (\$)	(0.74)	(0.57)	Period Ended	09/29/2022	09/29/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NA	NA
			TEV/ EBITDA (x)	NM	NA
			Price/ Book (x)	1.57	NA

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Vanguard Group Inc.	1,901,146.00	4.02	2.2
Geert R. Kersten	1,160,781.00	2.46	1.3
BlackRock Inc.	753,702.00	1.59	0.9
Davidson Investment Advisors Inc.	529,189.00	1.12	0.6
Geode Capital Management LLC	423,501.00	0.90	0.5

Market Data NYSEAM:CVM \$1.17 0.94% \$0.01			
Last (Delayed)	1.17	Avg Daily Volume	106,650
VWAP (Delayed)	1.18	Avg 3M Daily Volume	340,949
Open	1.16	Shares Out. (8/10/2023)	47,260,097
Previous Close	1.16	Float (%)	96.37
Day High/Low	1.23 / 1.15	Inst. Ownership (%)	11.91
52 wk High/Low	3.68 / 1.08	Shares Sold Short	5,350,168
Beta 3Y	1.03	Short Int/ShOut (%)	11.32
Market Cap. (\$M)	54.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	63.2		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Chronic Diseases, Dermatology, Immunology, Internal Diseases, Oncology, Rheumatology, Surgery

Officers & Directors	
Chief Executive & Financial Officer, T...	Geert R. Kersten
Senior VP of Operations & Corporate Se...	Patricia B. Prichep
Chief Scientific Officer	Eyal Talor

Debt Maturity
 No data available

Capitalization	
Reported Currency Code	USD
Closing Price	1.16
Ordinary Shares Outstanding (actual)	47,260,097
Market Capitalization	54,822
Cash & Short Term Investments	5,159
Total Debt	14,021
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	63,684
Total Common Equity	14,789
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	14,021
Total Capital	28,810





Citius Pharmaceuticals, Inc. (NASDAQM:CTXR) | Public Company

11 Commerce Drive | First Floor | Cranford, NJ 07016 | USA | (908) 967-6677 | www.citiuspharma.com

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with per... As of Date: 12/30/2022

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
		9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Total Revenue		NA	NA	NA	NA	54,016
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	70
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	(20.51)
Net Income Margin (%)		NA	NA	NA	NA	(28.58)
Diluted EPS Excl. Extra Items		(0.45)	(0.23)	(0.23)	(0.21)	(0.1)
Diluted EPS Before Extra, 1 Year Growth (%)		(41.95)	(49.64)	2.05	(8.7)	(52.38)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(0.21)	(0.10)	Period Ended	09/29/2022	09/29/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NA	NA
			TEV/ EBITDA (x)	NM	NA
			Price/ Book (x)	0.93	1.17

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Leonard L. Mazur	10,255,342.00	6.46	6.7
BlackRock Inc.	8,079,215.00	5.09	5.3
Vanguard Group Inc.	6,681,126.00	4.21	4.4
Geode Capital Management LLC	2,608,033.00	1.64	1.7
State Street Global Advisors Inc.	2,106,942.00	1.33	1.4

Market Data NASDAQM:CTXR \$0.67 3.06% \$0.02			
Last (Delayed)	0.67	Avg Daily Volume	162,278
VWAP (Delayed)	0.66	Avg 3M Daily Volume	1,103,132
Open	0.66	Shares Out. (8/14/2023)	158,857,798
Previous Close	0.65	Float (%)	92.25
Day High/Low	0.675 / 0.6505	Inst. Ownership (%)	15.97
52 wk High/Low	1.71 / 0.63	Shares Sold Short	19,418,577
Beta 3Y	0.87	Short Int/ShOut (%)	12.22
Market Cap. (\$M)	106.9	Div. Yield (%)	NA
Total Enterprise Value (\$M)	74.7		




Status: Operating

Primary Industry (CIQ/GICS): Pharmaceuticals

Topic Tags: Chronic Diseases, Hematology, Infectious Diseases, Inflammation, Oncology, Respiratory, Cancer

Officers & Directors	
Co-Founder, CEO, Chairman & Secretary	Leonard L. Mazur
Co-Founder & Executive Vice Chairman	Myron Z. Holubiak
Chief Business Officer, CFO & Chief Ac...	Jaime Bartushak



Capitalization	
Reported Currency Code	USD
Closing Price	0.65
Ordinary Shares Outstanding (actual)	158,857,798
Market Capitalization	103,686
Cash & Short Term Investments	33,282
Total Debt	533
Total Preferred Equity	NA
Total Minority Interest	600
Total Enterprise Value (TEV)	71,538
Total Common Equity	97,700
Total Preferred Equity	NA
Total Minority Interest	600
Total Debt	533
Total Capital	98,833




Clip Money Inc. (TSXV:CLIP) | Public Company

96 Riverdale Ave | Ottawa, Ontario K1S 1R2 | Canada | (844) 917-0917 | clipmoney.com

Clip Money Inc., a financial technology company, provides deposit network services to businesses and financial institutions in Canada and the United States. The company offers Clip Drop Platform, an end-to-end system that includes user registration, location services, bar code and RFID tracking of deposit bags, secure processing of deposits, and payment processing. Its platform enhances the transaction experience wh... As of Date: 5/8/2023

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY
		12/31/2020	12/31/2021	12/31/2022
Total Revenue		0	2	28
Total Revenues, 1 Year Growth (%)		NA	NM	NM
Gross Profit Margin (%)		NM	NM	NM
EBITDA Margin (%)		NM	NM	NM
EBIT Margin (%)		NM	NM	NM
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(0.05)	(0.11)	(0.22)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	115.99	97.01



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders			
Holder	Common Stock	% of Total Shares Outstanding	Market Value(mm)
NCR Corp.	28,596,826.00	27.31	7.7
Joseph Abou-Arrage	15,895,126.00	15.18	4.3
Daren Trousdell	14,921,192.00	14.25	4.0
John Jeffrey Gibson	8,882,691.00	8.48	2.4
Brian Joseph Bailey	1,776,153.00	1.70	0.5

Market Data TSXV:CLIP \$0.27			
Last (Delayed)	0.27	Avg Daily Volume	20,000
VWAP (Delayed)	0.27	Avg 3M Daily Volume	20,993
Open	0.27	Shares Out. (9/22/2023)	104,730,892
Previous Close	0.27	Float (%)	28.86
Day High/Low	0.269587 / 0.269587	Inst. Ownership (%)	NA
52 wk High/Low	0.54646 / 0.153009	Shares Sold Short	NA
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	28.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	35.4		

Multiples		2022 FY
Period Ended		12/30/2022
Price/ EPS (x)		NM
TEV/ Total Revenue (x)		NM
TEV/ EBITDA (x)		NM
Price/ Book (x)		9.49




Status: Operating

Primary Industry (CIQ/GICS): Application Software

Topic Tags: RFID (Radio Frequency Identification), Banking as a Service, Online Payments, Fintech, Rfid Trackin...

Officers & Directors	
Chairman of the Board	Peter A. Dorsman
Co-Founder, CEO & Director	Joseph "Joe" Abou-Arrage
President	Brian Joseph Bailey



Capitalization	
Reported Currency Code	USD
Closing Price	0.27
Ordinary Shares Outstanding (actual)	104,730,892
Market Capitalization	28,234
Cash & Short Term Investments	1,026
Total Debt	8,503
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	35,448
Total Common Equity	(1,244)
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	8,503
Total Capital	7,259




Multiples		2022 FY
Period Ended		12/30/2022
Price/ EPS (x)		NM
TEV/ Total Revenue (x)		NM
TEV/ EBITDA (x)		NM
Price/ Book (x)		9.49

COMSovereign Holding Corp. provides technologically-advanced telecom solutions for network operators, mobile device carriers, governmental units, and other enterprises worldwide. The company offers packet microwave solutions that transmit broadband voice, video, and data, as well as enable service providers, government agencies, enterprises, and other organizations; and in-band full-duplex technologies that alleviate... As of Date: 8/31/2022

Key Statistics	Last 5 Yr	2019 FY	2020 FY	2021 FY
	Trend	12/31/2019	12/31/2020	12/31/2021
Total Revenue		4,712	9,427	12,640
Total Revenues, 1 Year Growth (%)		NA	100.06	34.08
Gross Profit Margin (%)		36.53	51.25	48.6
EBITDA Margin (%)		NM	(153.16)	(195.56)
EBIT Margin (%)		NM	(286.08)	NM
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(170)	(81.87)	(219.56)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	(51.84)	168.19

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Holder	Common Stock	of Total Shares Outstanding	Market Value(mm)
Susquehanna International Group LLP	101,873.00	3.80	0.1
Phillip Frost	32,182.00	1.20	0.0
Vanguard Group Inc.	29,082.00	1.08	0.0
Delaware Street Capital	22,500.00	0.84	0.0
Alliance Financial Group Advisory Services LLC	18,146.00	0.68	0.0

Market Data NASDAQCM:COMS \$1.20 (0.94%) (\$0.01)			
Last (Delayed)	1.20	Avg Daily Volume	3,955
VWAP (Delayed)	1.18	Avg 3M Daily Volume	23,736
Open	1.23	Shares Out. (2/24/2023)	2,683,571
Previous Close	1.21	Float (%)	97.76
Day High/Low	1.225 / 1.14	Inst. Ownership (%)	8.01
52 wk High/Low	17 / 1.16	Shares Sold Short	68,151
Beta 3Y	1.09	Short Int/ShOut (%)	2.54
Market Cap. (\$M)	3.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	30.8		

Status: Operating

Primary Industry (CIQ/GICS): Communications Equipment

Officers & Directors	
CEO, President, Acting	David A. Knight
Principal Finan...	
Chief Operating Officer	Harold Marion "Bud" Patterson
Chief Technology Officer	Dustin H. McIntire

Debt Maturity: No data available

Capitalization	
Reported Currency Code	USD
Closing Price	1.21
Ordinary Shares Outstanding (actual)	2,683,571
Market Capitalization	3,244
Cash & Short Term Investments	571
Total Debt	28,049
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	30,722
Total Common Equity	14,410
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	28,049
Total Capital	42,459

Stock Chart



Multiples	
Period Ended	12/30/2021
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	2.47
TEV/ EBITDA (x)	NM
Price/ Book (x)	0.02

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm... As of Date: 4/17/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(3.96)	(3.69)	(0.93)	(1.34)	(1.05)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	(6.91)	(74.82)	44.09	(21.89)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023 FYE
EPS (\$)	(1.34)	(1.05)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NA	NA
			TEV/ EBITDA (x)	NM	NA
			Price/ Book (x)	0.64	NA

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Kepos Capital LP	1,000,000.00	6.26	1.4
Altium Capital Management LP	1,000,000.00	6.26	1.4
Martin A. Lehr	974,068.00	6.10	1.4
Sabby Management LLC	796,706.00	4.99	1.1
Ally Bridge Group	653,396.00	4.09	0.9

Market Data NASDAQCM:CNTX \$1.21 (12.95%) (\$0.18)			
Last (Delayed)	1.21	Avg Daily Volume	29,734
VWAP (Delayed)	1.25	Avg 3M Daily Volume	44,179
Open	1.39	Shares Out. (8/9/2023)	15,966,053
Previous Close	1.39	Float (%)	80.61
Day High/Low	1.39 / 1.2042	Inst. Ownership (%)	20.60
52 wk High/Low	1.69 / 0.47	Shares Sold Short	13,820
Beta 3Y	NA	Short Int/ShOut (%)	0.09
Market Cap. (\$M)	20.0	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(5.2)		

Status: Operating

Primary Industry (CIQ/GICS): Pharmaceuticals

Topic Tags: Chronic Diseases, Oncology, Cancer

Officers & Directors	
Chairman of the Board	Richard Jay Berman
Co-Founder, President, CEO & Director	Martin A. Lehr
Co-founder & Chair of Scientific Advis...	Felix Kim

Capitalization	
Reported Currency Code	USD
Closing Price	1.39
Ordinary Shares Outstanding (actual)	15,966,053
Market Capitalization	22,193
Cash & Short Term Investments	25,138
Total Debt	8
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(2,937)
Total Common Equity	24,005
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	8
Total Capital	24,013

Stock Chart





DarioHealth Corp. (NASDAQM:DRIO) | Public Company


18 West 18th Street | New York, NY 10011 | USA | (833) 914-3796 | www.dariohealth.com

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The c... As of Date: 10/2/2023

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
		12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		7,576	20,513	27,656	25,172	36,251
Total Revenues, 1 Year Growth (%)		0.23	170.76	34.82	(8.98)	44.01
Gross Profit Margin (%)		33.17	39.34	50.67	41.63	46.2
EBITDA Margin (%)		NM	NM	(188.36)	(110.52)	(53.58)
EBIT Margin (%)		NM	NM	(205.42)	(216.43)	(128.04)
Net Income Margin (%)		NM	NM	(224.88)	NA	NA
Diluted EPS Excl. Extra Items		(5.55)	(4.07)	(2.54)	(1.22)	(1)
Diluted EPS Before Extra, 1 Year Growth (%)		(39.78)	(26.68)	(37.59)	NA	NA

Estimates	Current Year ('23)	Next Year ('24)	Multiples	
EPS (\$)	(1.22)	(1.00)	2022 FY	2023FY E
RECOMMENDATION				
Period Ended	12/30/2022	12/30/2023		
Price/ EPS (x)			NM	NM
TEV/ Total Revenue (x)			2.49	2.69
TEV/ EBITDA (x)			NM	NM
Price/ Book (x)			1.06	NA

Revenue by Business and Geographic Segments



Top Holders

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Nantahala Capital Management LLC	2,418,507.00	8.88	8.0
More Investment House Ltd.	1,466,720.00	5.39	4.9
Phoenix Investments & Finances Ltd	1,341,027.00	4.92	4.4
Intergeml Provident Funds and Pension Ltd.	1,288,517.00	4.73	4.3
Appian Way Asset Management LP	1,281,158.00	4.71	4.2

Market Data NASDAQM:DRIO \$3.20 (3.47%) (\$0.11)			
Last (Delayed)	3.20	Avg Daily Volume	11,178
VWAP (Delayed)	3.23	Avg 3M Daily Volume	107,267
Open	3.25	Shares Out. (8/10/2023)	27,229,544
Previous Close	3.31	Float (%)	83.95
Day High/Low	3.3 / 3.1501	Inst. Ownership (%)	33.06
52 wk High/Low	6.78 / 2.55	Shares Sold Short	1,642,135
Beta 3Y	1.36	Short Int/ShOut (%)	6.03
Market Cap. (\$M)	89.9	Div. Yield (%)	NA
Total Enterprise Value (\$M)	67.4		



Status: Operating


Primary Industry (CIQ/GICS): Health Care Technology

Topic Tags: Cardiovascular, Chronic Diseases, Digital Mental Health, Digital Wellness, Endocrinology, Internal ...

Officers & Directors

Chairman of the Board	Yoav Shaked
CEO & Director	Erez Raphael
President	Richard A. "Rick" Anderson

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	3.31
Ordinary Shares Outstanding (actual)	27,229,544
Market Capitalization	90,130
Cash & Short Term Investments	52,602
Total Debt	30,124
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	67,652
Total Common Equity	78,404
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	30,124
Total Capital	108,528

Stock Chart



FAT Brands Inc. (NASDAQM:FAT) | Public Company


9720 Wilshire Boulevard | Suite 500 | Beverly Hills, CA 90212 | USA | (310) 319-1850 | www.fatbrands.com

FAT Brands Inc., a multi-brand restaurant company, acquires, develops, markets, and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts worldwide. It owns restaurant brands, including Round Table Pizza, Marble Slab Creamery, Great American Cookies, Hot Dog on a Stick, Pretzelmaker, Fazoli's, Fatburger, Johnny Rockets, Elevation Burger, Yalla Mediterranean, Buffalo's Cafe ... As of Date: 8/1/2023

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
		12/27/2020	12/26/2021	12/25/2022	12/31/2023	12/31/2024
Total Revenue		18,118	118,881	407,224	449,678	553,850
Total Revenues, 1 Year Growth (%)		(19.49)	NM	242.55	10.43	23.17
Gross Profit Margin (%)		71.2	47.67	34.62	NA	NA
EBITDA Margin (%)		(25.56)	12.26	5.77	20.52	18.9
EBIT Margin (%)		(32.03)	5.13	(0.87)	5.3	7.4
Net Income Margin (%)		(82.02)	(26.57)	(30.99)	(10.34)	(9.79)
Diluted EPS Excl. Extra Items		(1.01)	(2.16)	(7.66)	(3.09)	(3.19)
Diluted EPS Before Extra, 1 Year Growth (%)		NM	112.56	255.43	NA	NA

Estimates	Current Year ('23)	Next Year ('24)	Multiples	
EPS (\$)	(3.09)	(3.19)	2022 FY	2023FY E
RECOMMENDATION				
Period Ended	12/24/2022	12/30/2023		
Price/ EPS (x)			NM	NM
TEV/ Total Revenue (x)			3.28	3.07
TEV/ EBITDA (x)			51.44	14.94
Price/ Book (x)			NM	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Holder	Common Stock	% of Total Shares Outstanding	Market Value(mm)
Andrew A. Wiederhorn	7,753,428.00	46.44	50.2
Ls Global Franchise LP	2,259,594.00	13.53	14.6
Rachel Serruya	2,259,594.00	13.53	14.6
ADW Capital Management LLC	587,400.00	3.52	3.8
Gregory B. Fortunoff	363,352.00	2.18	2.4

Market Data NASDAQM:FAT \$6.68 3.09% \$0.20			
Last (Delayed)	6.68	Avg Daily Volume	2,268
VWAP (Delayed)	6.66	Avg 3M Daily Volume	14,832
Open	6.69	Shares Out. (8/4/2023)	15,424,709
Previous Close	6.48	Float (%)	13.70
Day High/Low	6.69 / 6.26	Inst. Ownership (%)	6.71
52 wk High/Low	8.485 / 4.73	Shares Sold Short	47,241
Beta 3Y	0.78	Short Int/ShOut (%)	0.31
Market Cap. (\$M)	110.8	Div. Yield (%)	8.38
Total Enterprise Value (\$M)	1,380.7		




Status: Operating Subsidiary

Primary Industry (CIQ/GICS): Restaurants

Officers & Directors

Chairman of the Board	Andrew A. "Andy" Wiederhorn
CFO & Co-CEO	Kenneth J. Kuick
Co-CEO & Head of Capital Markets	Robert G. Rosen

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	6.48
Ordinary Shares Outstanding (actual)	16,695,514
Market Capitalization	108,683
Cash & Short Term Investments	30,569
Total Debt	1,256,897
Total Preferred Equity	43,566
Total Minority Interest	NA
Total Enterprise Value (TEV)	1,378,577
Total Common Equity	(246,761)
Total Preferred Equity	43,566
Total Minority Interest	NA
Total Debt	1,256,897
Total Capital	1,053,702


Stock Chart



FG Financial Group, Inc. operates as a reinsurance, merchant banking, and asset management company in the United States. The company offers specialty property and casualty reinsurance products and services. It also operates a special purpose acquisition company platform (SPAC) that provides various strategic, administrative, and regulatory support services to newly formed SPACs for a monthly fee. The company was form... As of Date: 3/25/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY
	Trend	12/31/2020	12/31/2021	12/31/2022
Total Revenue		(17,156)	7,595	20,095
Total Revenues, 1 Year Growth (%)		NM	NM	164.58
Gross Profit Margin (%)		100	24.36	46.99
EBITDA Margin (%)		NA	NA	NA
EBIT Margin (%)		134.78	(96.55)	5.41
Net Income Margin (%)		130.9	(112.1)	5.41
Diluted EPS Excl. Extra Items		(4.15)	(1.99)	(0.09)
Diluted EPS Before Extra, 1 Year Growth (%)		NM	(52.17)	(95.6)

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders			
Holder	Common Stock	of Total Shares Outstanding	Market Value(mm)
Fundamental Global Investors LLC	5,666,111.00	54.99	8.8
Peter S Lynch	306,435.00	2.97	0.5
Hassan Raza Baqar	71,561.00	0.69	0.1
CSS LLC	63,144.00	0.61	0.1
Warberg Asset Management LLC	56,582.00	0.55	0.1

Market Data NASDAQM:FGF \$1.50 (3.23%) (\$0.05)			
Last (Delayed)	1.50	Avg Daily Volume	133,488
VWAP (Delayed)	1.60	Avg 3M Daily Volume	10,518
Open	1.55	Shares Out. (8/10/2023)	10,303,739
Previous Close	1.55	Float (%)	40.10
Day High/Low	1.85 / 1.2501	Inst. Ownership (%)	3.18
52 wk High/Low	3.18 / 1.1801	Shares Sold Short	39,530
Beta 3Y	0.81	Short Int/ShOut (%)	0.38
Market Cap. (\$M)	18.0	Div. Yield (%)	NA
Total Enterprise Value (\$M)	37.5		

Status: Operating
Primary Industry (CIQ/GICS): Property and Casualty Insurance

Officers & Directors	
Chairman of the Board	Daniel Kyle Cerminara
President, CEO & Director	Larry Gene Swets Jr.
Executive VP, CFO & Principal Financial...	Hassan Raza Baqar

Debt Maturity: No data available

Capitalization	
Reported Currency Code	USD
Closing Price	1.55
Ordinary Shares Outstanding (actual)	10,303,739
Market Capitalization	15,971
Cash & Short Term Investments	2,962
Total Debt	48
Total Preferred Equity	22,365
Total Minority Interest	NA
Total Enterprise Value (TEV)	35,422
Total Common Equity	14,642
Total Preferred Equity	22,365
Total Minority Interest	NA
Total Debt	48
Total Capital	37,055




Multiples 2022 FY	
Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	1.76
TEV/ EBITDA (x)	31.73
Price/ Book (x)	0.98

Foremost Lithium Resource & Technology Ltd., an exploration stage company, engages in the identification and development of mineral properties in Canada and the United States. It explores for lithium, silver, and gold properties. The company has 100% interests in the Zoro Lithium project that consists of 16 claims covering an area of approximately 3,003 hectares located in the Snow Lake, Manitoba; the Winston propert... As of Date: 5/19/2023

Key Statistics	Last 5 Yr	2021 FY	2022 FY	2023 FY
	Trend	3/31/2021	3/31/2022	3/31/2023
Total Revenue		NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA
EBITDA Margin (%)		NA	NA	NA
EBIT Margin (%)		NA	NA	NA
Net Income Margin (%)		NA	NA	NA
Diluted EPS Excl. Extra Items		(0.71)	(1.01)	0.18
Diluted EPS Before Extra, 1 Year Growth (%)		0.94	36	NM

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Jason Barnard	340,850.00	7.06	1.4
Christina Barnard	71,265.00	1.48	0.3
Johnathan A. More	19,000.00	0.39	0.1
Mark M. Fedikow	11,905.00	0.25	0.0
Andrew Lyons	10,500.00	0.22	0.0

Market Data CNSX:FAT \$4.13 4.04% \$0.16			
Last (Delayed)	4.13	Avg Daily Volume	1,200
VWAP (Delayed)	4.19	Avg 3M Daily Volume	11,994
Open	4.22	Shares Out. (9/11/2023)	4,830,417
Previous Close	3.97	Float (%)	90.35
Day High/Low	4.21867 / 4.13124	Inst. Ownership (%)	0.01
52 wk High/Low	9.83628 / 3.46091	Shares Sold Short	NA
Beta 3Y	1.22	Short Int/ShOut (%)	NA
Market Cap. (\$M)	19.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	20.1		



Status: Operating
Primary Industry (CIQ/GICS): Diversified Metals and Mining

Officers & Directors	
Chairman of the Board	Michael "Mike" McLeod
President, CEO & Director	Jason Barnard
CFO & Corporate Secretary	Baljinder K. Bhullar

Capitalization	
Reported Currency Code	CAD
Closing Price	3.97
Ordinary Shares Outstanding (actual)	4,830,417
Market Capitalization	19,181
Cash & Short Term Investments	34
Total Debt	968
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	20,083
Total Common Equity	7,537
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	968
Total Capital	8,505

Multiples 2023 FY	
Period Ended	03/30/2023
Price/ EPS (x)	22.71
TEV/ Total Revenue (x)	NA
TEV/ EBITDA (x)	NA
Price/ Book (x)	2.08



Forza X1, Inc. (NASDAQCM:FRZA) | Public Company

3101 S. US-1 | Fort Pierce, FL 34982 | USA | (772) 429-2525 | www.forzax1.com

Forza X1, Inc. focuses on designing, developing, and manufacturing electric boats in the United States. It intends to offer its products through a vertically integrated direct-to-consumer system. Forza X1, Inc. was incorporated in 2021 and is headquartered in Fort Pierce, Florida. Forza X1, Inc. is a subsidiary of Twin Vee Powercats Co. As of Date: 4/18/2023

Key Statistics	Last 5 Yr	2021 FY	2022 FY	2023 FY E	2024 FY E
	Trend	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	12,000
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	(2.71)
Net Income Margin (%)		NA	NA	NA	0.11
Diluted EPS Excl. Extra Items		(0.07)	(0.44)	(0.35)	NA
Diluted EPS Before Extra, 1 Year Growth (%)		NA	NM	NA	NA


Estimates	Multiples	2022 FY	2023 FY E
Period Ended		12/30/2022	12/30/2023
Price/ EPS (x)		NM	NM
TEV/ Total Revenue (x)		NA	NA
TEV/ EBITDA (x)		NM	NA
Price/ Book (x)		0.55	NA

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Twin Vee PowerCats Inc.	7,000,000.00	44.35	5.0
Sabby Management LLC	393,411.00	2.49	0.3
AWM Investment Co. Inc	334,410.00	2.12	0.2
Lynwood Capital Management Inc.	200,000.00	1.27	0.1
Joseph C. Visconti	70,000.00	0.44	0.1


Market Data NASDAQCM:FRZA \$0.72 0.70% \$0.01			
Last (Delayed)	0.72	Avg Daily Volume	56,189
VWAP (Delayed)	0.71	Avg 3M Daily Volume	164,783
Open	0.75	Shares Out. (8/28/2023)	15,784,000
Previous Close	0.72	Float (%)	54.92
Day High/Low	0.7499 / 0.68	Inst. Ownership (%)	6.24
52 wk High/Low	3.98 / 0.7008	Shares Sold Short	86,297
Beta 3Y	NA	Short Int/ShOut (%)	0.55
Market Cap. (\$M)	11.4	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(4.8)		

Status: Operating Subsidiary
Primary Industry (CIQ/GICS): Leisure Products

Officers & Directors	
Executive Chairman of the Board & Chief...	Joseph C. Visconti
President, CEO & Director	Jim Leffew
CFO and Interim Principal Financial & ...	Carrie L. Gunnerson



Capitalization	
Reported Currency Code	USD
Closing Price	0.72
Ordinary Shares Outstanding (actual)	15,784,000
Market Capitalization	11,286
Cash & Short Term Investments	16,516
Total Debt	301
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(4,930)
Total Common Equity	17,824
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	301
Total Capital	18,125




GreenPower Motor Company Inc. (NASDAQ:GP) | Public Company

209 Carrall Street | Suite 240 | Vancouver, British Columbia V6B 2J2 | Canada | (604) 563-4144 | www.greenpowermotor.com

GreenPower Motor Company Inc. designs, manufactures, and distributes electric vehicles for commercial markets in the United States and Canada. The company offers commercial vehicles for delivery, public transit, schools, vanpools, micro-transit, shuttles, and other; and passenger, student, low floor transit, and cargo transportation. It leases its vehicles to customers. GreenPower Motor Company Inc. was founded in 20... As of Date: 7/14/2023

Key Statistics	Last 5 Yr	2021 FY	2022 FY	2023 FY	2024 FY E	2025 FY E
	Trend	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Total Revenue		13,286	17,237	39,696	83,473	121,585
Total Revenues, 1 Year Growth (%)		(7.72)	29.74	130.3	110.28	45.66
Gross Profit Margin (%)		26.95	22.49	18.26	16.8	19.05
EBITDA Margin (%)		(41.86)	(78.46)	(30.4)	3.08	5.32
EBIT Margin (%)		(45.15)	(82.3)	(33.47)	(7.76)	0.7
Net Income Margin (%)			(58.98)	(87.08)	(37.9)	(6.47)
			0.26			
Diluted EPS Excl. Extra Items		(0.43)	(0.69)	(0.64)	NA	NA
Diluted EPS Before Extra, 1 Year Growth (%)		27.84	58.6	(6.78)	NA	NA



Top Holders			
Holder	Common Stock	% of Total Shares Outstanding	Market Value(mm)
David George Richardson	2,873,097.00	11.52	8.6
Fraser Atkinson	2,098,267.00	8.41	6.3
Koko Financial Services Ltd.	804,854.00	3.23	2.4
Malcolm Frank Clay	604,129.00	2.42	1.8
Axxcess Wealth Management LLC	120,411.00	0.48	0.4

Market Data TSXV:GPV \$3.11 3.63% \$0.11			
Last (Delayed)	3.11	Avg Daily Volume	2,432
VWAP (Delayed)	3.09	Avg 3M Daily Volume	11,971
Open	3.02	Shares Out. (8/11/2023)	24,948,305
Previous Close	3.01	Float (%)	73.56
Day High/Low	3.15563 / 3.01748	Inst. Ownership (%)	1.34
52 wk High/Low	5.08972 / 1.65052	Shares Sold Short	NA
Beta 3Y	2.20	Short Int/ShOut (%)	NA
Market Cap. (\$M)	74.9	Div. Yield (%)	NA
Total Enterprise Value (\$M)	82.0		



Status: Operating
Primary Industry (CIQ/GICS): Construction Machinery and Heavy Transportation Equipment
Topic Tags: ClimateTech, Electric Vehicle

Officers & Directors	
Executive Chairman & CEO	Fraser Atkinson
President & Director	Brendan Riley
CFO & Secretary	Michael Sieffert

Debt Maturity: No data available

Capitalization	
Reported Currency Code	USD
Closing Price	3.01
Ordinary Shares Outstanding (actual)	24,948,305
Market Capitalization	75,074
Cash & Short Term Investments	1,453
Total Debt	8,789
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	82,152
Total Common Equity	26,204
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	8,789
Total Capital	34,994



Multiples		2023 FY	2024 FY E
Period Ended		03/30/2023	03/30/2024
Price/ EPS (x)		NM	NA
TEV/ Total Revenue (x)		2.27	0.98
TEV/ EBITDA (x)		NM	31.98
Price/ Book (x)		2.69	NA



Holder Resources | Private Company

1024 Iron Point Rd Folsom, CA 95630

Building upon its 30-year strategic network in the region, Holder Resources, Inc (HRI) has evolved into a key player in both gold mining and sustainable logging in Guyana, utilizing innovative sustainability initiatives to prioritize both community and conservation. Guyana is a vibrant South American nation characterized by its lush rainforests, pristine rivers, and diverse cultural heritage. Located on the northeastern coast of the continent, it is the only English-speaking country in South America.

Status	Operating
Primary Industry (CIQ/GICS)	Metals & Logging
Topic Tags	Gold Mining, Gold, Opportunity, Guyana, Logging, Exotic Woods, & Sustainable Logging
Categories	Alluvial Gold Mining & Exotic Timber

Officers & Directors

CEO	Lance Misleau
COO	Caleb Ramsey
CFO	Todd Wille



Phone
+1 800-674-3340



HYDROGRAPH

HydroGraph Clean Power Inc. (CNSX:HG) | Public Company

1 King Street | Suite 4800-118 | Toronto, Ontario M5H 1A1 | Canada | www.hydrograph.com

HydroGraph Clean Power Inc. engages in the acquisition and development of graphene and hydrogen related products and services. It offers patented technology to produce graphene, hydrogen, syngas, and other products. The company was formerly known as Carbon-2D Graphene Inc and changed its name to HydroGraph Clean Power Inc. in March 2021.

HydroGraph Clean Power Inc. was incorporated in 2017 and is based in Toronto, Ca... *As of Date: 1/30/2023*

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Richmond Bridge Capital Ltd.	1,500,000.00	0.86	0.1
Stuart Raul Jara	1,250,000.00	0.72	0.1
Robert J. Wowk	1,000,000.00	0.57	0.1
David Morris	600,000.00	0.34	0.0
Kjirstin Breure	450,000.00	0.26	0.0

Market Data CNSX:HG \$0.06			
Last (Delayed)	0.06	Avg Daily Volume	5,480
VWAP (Delayed)	0.06	Avg 3M Daily Volume	104,153
Open	0.06	Shares Out. (4/26/2023)	174,775,224
Previous Close	0.06	Float (%)	97.10
Day High/Low	0.058289 / 0.058289	Inst. Ownership (%)	NA
52 wk High/Low	0.163938 / 0.051003	Shares Sold Short	NA
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	10.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	NA		



Status: Operating

Primary Industry (CIQ/GICS): Commodity Chemicals

Officers & Directors

CEO & Director	Stuart Raul Jara
President & Director	Kjirstin Breure
CFO & Corporate Secretary	Robert J. "Bob" Wowk

Stock Chart



Estimates





Immix Biopharma, Inc. (NASDAQCM:IMMX) | Public Company

11400 West Olympic Boulevard | Suite 200 | Los Angeles, CA 90064 | USA | (310) 651-8041 | www.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific... *As of Date: 4/18/2023*

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FY E 12/31/2023	2024FY E 12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(0.34)	(6.64)	(0.59)	(0.87)	(0.84)
Diluted EPS Before Extra, 1 Year Growth (%)		17.99	NM	(91.07)	NA	NA

Estimates	Multiples	2022 FY 12/30/2022	2023FYE 12/30/2023
Price/ EPS (x)		NM	NM
TEV/ Total Revenue (x)		NA	NA
TEV/ EBITDA (x)		NM	NA
Price/ Book (x)		4.82	NA

Top Holders	Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
	Veritas Liberabit Vos LLC	3,915,913.00	19.90	17.9
	Yekaterina Chudnovsky	3,241,076.00	16.47	14.8
	Mesa Verde Venture Partners	1,025,221.00	5.21	4.7
	Vladimir P. Torchilin	905,200.00	4.60	4.1
	Ilya Rachman	902,493.00	4.59	4.1


Market Data NASDAQCM:IMMX \$4.46 (2.14%) (\$0.10)			
Last (Delayed)	4.46	Avg Daily Volume	245,120
VWAP (Delayed)	4.49	Avg 3M Daily Volume	179,757
Open	4.78	Shares Out. (9/25/2023)	19,681,091
Previous Close	4.56	Float (%)	39.94
Day High/Low	4.82 / 4.15	Inst. Ownership (%)	4.59
52 wk High/Low	4.7999 / 0.68	Shares Sold Short	71,896
Beta 3Y	NA	Short Int/ShOut (%)	0.44
Market Cap. (\$M)	90.1	Div. Yield (%)	NA
Total Enterprise Value (\$M)	77.4		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Chronic Diseases, Gastroenterology, Immunology, Inflammation, Oncology, Rheumatology, Cancer

Officers & Directors	
Co-Founder, CEO & Chairman	Ilya Rachman
Co-Founder	Sean Senn
Scientific Co-Founder	Vladimir P. Torchilin

Capitalization	
Reported Currency Code	USD
Closing Price	4.56
Ordinary Shares Outstanding (actual)	19,681,091
Market Capitalization	89,746
Cash & Short Term Investments	12,654
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	(57)
Total Enterprise Value (TEV)	77,035
Total Common Equity	13,227
Total Preferred Equity	NA
Total Capital	13,171



Immunophotonics, Inc. | Private Company

4340 Duncan Ave. BioGenerator Labs Suite 212 | Saint Louis, MO 63110 | USA

Immunophotonics, Inc. operates as a biotechnology company that engages in the development of a drug product for use in an in situ autologous cancer vaccine for the treatment of metastatic solid tumor cancers. The company develops IP-001, which transforms a routine tumor ablation into systemically active cancer immunotherapy. The company was incorporated in 2012 and is based in Saint Louis, Missouri with an additional...

Corporate Data	
Status	Operating
Primary Industry (CIQ/GICS)	Biotechnology
Topic Tags	Chronic Diseases, Immunology, Oncology, Vaccines, Cancer, Immunotherapy, Tumor
Categories ¹	Biotechnology, Life Science
Date of Incorporation	07/17/2012
SIC Code	2836
NACE Code	21.20 - Manufacture of pharmaceutical preparations
NAICS Code	325412 - Pharmaceutical Preparation Manufacturing
U.S. Number Of Employees 2022	2
U.S. Number Of Employees 2021	1
U.S. Latest Employee Growth %	100.00



Officers & Directors	
Chairman of the Board	Bobby W. Sandage Jr.
Co-Founder, CEO & Director	Luciano Alleruzzo
Co-Founder, Chief Innovation Officer, President & Director	Tomas Hode

Funding Overview	
Summary	24.54 (\$M) Raised in 4 Disclosed Rounds by 6 Investors.
Total Funding	It has been 8 Months since the last funding round.

Announced Date	Round Type	Round Number	Size (\$000)	Pre-Money (\$M)	Post-Money (\$M)
2/14/2023	Mature	7	NA	NA	NA
10/9/2019	Series B	6	21,400	NA	NA
6/1/2018	Venture	5	NA ¹	NA	NA
12/28/2015	Venture	4	NA	NA	NA
9/3/2014	Venture	3	2,487	NA	NA
6/28/2011	Pre-Seed	2	100 ¹	NA	NA
4/27/2010	Pre-Seed	1	550 ¹	NA	NA

*This number reflects the estimated value of the total new money raised through private placement rounds.

Current/Pending Investors				
INVESTOR	INITIAL INVESTMENT DATE	LAST INVESTMENT DATE	STAKE TYPE	AGGREGATE LATEST AMOUNT INVESTED (\$000)
ROVAQ Ventures, LLC	Apr-06-2022	Apr-06-2022	Minority	NA Series B
Zubizoom LLC	Apr-06-2022	Apr-06-2022	Unknown	NA Series B
iSelect Fund Management, LLC	Dec-28-2015	Apr-06-2022	Unknown	NA Series B
BioGenerator Ventures	Jan-21-2015	Jan-21-2015	Minority	NA Venture
Cultivation Capital, LLC	Jan-21-2015	Jan-21-2015	Minority	NA Venture



IperionX Limited (ASX:IPX) | Public Company

129 West Trade Street | Suite 1405 | Charlotte, NC 28202 | USA | (980) 237-8900 | iperionx.com

IperionX Limited engages in exploration and development of its mineral properties in the United States. It holds a 100% interest in the critical minerals Titan project, which has the resource of titanium, rare earth, and zircon rich mineral sands covering approximately 11,071 acres of surface and associated mineral rights in Tennessee, the United States. The company also produces titanium products made from scrap tit... As of Date: 9/18/2023

Key Statistics	Last 5 Yr	2021 FY	2022 FY	2023 FY	2024 FY E
	Trend	6/30/2021	6/30/2022	6/30/2023	6/30/2024
Total Revenue		NA	NA	NA	8,500
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	42.94
Net Income Margin (%)		NA	NA	NA	(33.53)
Diluted EPS Excl. Extra Items		(0.21)	(0.16)	(0.1)	NA
Diluted EPS Before Extra, 1 Year Growth (%)		NM	(23.74)	(35.11)	NA

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
BNY Asset Management	27,071,540.00	13.90	23.9
Fidelity International Ltd.	18,974,648.00	9.74	16.7
FMR LLC	16,789,000.00	8.62	14.8
Todd William Hannigan	14,479,717.00	7.44	12.8
B. Riley Capital Management LLC	14,395,000.00	7.39	12.7

Market Data ASX:IPX \$0.88 (2.78%) (\$0.03)		
Last (Delayed)	Avg Daily Volume	305,522
0.88	Avg 3M Daily Volume	239,841
VWAP (Delayed)	Shares Out. (8/8/2023)	194,718,973
0.88	Float (%)	86.52
Open	Inst. Ownership (%)	41.42
0.90	Shares Sold Short	NA
Previous Close	Short Int/ShOut (%)	NA
0.91	Div. Yield (%)	NA
Day High/Low 0.881168		
52 wk High/Low 1.05111 / 0.409114		
Beta 3Y		
1.50		
Market Cap. (\$M)		
171.6		
Total Enterprise Value (\$M)		
161.2		

Status: Operating
Primary Industry (CIQ/GICS): Precious Metals and Minerals

Officers & Directors	
Executive Chairman	Todd William "Tom" Hannigan
Founder, MD, CEO & Executive Director	Anastasios "Taso" Arima
President & Chief Strategy Officer	Toby Edgcumbe Symonds

Capitalization	
Reported Currency Code	USD
Closing Price	0.88
Ordinary Shares Outstanding (actual)	194,718,973
Market Capitalization	171,580
Cash & Short Term Investments	11,938
Total Debt	975
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	161,213
Total Common Equity	20,563
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	975
Total Capital	21,539



Multiples	2023 FY	2024 FY E
Period Ended	06/29/2023	06/29/2024
Price/ EPS (x)	NM	NA
TEV/ Total Revenue (x)	NA	18.97
TEV/ EBITDA (x)	NM	NA
Price/ Book (x)	8.31	NA




iSun, Inc. (NASDAQM:ISUN) | Public Company

400 Avenue D | Suite 10 | Williston, VT 05495 | USA | (802) 658-3378 | www.isunenergy.com

iSun, Inc., a solar energy company, provides design, development, engineering, procurement, installation, storage, and electric vehicle infrastructure services for residential, commercial, industrial, and utility customers in the United States. It also provides electrical contracting services; and data and communication services. The company was formerly known as The Peck Company Holdings, Inc. and changed its name t... As of Date: 4/20/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023 FY E	2024 FY E
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		21,052	45,312	76,453	100,356	115,809
Total Revenues, 1 Year Growth (%)		(25.4)	115.24	68.73	31.27	15.4
Gross Profit Margin (%)		11.13	14.1	20.89	22.33	23.07
EBITDA Margin (%)		(5.22)	(18.53)	(14.63)	(0.12)	3.02
EBIT Margin (%)		(8.01)	(20.7)	(23.88)	(4.32)	(0.01)
Net Income Margin (%)		(4.66)	(13.77)	(70.34)	(6.19)	(1.19)
Diluted EPS Excl. Extra Items		(0.24)	(0.68)	(3.82)	(0.32)	(0.05)
Diluted EPS Before Extra, 1 Year Growth (%)		NM	187.61	NM	(76.65)	(83.16)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023 FY E
EPS (\$)	(0.32)	(0.05)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	0.30	0.19
			TEV/ EBITDA (x)	NM	NM
			Price/ Book (x)	0.17	NA



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders			
Holder	Common Stock	% of Total Shares Outstanding	Market Value(mm)
Jeffrey Peck	1,613,055.00	4.88	0.4
Ceyhun Demiralp	1,000,000.00	3.02	0.2
Frederick A. Myrick Jr.	744,158.00	2.25	0.2
Sass M. Peress	491,500.00	1.49	0.1
Vanguard Group Inc.	339,799.00	1.03	0.1

Market Data NASDAQM:ISUN \$0.22 1.28% \$0.00			
Last (Delayed)	0.22	Avg Daily Volume	713,872
VWAP (Delayed)	0.21	Avg 3M Daily Volume	833,849
Open	0.22	Shares Out. (9/8/2023)	33,068,512
Previous Close	0.22	Float (%)	84.46
Day High/Low	0.23 / 0.203	Inst. Ownership (%)	7.54
52 wk High/Low	2.555 / 0.203	Shares Sold Short	1,382,372
Beta 3Y	1.36	Short Int/ShOut (%)	4.49
Market Cap. (\$M)	7.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	18.8		

Status: Operating
Primary Industry (CIQ/GICS): Construction and Engineering
Topic Tags: ClimateTech, Clean Energy, Electric Vehicle

Officers & Directors	
CEO, President & Chairman	Jeffrey Peck
Chief Financial Officer	John Patrick Sullivan
Chief Strategy Officer	Michael D'Amato

Debt Maturity	
	No data available
Capitalization	
Reported Currency Code	USD
Closing Price	0.22
Ordinary Shares Outstanding (actual)	33,068,512
Market Capitalization	7,242
Cash & Short Term Investments	6,105
Total Debt	17,666
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	18,803
Total Common Equity	20,561
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	17,666
Total Capital	38,227






Jackpot Digital Inc. (TSXV:JJ) | Public Company

570 Granville Street | Suite 303 | Vancouver, British Columbia V6C 3P1 | Canada | (604) 681-0204 | www.jackpotdigital.com

Jackpot Digital Inc. develops, markets, and leases electronic table games to casino operators. It offers multiplayer gaming products, such as poker and casino games to the cruise ship and regulated casino industries. The company also develops and licenses iGaming platform with HTML5 poker, casino, and bingo games. Its iGaming platform offers remote gaming systems, including poker platform that offers poker games, suc... *As of Date: 6/1/2023*

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY
		12/31/2020	12/31/2021	12/31/2022
Total Revenue		456	335	1,100
Total Revenues, 1 Year Growth (%)		(71.93)	(31.33)	240.97
Gross Profit Margin (%)		51.16	47.44	74.55
EBITDA Margin (%)		(274.12)	NM	(192.9)
EBIT Margin (%)		NM	NM	(231.98)
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(0.18)	(0.07)	(0.04)
Diluted EPS Before Extra, 1 Year Growth (%)		24.19	(61.78)	(48.96)

Revenue by Business and Geographic Segments



Multiples	2022 FY
Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	13.19
TEV/ EBITDA (x)	NM
Price/ Book (x)	NM

Top Holders

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
AlphaNorth Asset Management	18,181,838.00	10.11	1.0
Jacob Hagop Kalpakian	1,265,743.00	0.70	0.1
Bedo H. Kalpakian	875,334.00	0.49	0.0
30 Rock Management Inc	363,500.00	0.20	0.0
AI Artificial Intelligence Ventures Inc.	250,000.00	0.14	0.0

Market Data TSXV:JJ \$0.05

15.38% \$0.01

Last (Delayed)	0.05	Avg Daily Volume	2,200
VWAP (Delayed)	0.05	Avg 3M Daily Volume	62,878
Open	0.05	Shares Out. (8/29/2023)	179,792,002
Previous Close	0.05	Float (%)	88.37
Day High/Low	0.054646 / 0.054646	Inst. Ownership (%)	0.14
52 wk High/Low	0.069218 / 0.032788	Shares Sold Short	NA
Beta 3Y	0.80	Short Int/ShOut (%)	NA
Market Cap. (\$M)	9.8	Div. Yield (%)	NA
Total Enterprise Value (\$M)	13.8		



Status: Operating


Primary Industry (CIQ/GICS): Casinos and Gaming

Topic Tags: Entertainment Systems, Network Security, Web Development, Casino Operator, Casino Operators, Slot M...

Officers & Directors

Co-Founder, President & CEO	Jacob Hagop "Jake" Kalpakian
Chief Financial Officer	Neil Spellman
Chief Strategy Officer	Angelo Palmisano

Debt Maturity



Capitalization

Reported Currency Code	CAD
Closing Price	0.05
Ordinary Shares Outstanding (actual)	179,792,002
Market Capitalization	9,825
Cash & Short Term Investments	83
Total Debt	4,185
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	13,783
Total Common Equity	(6,686)
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	4,185
Total Capital	(2,501)

Stock Chart



KWESST Micro Systems Inc. (NASDAQ:KWE) | Public Company

155Terence Matthews Crescent | Unit No. 1 | Ottawa, Ontario K2M 2A8 | Canada | www.kwesst.com

KWESST Micro Systems Inc. engages in the development and commercialization of tactical systems and ammunitions for military, public safety agencies, and personal defense markets. It provides non-lethal products, including non-reciprocating and reciprocating PARA OPS devices and ARWEN products with application in the professional and personal defense; modernized digitization products and services of tactical teams for... *As of Date: 2/1/2023*


Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY	2023FYE
		9/30/2020	9/30/2021	9/30/2022	9/30/2023
Total Revenue		644	1,010	565	767
Total Revenues, 1 Year Growth (%)		NA	47.38	(43.45)	42.62
Gross Profit Margin (%)		70.54	37.38	25.61	43
EBITDA Margin (%)		NM	NM	NM	NA
EBIT Margin (%)		NM	NM	NM	NM
Net Income Margin (%)		NM	NM	NM	NA
Diluted EPS Excl. Extra Items		(7.79)	(11.65)	(11.28)	NA
Diluted EPS Before Extra, 1 Year Growth (%)		NA	40.6	(2.12)	NA

Estimates



Multiples	2022 FY	2023FY E
Period Ended	09/29/2022	09/29/2023
Price/ EPS (x)	NM	NA
TEV/ Total Revenue (x)	21.21	11.15
TEV/ EBITDA (x)	NM	NA
Price/ Book (x)	NM	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Holder	Common Stock	of Total Shares Outstanding	Market Value(mm)
		% Equivalent Held	
Martin Chopp	559,000.00	9.95	0.9
Aigh Capital Management LLC	556,175.00	9.90	0.9
Globis Capital Management, LLC	262,893.00	4.68	0.4
Jeffrey Dean MacLeod	141,361.00	2.52	0.2
SOL Global Investments Corp.	119,250.00	2.12	0.2

Market Data TSXV:KWE \$1.68

Last (Delayed)	1.68	Avg Daily Volume	0
VWAP (Delayed)	NA	Avg 3M Daily Volume	1,763
Open	NA	Shares Out. (8/14/2023)	5,616,782
Previous Close	1.68	Float (%)	76.16
Day High/Low	NA / 1.67581	Inst. Ownership (%)	7.86
52 wk High/Low	6.37537 / 1.44994	Shares Sold Short	NA
Beta 3Y	1.13	Short Int/ShOut (%)	NA
Market Cap. (\$M)	9.4	Div. Yield (%)	NA
Total Enterprise Value (\$M)	8.4		



Status: Operating

Primary Industry (CIQ/GICS): Aerospace and Defense

Officers & Directors

Executive Chairman	David E. Luxton
Founder, President, CEO & Director	Jeffrey Dean MacLeod
CFO & Chief Compliance Officer	Sean Homuth

Capitalization

Reported Currency Code	CAD
Closing Price	1.68
Ordinary Shares Outstanding (actual)	5,616,782
Market Capitalization	9,458
Cash & Short Term Investments	1,329
Total Debt	235
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	8,397
Total Common Equity	2,740
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	235
Total Capital	2,975

Stock Chart





Lantern Pharma Inc. (NASDAQCM:LTRN) | Public Company

1920 McKinney Avenue | 7th Floor | Dallas, TX 75201 | USA | (972) 277-1136 | www.lanternpharma.com

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284,... As of Date: 4/17/2023

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FY E 12/31/2023	2024FY E 12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(1.37)	(1.13)	(1.31)	(1.78)	(2.53)
Diluted EPS Before Extra, 1 Year Growth (%)		11.81	(17.39)	15.92	NA	NA

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY 12/30/2022	2023FYE 12/30/2023
EPS (\$)	(1.78)	(2.53)	Period Ended	12/30/2022	12/30/2023
RECOMMENDATION	3.00 - Hold		Price/ EPS (x)	NM	NM
TEV/ Total Revenue (x)			TEV/ Total Revenue (x)	NA	NA
TEV/ EBITDA (x)			TEV/ EBITDA (x)	NM	NA
Price/ Book (x)			Price/ Book (x)	0.58	NA

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Holder			
Bios Equity Partners LP	1,533,018.00	14.10	4.6
Biological Mimetics, Inc.	944,458.00	8.69	2.8
ProPhase Labs Inc.	910,000.00	8.37	2.7
Vanguard Group Inc.	367,454.00	3.38	1.1
NewEdge Advisors LLC	171,465.00	1.58	0.5

Market Data NASDAQCM:LTRN \$3.01			
Last (Delayed)	3.01	Avg Daily Volume	5,386
VWAP (Delayed)	3.04	Avg 3M Daily Volume	36,007
Open	3.10	Shares Out. (8/9/2023)	10,869,040
Previous Close	3.01	Float (%)	68.43
Day High/Low	3.1 / 3	Inst. Ownership (%)	10.86
52 wk High/Low	6.2 / 2.99	Shares Sold Short	155,186
Beta 3Y	1.05	Short Int/ShOut (%)	1.43
Market Cap. (\$M)	33.7	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(13.9)		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Artificial Intelligence, Chronic Diseases, Hematology, Machine Learning, Oncology, Pulmonology, Gen...

Officers & Directors	
Chairman of the Board	Donald Jeffrey "Jeff" Keyser
President, CEO & Director	Panna Sharma
Co-Founder & Advisor	Peter L. Nara

Capitalization	
Reported Currency Code	USD
Closing Price	3.01
Ordinary Shares Outstanding (actual)	10,869,040
Market Capitalization	32,716
Cash & Short Term Investments	47,949
Total Debt	314
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(14,919)
Total Common Equity	48,259
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	314
Total Capital	48,573




LiveOne, Inc. (NASDAQCM:LVO) | Public Company

269 South Beverly Drive | Suite 1450 | Beverly Hills, CA 90212 | USA | (310) 601-2505 | www.liveone.com

LiveOne, Inc., a digital media company, engages in the acquisition, distribution, and monetization of live music, Internet radio, podcasting/vodcasting, and music-related streaming and video content. It operates LiveXLive, a live music streaming platform; PodcastOne, a podcasting platform; and Slacker, an integrated membership and advertising streaming music service, as well as produces original music-related content... As of Date: 8/14/2023

Key Statistics	Last 5 Yr Trend	2021 FY 3/31/2021	2022 FY 3/31/2022	2023 FY 3/31/2023	2024FYE 3/31/2024	2025FYE 3/31/2025
Total Revenue		65,230	117,019	99,611	125,663	152,565
Total Revenues, 1 Year Growth (%)		68.73	79.39	(14.88)	26.15	21.41
Gross Profit Margin (%)		24.9	20.54	32.96	29.55	30
EBITDA Margin (%)		(31.58)	(24.12)	7.17	10.58	14.13
EBIT Margin (%)		(45.03)	(32.35)	(0.83)	3.34	7.88
Net Income Margin (%)		(64.11)	(37.53)	(10.06)	0.23	6.52
Diluted EPS Excl. Extra Items		(0.61)	(0.56)	(0.12)	NA	0.1
Diluted EPS Before Extra, 1 Year Growth (%)		(12.54)	(8.33)	(78.71)	(100)	NA

Estimates	Current Year ('24)	Next Year ('25)	Multiples	2023 FY 03/30/2023	2024FYE 03/30/2024
EPS (\$)	0.00	0.10	Period Ended	03/30/2023	03/30/2024
RECOMMENDATION	1.33 - Buy		Price/ EPS (x)	NM	NA
TEV/ Total Revenue (x)			TEV/ Total Revenue (x)	1.05	0.85
TEV/ EBITDA (x)			TEV/ EBITDA (x)	13.50	7.99
Price/ Book (x)			Price/ Book (x)	NM	NA



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts


Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value(mm)
Robert S. Ellin	8,907,476.00	10.21	8.2
Trinad Management LLC	7,539,899.00	8.64	6.9
FMR LLC	6,932,900.00	7.95	6.4
Vanguard Group Inc.	2,676,757.00	3.07	2.5
Rho Capital Partners Inc.	1,756,899.00	2.01	1.6

Market Data NASDAQCM:LVO \$0.90 (1.89%) (\$0.02)			
Last (Delayed)	0.90	Avg Daily Volume	136,974
VWAP (Delayed)	0.89	Avg 3M Daily Volume	299,143
Open	0.91	Shares Out. (8/15/2023)	87,222,986
Previous Close	0.92	Float (%)	79.89
Day High/Low	0.92 / 0.8401	Inst. Ownership (%)	21.85
52 wk High/Low	2.19 / 0.483	Shares Sold Short	2,129,674
Beta 3Y	1.39	Short Int/ShOut (%)	2.44
Market Cap. (\$M)	80.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	106.5		



Status: Operating
Primary Industry (CIQ/GICS): Movies and Entertainment
Topic Tags: Digital Media, Music Streaming, Podcast, Video Streaming, Digital Media Company, Media Company, Mus...

Officers & Directors	
Founder, Chairman & CEO	Robert S. Ellin
President	Dermot A. McCormack
Interim CFO, Executive VP, Controller,...	Aaron Sullivan



Capitalization	
Reported Currency Code	USD
Closing Price	0.92
Ordinary Shares Outstanding (actual)	87,222,986
Market Capitalization	80,010
Cash & Short Term Investments	4,990
Total Debt	10,226
Total Preferred Equity	21,004
Total Minority Interest	NA
Total Enterprise Value (TEV)	106,250
Total Common Equity	(18,467)
Total Preferred Equity	21,004
Total Minority Interest	NA
Total Debt	10,226
Total Capital	12,763





LuxUrban Hotels Inc. (NASDAQCM:LUXH) | Public Company


2125 Biscayne Boulevard | Suite 253 | Miami, FL 33137 | USA | (833) 723-7368 | www.luxurbanhotels.com

LuxUrban Hotels Inc. utilizes a long-term lease, asset-light business model to acquire and manage a growing portfolio of short-term rental properties in major metropolitan cities. The Company's future growth focuses primarily on seeking to create "win-win" opportunities for owners of dislocated hotels, including those impacted by COVID-19 travel restrictions, while providing LuxUrban Hotels favorable operating margin... As of Date: 7/2/2023

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FYE 12/31/2023	2024FYE 12/31/2024
Total Revenue		11,340	21,380	43,825	127,385	226,016
Total Revenues, 1 Year Growth (%)		108.71	88.53	104.98	190.67	77.43
Gross Profit Margin (%)		0.95	9.87	28.24	30.77	34.47
EBITDA Margin (%)		NA	NA	6.94	21.74	25.96
EBIT Margin (%)		(8.81)	(3.43)	6.92	14.04	18.84
Net Income Margin (%)		(40.7)	(10.45)	(21.43)	6.48	16.07
Diluted EPS Excl. Extra Items		NA	(0.1)	(0.4)	0.22	0.86
Diluted EPS Before Extra, 1 Year Growth (%)		NA	NA	288.91	NM	290.91

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FYE
EPS (\$)	0.22	0.86	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	21.59
			TEV/ Total Revenue (x)	6.21	2.80
			TEV/ EBITDA (x)	18.83	12.86
			Price/ Book (x)	NM	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Holder	Common Stock	of Total Shares Outstanding	Market Value(mm)
Brian Ferdinand	16,205,628.00	45.04	77.0
Greenle Partners Llc Series Alpha P.S.	3,019,747.00	8.39	14.3
Goudy Park Capital	2,484,796.00	6.91	11.8
Edward Rogers	1,840,300.00	5.11	8.7
Jimmie Chatmon	1,613,000.00	4.48	7.7

Market Data NASDAQCM:LUXH \$5.14	8.25% \$0.39		
Last (Delayed)	5.14	Avg Daily Volume	279,975
VWAP (Delayed)	5.05	Avg 3M Daily Volume	88,049
Open	4.78	Shares Out. (9/1/2023)	35,981,674
Previous Close	4.75	Float (%)	21.08
Day High/Low	5.2836 / 4.7473	Inst. Ownership (%)	1.22
52 wk High/Low	4.85 / 1.24	Shares Sold Short	18,596
Beta 3Y	NA	Short Int/ShOut (%)	0.05
Market Cap. (\$M)	170.8	Div. Yield (%)	NA
Total Enterprise Value (\$M)	356.0		



Status: Operating
Primary Industry (CIQ/GICS): Real Estate Operating Companies
Topic Tags: COVID-19, Infectious Diseases, Respiratory, Vaccines

Officers & Directors	
CEO & Chairman	Brian Ferdinand
CFO, President & Secretary	Shanoop Kothari
Executive VP, COO & Executive Director	Jimmie Chatmon

Capitalization	
Reported Currency Code	USD
Closing Price	4.75
Ordinary Shares Outstanding (actual)	35,981,674
Market Capitalization	170,913
Cash & Short Term Investments	3,778
Total Debt	188,944
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	356,080
Total Common Equity	13,448
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	188,944
Total Capital	202,392



MAIA Biotechnology, Inc. (NYSEAM:MAIA) | Public Company

444 West Lake Street | Suite 1700 | Chicago, IL 60606 | USA | (312) 416-8592 | www.MAIBiotech.com

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnolog... As of Date: 6/9/2023

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FY E 12/31/2023	2024FY E 12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(1.5)	(2.37)	(1.75)	(1.51)	(1.32)
Diluted EPS Before Extra, 1 Year Growth (%)		(12.96)	58.02	(26.19)	(14.16)	(12.58)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FYE
EPS (\$)	(1.51)	(1.32)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NA	NA
			TEV/ EBITDA (x)	NA	NM
			Price/ Book (x)	3.02	NA

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Vlad Vitoc	1,019,121.00	7.45	2.4
Ngar Yee Louie	976,584.00	7.14	2.3
Jerry W. Shay	700,000.00	5.12	1.6
Stan V. Smith	686,628.00	5.02	1.6
Frank Perabo	492,544.00	3.60	1.2

Market Data NYSEAM:MAIA \$2.15 (8.45%) (\$0.20)			
Last (Delayed)	2.15	Avg Daily Volume	74,007
VWAP (Delayed)	2.22	Avg 3M Daily Volume	51,206
Open	2.32	Shares Out. (9/1/2023)	13,680,925
Previous Close	2.35	Float (%)	63.44
Day High/Low	2.38 / 2.1	Inst. Ownership (%)	2.33
52 wk High/Low	5.22 / 1.42	Shares Sold Short	21,088
Beta 3Y	NA	Short Int/ShOut (%)	0.15
Market Cap. (\$M)	32.5	Div. Yield (%)	NA
Total Enterprise Value (\$M)	23.3		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Chronic Diseases, Oncology, Pulmonology, Cancer, Lung Cancer

Officers & Directors	
Co-Founder, President, CEO & Chairman ...	Vlad Vitoc
Chief Financial Officer	Joseph F. "Joe" McGuire
Chief Scientific Officer	Sergei M. Gryaznov

Capitalization	
Reported Currency Code	USD
Closing Price	2.35
Ordinary Shares Outstanding (actual)	13,680,925
Market Capitalization	32,150
Cash & Short Term Investments	9,146
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	23,004
Total Common Equity	6,874
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	6,874





Marpai, Inc. (NASDAQCM:MRAI) | Public Company

401 Park Avenue South | Floor 10 | New York, NY 10016 | USA | (855) 389-7330 | www.marpaihealth.com


Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, bill review and cost containment services. It also develops artificial intelligence and healthcare technology. Marpai, Inc. was i... *As of Date: 4/26/2023*

Status: Operating
Primary Industry (CIQ/GICS): Insurance Brokers
Topic Tags: Artificial Intelligence, Machine Learning

	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FYE 12/31/2023	2024FYE 12/31/2024
Total Revenue		NA	14,227	24,342	36,375	48,600
Total Revenues, 1 Year Growth (%)		NA	NA	71.1	49.43	NA
Gross Profit Margin (%)		NA	27.68	29.6	36.3	40
EBITDA Margin (%)		NA	(106.04)	(104.61)	(56.15)	(13.27)
EBIT Margin (%)		NA	(111.49)	(109.62)	(76.95)	(30.84)
Net Income Margin (%)		NA	(112.36)	(108.74)	(69.13)	(25.76)
Diluted EPS Excl. Extra Items		(6.37)	(6.35)	(5.23)	(2.45)	(1.12)
Diluted EPS Before Extra, 1 Year Growth (%)		25.92	(0.39)	(17.56)	(52.68)	(54.29)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(2.45)	(1.12)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NM	0.02
			TEV/ EBITDA (x)	NM	NM
			Price/ Book (x)	0.58	NA

Revenue by Business and Geographic Segments




* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value(mm)
WellEnterprises USA LLC	931,674.00	12.84	0.6
Damien Francis Lamendola	701,306.00	9.67	0.5
Sabby Management LLC	375,968.00	5.18	0.3
Edmundo Gonzalez	342,325.00	4.72	0.2
Lutz Finger	238,618.00	3.29	0.2

Market Data NASDAQCM:MRAI \$0.68 0.22% \$0.00			
Last (Delayed)	0.68	Avg Daily Volume	6,906
VWAP (Delayed)	0.67	Avg 3M Daily Volume	108,486
Open	0.68	Shares Out. (8/3/2023)	7,255,814
Previous Close	0.67	Float (%)	61.05
Day High/Low	0.68 / 0.658	Inst. Ownership (%)	3.61
52 wk High/Low	13.6 / 0.6184	Shares Sold Short	182,198
Beta 3Y	NA	Short Int/ShOut (%)	2.51
Market Cap. (\$M)	4.9	Div. Yield (%)	NA
Total Enterprise Value (\$M)	0.9		

Officers & Directors	
Co-Founder & Chairman of the Board	Yaron I. Eitan
Co-Founder, CEO, Secretary & Director	Edmundo Gonzalez
Co-Founder & Chief Science Advisor	Eli David

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	0.67
Ordinary Shares Outstanding (actual)	7,255,814
Market Capitalization	4,887
Cash & Short Term Investments	8,726
Total Debt	4,740
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	901
Total Common Equity	(2,669)
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	4,740
Total Capital	2,071

Stock Chart



Matinas BioPharma Holdings, Inc. (NYSEAM:MTNB) | Public Company

1545 Route 206 South | Suite 302 | Bedminster, NJ 07921 | USA | (908) 484-8805 | www.matinasbiopharma.com


Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product... *As of Date: 9/15/2023*

Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Allergy, Cardiovascular, Dermatology, Infectious Diseases, Vaccines, Genetics, Health Diagnostics

	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FY E 12/31/2023	2024FYE 12/31/2024
Total Revenue		158	33	3,188	1,100	NA
Total Revenues, 1 Year Growth (%)		76.29	(79.16)	NM	(65.5)	(100)
Gross Profit Margin (%)		NM	NM	NM	NA	NA
EBITDA Margin (%)		NM	NM	NM	NA	NA
EBIT Margin (%)		NM	NM	NM	NM	NA
Net Income Margin (%)		NM	NM	NM	NM	NA
Diluted EPS Excl. Extra Items		(0.12)	(0.11)	(0.1)	(0.12)	(0.14)
Diluted EPS Before Extra, 1 Year Growth (%)		(6.33)	(4.55)	(14.04)	20	16.67

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(0.12)	(0.14)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	0.63	7.25
			TEV/ EBITDA (x)	NM	NA
			Price/ Book (x)	0.73	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Holder	Common Stock Equivalent Held	% Total Shares of Outstanding	Market Value(mm)
Vanguard Group Inc.	8,720,418.00	4.01	1.1
Herbert J. Conrad	4,694,566.00	2.16	0.6
Sargent Investment Group LLC	3,923,000.00	1.81	0.5
BlackRock Inc.	2,507,699.00	1.15	0.3
Geode Capital Management LLC	1,958,952.00	0.90	0.2

Market Data NYSEAM:MTNB \$0.12 (0.08%) \$0.00

Last (Delayed)	0.12	Avg Daily Volume	203,071
VWAP (Delayed)	0.12	Avg 3M Daily Volume	721,245
Open	0.12	Shares Out. (9/19/2023)	217,264,526
Previous Close	0.12	Float (%)	96.89
Day High/Low	0.1276 / 0.119	Inst. Ownership (%)	12.11
52 wk High/Low	0.89 / 0.1103	Shares Sold Short	278,532
Beta 3Y	0.99	Short Int/ShOut (%)	0.13
Market Cap. (\$M)	27.1	Div. Yield (%)	NA
Total Enterprise Value (\$M)	8.5		

Officers & Directors	
Chairman of the Board	Eric J. Ende
Co-Founder, CEO, President & Director	Jerome D. "Jerry" Jabbour
Chief Financial Officer	Keith A. Kucinski

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	0.12
Ordinary Shares Outstanding (actual)	217,264,526
Market Capitalization	26,637
Cash & Short Term Investments	22,513
Total Debt	3,854
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	7,978
Total Common Equity	27,854
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	3,854
Total Capital	31,708

Stock Chart






MEDIROM Healthcare Technologies Inc. - 株式会社メディロム (NASDAQCM:MRM) | Public Company

Tradepia Odaiba, 16th Floor, 2-3-1 Daiba, Minato-ku | Tokyo, 135-0091 | Japan | 81 3 6721 7364 | medirom.co.jp

MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. The Relaxation Salon segment owns and franchises relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual s... As of Date: 1/11/2023

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY
		12/31/2020	12/31/2021	12/31/2022
Total Revenue		31,309	49,285	53,229
Total Revenues, 1 Year Growth (%)		(14.5)	61.89	28.55
Gross Profit Margin (%)		12.84	26.16	27.36
EBITDA Margin (%)		(17.28)	(4.98)	4.04
EBIT Margin (%)		(19.14)	(7.31)	1.39
Net Income Margin (%)		(16.14)	(18.31)	2.14
Diluted EPS Excl. Extra Items		(1.26)	(1.85)	0.21
Diluted EPS Before Extra, 1 Year Growth (%)		NM	51.62	NM

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value(mm)
Kouji Eguchi	1,884,961.00	38.61	10.7
Fumitoshi Fujiwara	40,000.00	0.82	0.2
Tomoya Ogawa	28,500.00	0.58	0.2
Osamu Sato	17,500.00	0.36	0.1

Market Data NASDAQCM:MRM \$5.63 (1.23%) (\$0.07)			
Last (Delayed)	5.63	Avg Daily Volume	601
VWAP (Delayed)	5.44	Avg 3M Daily Volume	4,719
Open	5.41	DR Units	NA
Previous Close	5.70	Float (%)	59.63
Day High/Low	5.63 / 5.4	Inst. Ownership (%)	0.00
52 wk High/Low	7.4 / 4.0101	Shares Sold Short	7,131
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	27.8	Div. Yield (%)	NA
Total Enterprise Value (\$M)	47.7		



Primary Industry (CIQ/GICS): Specialized Consumer Services

Topic Tags: Fitness

Status: Operating

Officers & Directors	
CEO & Representative Director	Kouji Eguchi
CFO & Director	Fumitoshi Fujiwara
Executive Officer & Chief Medical Officer	Akira Aoki

Capitalization	
Reported Currency Code	JPY
Closing Price	5.70
Ordinary Shares Outstanding (actual)	4,882,501
Market Capitalization	27,830
Cash & Short Term Investments	4,595
Total Debt	24,503
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	47,739
Total Common Equity	(450)
Total Minority Interest	NA
Total Debt	24,503
Total Capital	24,053



Multiples	2022 FY
Period Ended	12/30/2022
Price/ EPS (x)	31.23
TEV/ Total Revenue (x)	0.97
TEV/ EBITDA (x)	5.61
Price/ Book (x)	NM




Mobilicom Limited (NASDAQ:MOB) | Public Company

1 Rakefet Street | Shoham, Central 6083705 | Israel | 61 3 8630 3321 | www.mobilicom-ltd.com.au

Mobilicom Limited operates as an end-to-end provider of cybersecurity and smart solutions for drones, robotics, and autonomous platforms. It designs, develops, and delivers smart solutions, such as cloud management software, communication datalink and mobile mesh networking terminals, handheld control terminals, and professional services and support for drone, robotics, and autonomous system manufacturers, as well as... As of Date: 4/29/2023

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY
		12/31/2020	12/31/2021	12/31/2022
Total Revenue		1,428	3,282	4,994
Total Revenues, 1 Year Growth (%)		(39.85)	111.36	64.56
Gross Profit Margin (%)		64.9	72.7	88.17
EBITDA Margin (%)		(112.03)	(55.77)	(19.39)
EBIT Margin (%)		(125.83)	(56.26)	(20)
Net Income Margin (%)		(134.62)	(61.93)	(4.75)
Diluted EPS Excl. Extra Items		(0.01)	(0.01)	(0)
Diluted EPS Before Extra, 1 Year Growth (%)		(27.51)	(15.74)	(94.35)

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstandings	Market Value(mm)
Bank of New York Mellon Corp.	971,472,975.00	73.23	3.7
AWM Investment Co. Inc	117,330,400.00	8.84	0.4
Brio Capital L.P.	59,885,375.00	4.51	0.2
Bard Associates Inc.	56,320,000.00	4.25	0.2
Oren Elkayam	38,929,774.00	2.93	0.1

Market Data ASX:MOB \$0.00			
Last (Delayed)	0.00	Avg Daily Volume	6,108,915
VWAP (Delayed)	0.00	Avg 3M Daily Volume	4,918,565
Open	0.00	Shares Out. (8/31/2023)	1,326,676,694
Previous Close	0.00	Float (%)	11.35
Day High/Low	0.004406 / 0.003776	Inst. Ownership (%)	12.42
52 wk High/Low	0.028323 / 0.003147	Shares Sold Short	NA
Beta 3Y	0.84	Short Int/ShOut (%)	NA
Market Cap. (\$M)	5.0	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(4.8)		



Status: Operating

Primary Industry (CIQ/GICS): Communications Equipment

Topic Tags: Cloud Infrastructure, Cloud Management, IaaS (Infrastructure as a Service)

Officers & Directors	
Co-Founder, Chairman, CEO & MD	Oren Elkayam
Co-Founder, VP of R&D and Executive Di...	Yossi Segal
Director of Finance	Liad Gelfer

Debt Maturity	
	No data available

Capitalization	
Reported Currency Code	AUD
Closing Price	0.00
Ordinary Shares Outstanding (actual)	1,326,676,694
Market Capitalization	5,010
Cash & Short Term Investments	10,597
Total Debt	234
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(4,791)
Total Common Equity	9,898
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	234
Total Capital	10,132



Multiples	2022 FY
Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	NM
TEV/ EBITDA (x)	NM
Price/ Book (x)	0.46




Nano Dimension Ltd. - ננו דימנשן בע"מ (NASDAQCM:NNDM) | Public Company

Ness-Ziona Science Park | 2 Ilan Ramon Street | Ness Ziona, Central 7403635 | Israel | 972 7 375 09142 | www.nano-di.com


Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. The company offers 3D printers, comprising DragonFly IV that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; digital light processing printers (DLP) that achieves pro... *As of Date: 9/2/2023*

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022
Total Revenue		3,399	10,493	43,633
Total Revenues, 1 Year Growth (%)		(51.92)	208.71	NM
Gross Profit Margin (%)		54.02	45.39	42.84
EBITDA Margin (%)		NM	NM	(291.73)
EBIT Margin (%)		NM	NM	NM
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(1.13)	(0.83)	(0.88)
Diluted EPS Before Extra, 1 Year Growth (%)		(52.52)	(26.88)	6.84



Estimates	2022 FY
Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	NM
TEV/ EBITDA (x)	NM
Price/ Book (x)	0.59

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstandings	Market Value(mm)
Anson Group	16,341,063.00	6.72	43.1
Boothbay Fund Management LLC	7,500,000.00	3.08	19.8
Murchinson Ltd.	7,500,000.00	3.08	19.8
EOM Management, Ltd.	7,500,000.00	3.08	19.8
State Street Global Advisors Inc.	6,750,037.00	2.78	17.8

Market Data NASDAQCM:NNDM \$2.66	0.76%	\$0.02	
Last (Delayed)	2.66	Avg Daily Volume	698,111
VWAP (Delayed)	2.67	Avg 3M Daily Volume	2,334,852
Open	2.63	DR Units (7/13/2020)	46,400,000
Previous Close	2.64	Float (%)	91.48
Day High/Low	2.71 / 2.63	Inst. Ownership (%)	24.98
52 wk High/Low	3.35 / 2.06	Shares Sold Short	15,367,944
Beta 3Y	0.31	Short Int/ShOut (%)	33.12
Market Cap. (\$M)	642.1	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(300.3)		




Status: Operating
Primary Industry (CIQ/GICS): Technology Hardware, Storage and Peripherals
Topic Tags: Industrial Automation

Officers & Directors	
Chairman of the Board	Yoav Nissan-Cohen
CEO & Director	Yoav Stern
President	Zivi R. Nedivi

Debt Maturity
 No data available

Capitalization	
Reported Currency Code	USD
Closing Price	2.64
Ordinary Shares Outstanding (actual)	243,224,889
Market Capitalization	642,114
Cash & Short Term Investments	954,396
Total Debt	11,089
Total Preferred Equity	NA
Total Minority Interest	892
Total Enterprise Value (TEV)	(300,301)
Total Common Equity	1,148,664
Total Preferred Equity	NA
Total Minority Interest	892
Total Debt	11,089
Total Capital	1,160,645




Netcapital Inc. (NASDAQCM:NCPL) | Public Company

State Street Financial Center | One Lincoln Street | Boston, MA 02111 | USA | (781) 925-1700 | www.netcapitalinc.com


Netcapital Inc. operates as a fintech company. It offers Netcapital.com, an SEC-registered funding portal that enables private companies to raise capital online, as well as allows investors to invest from anywhere in the world. The company also provides various services, including automated onboarding process and filing of required regulatory documents; compliance review; custom-built offering page on its portal webs... *As of Date: 7/27/2023*

Key Statistics	Last 5 Yr Trend	2021 FY 4/30/2021	2022 FY 4/30/2022	2023 FY 4/30/2023	2024 FYE 4/30/2024
Total Revenue		4,721	5,481	8,494	11,000
Total Revenues, 1 Year Growth (%)		169.22	16.1	54.98	29.5
Gross Profit Margin (%)		83.92	97.99	99	NA
EBITDA Margin (%)		NA	NA	27.36	NA
EBIT Margin (%)		(8.51)	(18.36)	26.22	28.46
Net Income Margin (%)		31.13	63.92	34.79	NA
Diluted EPS Excl. Extra Items		0.89	1.27	0.63	NA
Diluted EPS Before Extra, 1 Year Growth (%)		(40.67)	42.7	(50.39)	NA



Estimates	2023 FY	2024 FYE
Period Ended	04/29/2023	04/29/2024
Price/ EPS (x)	0.58	NA
TEV/ Total Revenue (x)	0.67	0.44
TEV/ EBITDA (x)	2.43	NA
Price/ Book (x)	0.06	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value(mm)
Holder			
NetCapital Systems LLC	1,711,261.00	18.14	0.6
Bard Associates Inc.	1,276,335.00	13.53	0.5
Sabby Management LLC	381,301.00	4.04	0.1
Stock Loan Solutions LLC	118,337.00	1.26	0.0
Winthrop Advisory Group LLC	91,199.00	0.97	0.0


Market Data NASDAQCM:NCPL \$0.37	1.54%	\$0.01	
Last (Delayed)	0.37	Avg Daily Volume	19,747
VWAP (Delayed)	0.36	Avg 3M Daily Volume	149,373
Open	0.35	Shares Out. (9/14/2023)	9,434,132
Previous Close	0.36	Float (%)	79.80
Day High/Low	0.3698 / 0.3533	Inst. Ownership (%)	20.81
52 wk High/Low	3.24 / 0.3386	Shares Sold Short	31,747
Beta 3Y	NA	Short Int/ShOut (%)	0.34
Market Cap. (\$M)	3.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	4.7		



Status: Operating
Primary Industry (CIQ/GICS): Asset Management and Custody Banks
Topic Tags: Software Development, Web Development, Fintech, Website Design, Fintech Company

Officers & Directors	
Chairman of the Board	Cecilia Lenk
CEO & Director	Martin Kay
Chief Financial Officer	Coreen S. Kraysler

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	0.36
Ordinary Shares Outstanding (actual)	9,434,132
Market Capitalization	3,436
Cash & Short Term Investments	1,031
Total Debt	2,435
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	4,840
Total Common Equity	38,465
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	2,435
Total Capital	40,901

Stock Chart





NeuroOne Medical Technologies Corporation (NASDAQCM:NMTC) | Public Company


7599 Anagram Drive | Eden Prairie, MN 55344 | USA | (952) 426-1383 | www.n1mtc.com

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential t... As of Date: 1/3/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FYE	2024FYE
	Trend	9/30/2020	9/30/2021	9/30/2022	9/30/2023	9/30/2024
Total Revenue		1,927	243	2,120	3,500	6,900
Total Revenues, 1 Year Growth (%)		NA	(87.39)	NM	65.09	97.14
Gross Profit Margin (%)		3.28	NM	(143.93)	58.4	54.15
EBITDA Margin (%)		(251.99)	NM	NM	NM	(169.57)
EBIT Margin (%)		(254.46)	NM	NM	NM	(171.01)
Net Income Margin (%)		NM	NM	NM	NM	(170.29)
Diluted EPS Excl. Extra Items		(2.52)	(0.93)	(0.63)	(0.7)	(0.42)
Diluted EPS Before Extra, 1 Year Growth (%)		46.81	(63.08)	(32.79)	10.32	(40.29)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(0.70)	(0.42)	Period Ended	09/29/2022	09/29/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	4.55	5.06
			TEV/ EBITDA (x)	NM	NM
			Price/ Book (x)	1.45	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value(mm)
Manchester Management Co. LLC	2,364,052.00	9.88	2.0
AWM Investment Co. Inc	550,000.00	2.30	0.5
Vanguard Group Inc.	440,253.00	1.84	0.4
David A. Rosa	353,674.00	1.48	0.3
Mark Christianson	331,329.00	1.39	0.3

Market Data NASDAQCM:NMTC \$0.86	(0.02%) \$0.00		
Last (Delayed)	0.86	Avg Daily Volume	18,765
VWAP (Delayed)	0.86	Avg 3M Daily Volume	155,626
Open	0.86	Shares Out. (8/14/2023)	23,919,184
Previous Close	0.86	Float (%)	85.43
Day High/Low	0.92 / 0.855	Inst. Ownership (%)	6.18
52 wk High/Low	2.87 / 0.8	Shares Sold Short	135,482
Beta 3Y	0.75	Short Int/ShOut (%)	0.57
Market Cap. (\$M)	20.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	17.7		

Status: Operating

Primary Industry (CIQ/GICS): Health Care Equipment
Topic Tags: RFID (Radio Frequency Identification), Central Nervous System, Neurology, Pain Management, Neurosci...

Officers & Directors	
Chairman of the Board	Paul R. Buckman
President, CEO & Director	David A. "Dave" Rosa
Co-Founder, Business	Mark Christianson
Development Direc...	

Debt Maturity: No data available

Capitalization	
Reported Currency Code	USD
Closing Price	0.86

Ordinary Shares Outstanding (actual)	23,919,184
Market Capitalization	20,575
Cash & Short Term Investments	3,083
Total Debt	214
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	17,706
Total Common Equity	3,921
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	214
Total Capital	4,136



NeuroSense Therapeutics Ltd. (NASDAQCM:NRSN) | Public Company

Building B | 11 HaMenofim Street | Herzliya, Tel Aviv 4672562 | Israel | 972 9 799 6183 | www.neurosense-tx.com

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's p... As of Date: 4/17/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(0.51)	(0.65)	(1.07)	NA	NA
Diluted EPS Before Extra, 1 Year Growth (%)		94.31	26.31	65.72	NA	NA

Estimates	Multiples	2022 FY	2023FY E
Period Ended		12/30/2022	12/30/2023
Price/ EPS (x)		NM	NA
TEV/ Total Revenue (x)		NA	NA
TEV/ EBITDA (x)		NM	NA
Price/ Book (x)		1.46	NA

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Alon Ben-Noon	3,036,600.00	22.29	2.1
Armistice Capital LLC	1,266,000.00	9.29	0.9
Ariel Gordon	1,033,307.00	7.58	0.7
Real Property Investment Ltd	452,502.00	3.32	0.3
Or Eisenberg	226,480.00	1.66	0.2


Market Data NASDAQCM:NRSN \$0.66 (5.76%) (\$0.04)			
Last (Delayed)	0.66	Avg Daily Volume	1,350,060
VWAP (Delayed)	0.72	Avg 3M Daily Volume	50,663
Open	0.78	Shares Out. (8/16/2023)	13,623,042
Previous Close	0.70	Float (%)	57.53
Day High/Low	0.8197 / 0.6226	Inst. Ownership (%)	4.85
52 wk High/Low	2.91 / 0.69	Shares Sold Short	23,818
Beta 3Y	NA	Short Int/ShOut (%)	0.17
Market Cap. (\$M)	10.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	3.2		

Status: Operating

Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Central Nervous System, Neurology, Neuroscience, Parkinson's, Amyotrophic Lateral Sclerosis, Ne...

Officers & Directors	
Chairman of the Board	Mark Wayne Leuchtenberger
Co-Founder, CEO & Director	Alon Ben-Noon
Chief Financial Officer	Or Eisenberg

Capitalization	
Reported Currency Code	USD
Closing Price	0.70
Ordinary Shares Outstanding (actual)	13,623,042
Market Capitalization	9,468
Cash & Short Term Investments	7,089
Total Debt	104
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	2,483
Total Common Equity	(1,545)
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	104
Total Capital	(1,441)





Nomax Therapeutics, Inc | Private Company
3363 NE 163 Street Suite 708 D | North Miami Beach, FL 33160 | USA


Nomax Therapeutics, Inc operates as a biotechnology company. The company develops therapy for neurodegenerative diseases. It offers NT2021-1, a light-isotope substitution zinc (Zn) and L-Amino acid investigational therapeutic. Nomax Therapeutics, Inc was formerly known as Nomax Therapeutics, Inc and changed its name to Nomax Therapeutics, Inc in November 2011. Nomax Therapeutics, Inc was incorporated in 2021.

Phone (305) 331-1213

Corporate Data Latest Rounds of Funding

Company Data

Status Operating
Primary Industry **Biotechnology**
Primary Industry (CIQ/GICS)
Topic Tags Neurology, Neurodegenerative Disease
Categories¹ Biotechnology, Health Care, Information Technology, Life Science
Date of Incorporation 02/09/2021



Officers & Directors

President Max Temnik

Funding Overview

Summary
0.63 (\$M) Raised in 2 Disclosed Rounds. Investors were n disclosed.
Total Funding It has been **1 Month** since the last funding round

Overview

Announced Date	Round Type Post-Money (\$M)	Round Number	Size (\$000)	Pre-Money (\$M)
9/11/2023	Seed NA	3	534 ¹	NA
11/26/2021	Venture NA	2	NA	NA
11/17/2021	Seed NA	1	100 ¹	NA

¹This number reflects the estimated value of the total new money raised through private placement rounds.

Latest Activity

Key Developments

Nomax Therapeutics, Inc announced that it has received \$0.1 million in funding
Private Placement 11/17/2021

Nomax Therapeutics, Inc announced a financing transaction
Private Placement 10/18/2021

Nomax Therapeutics, Inc announced that it expects to receive \$0.1 million in funding
Private Placement 10/14/2021



Odd Burger Corporation (TSXV:ODD) | Public Company


505 Consortium Court | London, Ontario N6E 2S8 | Canada | (800) 286-2145 | www.oddburger.com

Odd Burger Corporation operates as a plant-based food technology company in Canada. It manufactures and distributes plant-based proteins and dairy alternatives through a food service product line that is used at corporate owned and franchised vegan restaurant locations. The company was founded in 2014 and is headquartered in London, Canada. As of Date: 3/28/2023

Key Statistics

	Last 5 Yr Trend	2020 FY 9/30/2020	2021 FY 9/30/2021	2022 FY 9/30/2022
Total Revenue		795	925	2,312
Total Revenues, 1 Year Growth (%)		6.08	9.43	152.45
Gross Profit Margin (%)		18.66	4.77	13.96
EBITDA Margin (%)		(41.01)	(237.39)	(122.2)
EBIT Margin (%)		(48.12)	(249.43)	(136.64)
Net Income Margin (%)		(260.27)	NM	(145.18)
Diluted EPS Excl. Extra Items		(0.04)	(0.06)	(0.04)
Diluted EPS Before Extra, 1 Year Growth (%)		NM	41.14	(29.65)

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Vasiliki McInnes	22,417,857.00	24.52	3.8
James McInnes	22,417,857.00	24.52	3.8
BoxOne Ventures	13,402,500.00	14.66	2.2
Francois Arbour	2,105,087.00	2.30	0.4
Utsang Desai	350,000.00	0.38	0.1

Market Data TSXV:ODD \$0.17

Last (Delayed)	0.17	Avg Daily Volume	20,500
VWAP (Delayed)	0.17	Avg 3M Daily Volume	17,831
Open	0.17	Shares Out. (8/29/2023)	91,419,417
Previous Close	0.17	Float (%)	33.61
Day High/Low	0.167581 / 0.167581	Inst. Ownership (%)	0.04
52 wk High/Low	0.291445 / 0.072861	Shares Sold Short	NA
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	15.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	17.3		

Multiples 2022 FY

Period Ended	09/29/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	7.75
TEV/ EBITDA (x)	NM
Price/ Book (x)	19.17



Status: Operating


Primary Industry (CIQ/GICS): Restaurants

Topic Tags: AgriTech, Alternative Protein, Plant-based Food Technology

Officers & Directors

Co-Founder, Chairman, President & CEO James McInnes
CFO & Director Edward "Ted" Sehl
COO & Director Vasiliki McInnes

Debt Maturity



Capitalization

Reported Currency Code	CAD
Closing Price	0.17
Ordinary Shares Outstanding (actual)	91,419,417
Market Capitalization	15,320
Cash & Short Term Investments	78
Total Debt	2,082
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	17,254
Total Common Equity	(240)
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	2,082
Total Capital	1,842

Stock Chart





OMNIQ Corp. (NASDAQCM:OMQS) | Public Company

1865 West 2100 South | Salt Lake City, UT 84119 | USA | (800) 242-7272 | www.omniq.com


OMNIQ Corp. provides artificial intelligence based solutions in the United States. It provides computerized and machine vision image processing solution to deliver data collection, real time surveillance, and monitoring for supply chain management, homeland security, public safety, traffic and parking management, and access control applications. The company offer end-to-end solutions, which includes hardware, softwar... As of Date: 9/9/2023

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023 FYE 12/31/2023	2024 FYE 12/31/2024
Total Revenue		55,209	78,251	102,545	103,567	131,500
Total Revenues, 1 Year Growth (%)		(3.48)	41.74	31.05	1	26.97
Gross Profit Margin (%)		19.77	21.3	21.56	20.4	25.65
EBITDA Margin (%)		(12.12)	(9.03)	(7.25)	(1.5)	4.78
EBIT Margin (%)		(16.27)	(13.39)	(9.32)	(5.79)	1.04
Net Income Margin (%)		(20.84)	(17.08)	(13.34)	NA	NA
Diluted EPS Excl. Extra Items		(2.71)	(2.21)	(1.83)	NA	NA
Diluted EPS Before Extra, 1 Year Growth (%)		97.5	(18.35)	(17.04)	NA	NA



Multiples	2022 FY 12/30/2022	2023 FYE 12/30/2023
Price/ EPS (x)	NM	NA
TEV/ Total Revenue (x)	0.26	0.25
TEV/ EBITDA (x)	NM	NM
Price/ Book (x)	NM	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Shai Shalom Lustgarten	974,822.00	12.35	1.5
Campbetown Consulting Ltd.	739,308.00	9.37	1.1
Vanguard Group Inc.	215,007.00	2.72	0.3
Neev Nissenson	58,440.00	0.74	0.1
Carlos Jaime Nissensohn	57,026.00	0.72	0.1

Market Data NASDAQCM:OMQS \$1.54 (6.30%) (\$0.10)		
Last (Delayed)	1.54	Avg Daily Volume 2,558
VWAP (Delayed)	1.54	Avg 3M Daily Volume 14,649
Open	1.64	Shares Out. (8/14/2023) 7,890,837
Previous Close	1.64	Float (%) 85.82
Day High/Low	1.64 / 1.5366	Inst. Ownership (%) NA
52 wk High/Low	7 / 1.52	Shares Sold Short 705
Beta 3Y	0.47	Short Int/ShOut (%) 0.00
Market Cap. (\$M)	12.1	Div. Yield (%) NA
Total Enterprise Value (\$M)	25.6	

Status: Operating


Primary Industry (CIQ/GICS): IT Consulting and Other Services

Topic Tags: RFID (Radio Frequency Identification), Artificial Intelligence, Machine Learning, Computer Vision, ...

Officers & Directors

Chairman of the Board, CEO & President	Shai Shalom Lustgarten
CFO & Director	Neev Nissenson
Chief Operating Officer	Eli Uziel

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	1.54
Ordinary Shares Outstanding (actual)	7,890,837
Market Capitalization	12,125
Cash & Short Term Investments	1,998
Total Debt	15,437
Total Preferred Equity	1
Total Minority Interest	NA
Total Enterprise Value (TEV)	25,565
Total Common Equity	(15,913)
Total Preferred Equity	1
Total Minority Interest	NA
Total Debt	15,437
Total Capital	(475)

Stock Chart




OneMeta Inc. (OTCPK:ONEI) | Public Company

450 South 400 East | Suite 200 | Bountiful, UT 84010 | USA | (775) 464-1980 | www.onemeta.ai

OneMeta Inc. engages in developing artificial intelligence products that enable companies and individuals by eliminating language barriers in daily communications by providing interpretation and translation services using natural language processing (NLP) technology. Its products include Verbum, a platform that enables fluent and effective communication among individuals that do not speak a similar language; and Verb... As of Date: 8/16/2023

Key Statistics	Last 5 Yr Trend	2013 FY 12/31/2013	2021 FY 12/31/2021	2022 FY 12/31/2022
Total Revenue		NA	4	1
Total Revenues, 1 Year Growth (%)		NA	NA	(69.64)
Gross Profit Margin (%)		NA	100	100
EBITDA Margin (%)		NA	NA	NA
EBIT Margin (%)		NA	NM	NM
Net Income Margin (%)		NA	NM	NM
Diluted EPS Excl. Extra Items		(1.62)	(0.05)	(0.06)
Diluted EPS Before Extra, 1 Year Growth (%)		(60.56)	NA	20.77

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Rowland W. Day II	2,142,800.00	7.09	1.3
Saul I. Leal	2,142,800.00	7.09	1.3
Melinda Day	0.00	0.00	0.0

Market Data OTCPK:ONEI \$0.45 (25.00%) (\$0.15)		
Last (Delayed)	0.45	Avg Daily Volume 17,572
VWAP (Delayed)	0.56	Avg 3M Daily Volume 4,536
Open	0.65	Shares Out. (8/18/2023) 30,185,560
Previous Close	0.60	Float (%) 85.82
Day High/Low	0.72 / 0.45	Inst. Ownership (%) NA
52 wk High/Low	1.66 / 0.0575	Shares Sold Short 705
Beta 3Y	(1.80)	Short Int/ShOut (%) 0.00
Market Cap. (\$M)	18.1	Div. Yield (%) NA
Total Enterprise Value (\$M)	23.8	

Status: Operating

Primary Industry (CIQ/GICS): Application Software

Topic Tags: Mobile Development Tools, Software Development, Artificial Intelligence, Machine Learning, Natural ...

Officers & Directors

President, CFO, Secretary & Chairman o...	Rowland W. Day II
CEO & Director	Saul I. Leal
Chief Technology Officer	Eric Wise

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	0.60
Ordinary Shares Outstanding (actual)	30,225,560
Market Capitalization	18,135
Cash & Short Term Investments	623
Total Debt	222
Total Preferred Equity	6,102
Total Minority Interest	NA
Total Enterprise Value (TEV)	23,837
Total Common Equity	(5,631)
Total Preferred Equity	6,102
Total Minority Interest	NA
Total Debt	222
Total Capital	694

Stock Chart



Multiples

Multiples	2022 FY 12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	NM
TEV/ EBITDA (x)	NA
Price/ Book (x)	NM



OppFi Inc. (NYSE:OPFI) | Public Company


One Prudential Plaza | Suite 3400, 130 East Randolph Street | Chicago, IL 60601 | USA | (312)212-8079 | www.opfi.com

OppFi Inc. operates a financial technology platform that allows banks to offer lending products. Its platform facilitates the OppLoans, an installment loan product; SalaryTap, a payroll deduction secured installment loan product; and OppFi Card, a credit card product. The company was founded in 2012 and is headquartered in Chicago, Illinois. As of Date: 7/4/2023

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY	2023 FYE	2024 FYE
		12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		188,167	239,423	181,798	510,708	592,154
Total Revenues, 1 Year Growth (%)		75.37	27.24	(24.07)	12.77	15.95
Net Income Margin (%)		41.2	10.67	3.9	6.46	7.26
Diluted EPS Excl. Extra Items		NA	0.48	0.05	0.39	0.5
Diluted EPS Before Extra, 1 Year Growth (%)		NA	NA	(89.41)	NM	28.21

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023 FY E
EPS (\$)	0.39	0.50	Period Ended	12/30/2022	12/30/2023
	Target: 0.38				
	Price/ EPS (x)				
	Price/ Book (x)				

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
BlackRock Inc.	748,898.00	4.53	1.8
Elgethun Capital Management	739,815.00	4.47	1.8
Vanguard Group Inc.	728,506.00	4.41	1.8
Theodore G. Schwartz	664,608.00	4.02	1.6
Todd G. Schwartz	545,683.00	3.30	1.3

Market Data NYSE:OPFI \$2.34 (4.88%) (\$0.12)			
Last (Delayed)	2.34	Avg Daily Volume	43,869
VWAP (Delayed)	2.37	Avg 3M Daily Volume	96,511
Open	2.44	Shares Out. (8/9/2023)	16,537,256
Previous Close	2.46	Float (%)	88.96
Day High/Low	2.44 / 2.32	Inst. Ownership (%)	22.70
52 wk High/Low	2.74 / 1.7	Shares Sold Short	737,200
Beta 3Y	NA	Short Int/ShOut (%)	4.46
Market Cap. (\$M)	40.4	Div. Yield (%)	NA
Implied Market Cap. (\$M)	271.5		



Status: Operating

Primary Industry (CIQ/GICS): Consumer Finance


Topic Tags: Banking as a Service, Credit Cards, Fintech,

Financial Technology, Financial Technology Platform

Officers & Directors

Founder, Executive	Todd G. Schwartz
Chairman & CEO	
Co-Founder & Director	Theodore G. "Ted" Schwartz
CFO, Chief Accounting	Pamela D. Johnson
Officer and Prin...	


Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	2.46
Ordinary Shares Outstanding (actual)	16,537,256
Market Capitalization	40,682
Total Common Equity	7,447
Total Preferred Equity	NA
Total Equity	176,990
Tier 1 Capital	NA
Tier 2 Capital	NA
Total Capital	NA
Tier 1 Capital Ratio (%)	NA
Total Capital Ratio (%)	NA
Leverage Ratio (%)	NA

Stock Chart



Parabole LLC | Private Company

1100 Cornwall Road Monmouth Junction, NJ 08852 USA

Parabole LLC develops a robotic solution for automating repeatable, regulatory, and compliance tasks in banking and financial services sectors. The company offers TRAIN, a platform that uses advanced algorithms and deep learning to extract knowledge from documents, people's mind, and data silos, as well as translates this knowledge into actionable insights for making better decisions.

Corporate Data

Status	Operating
Primary Industry (CIQ/GICS)	Application Software
Topic Tags	Industrial Automation, Artificial Intelligence, Machine Learning, Computer Vision, Robotic Solution, Deep Learning, Actionable Insight
Categories ¹	Banking, Digital Media, Machine Learning, Manufacturing, Pharmaceutical, Service Industry
Date of Incorporation	04/14/2014
SIC Code	7372
NACE Code	58.29 - Other software publishing
NAICS Code	513210 - Software Publishers


Officers & Directors

Co-founder, CEO & Director	Rajib Kumar Saha
Co-Founder, CTO & Director	Sandip Bhaumik
Co-founder & COO	Manesh Nair

Latest Activity

Key Developments	Product-related Announcement	Date
Parabole.ai Announces the Release of ESG-RC		9/19/2023

Latest Rounds of Funding



Funding Overview

Summary	6.65 (\$M)* Raised in 3 Disclosed Rounds. Investors were not disclosed.
Total Funding	It has been 4 years and 2 months since the last funding round.

Overview

Announced Date	Round Type	Round Number	Size (\$000)	Pre-Money	Post-Money
9/4/2019	Debt	3	3,800 ¹	NA	NA
3/7/2018	Seed	2	1,650 ¹	NA	NA
5/1/2017	Debt	1	1,200	NA	NA

*This number reflects the estimated value of the total new money raised through private placement rounds.




PetVivo Holdings, Inc. (NASDAQM:PETV) | Public Company

5251 Edina Industrial Boulevard | Suite 575, Edina | Minneapolis, MN 55439 | USA | (952) 405-6216 | www.petvivo.com

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline prod... As of Date: 6/30/2023

Key Statistics	Last 5 Yr	2021 FY	2022 FY	2023 FY
	Trend	3/31/2021	3/31/2022	3/31/2023
Total Revenue		13	116	917
Total Revenues, 1 Year Growth (%)		250.56	NM	NM
Gross Profit Margin (%)		14.97	(74.03)	42.56
EBITDA Margin (%)		NM	NM	NM
EBIT Margin (%)		NM	NM	NM
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(0.57)	(0.57)	(0.85)
Diluted EPS Before Extra, 1 Year Growth (%)		44.77	0.73	48.97

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
A.L. Sarroff Management, LLC	1,583,911.00	11.51	3.0
Stanley C. Cruden	1,102,740.00	8.01	2.1
John Lai	1,078,292.00	7.84	2.1
David B. Masters	708,727.00	5.15	1.4
Randall A. Meyer	585,235.00	4.25	1.1

Market Data NASDAQM:PETV \$1.88 (2.34%) (\$0.04)			
Last (Delayed)	1.88	Avg Daily Volume	224
VWAP (Delayed)	1.88	Avg 3M Daily Volume	16,130
Open	1.88	Shares Out. (8/24/2023)	13,760,887
Previous Close	1.92	Float (%)	66.01
Day High/Low	1.875 / 1.875	Inst. Ownership (%)	17.79
52 wk High/Low	3.6 / 1.66	Shares Sold Short	133,780
Beta 3Y	0.65	Short Int/ShOut (%)	0.97
Market Cap. (\$M)	26.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	27.7		



Status: Operating

Primary Industry (CIQ/GICS): Health Care Equipment

Topic Tags: Rheumatology, Arthritis, Osteoarthritis

Officers & Directors

Chairman of the Board	James Rudolph "Jim" Martin
CEO, President & Director	John Lai
Chief Financial Officer	Robert J. "Bob" Folkes

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	1.92
Ordinary Shares Outstanding (actual)	13,760,887

Market Capitalization 26,562

Cash & Short Term Investments	219
Total Debt	1,395

Total Preferred Equity	NA
Total Minority Interest	NA

Total Enterprise Value (TEV) 27,738

Total Common Equity	398
Total Preferred Equity	NA

Total Minority Interest	NA
Total Debt	1,395

Total Capital 1,794

Stock Chart



Multiples

2023 FY	
Period Ended	03/30/2023
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	28.82
TEV/ EBITDA (x)	NM
Price/ Book (x)	29.09



Piedmont Lithium Inc. (NASDAQ:PLL) | Public Company

42 E Catawba Street | Belmont, NC 28012 | USA | (704) 461-8000 | www.piedmontlithium.com

Piedmont Lithium Inc., a development stage company, engages in the exploration and development of resource projects in the United States. The company primarily holds a 100% interest in the Carolina Lithium Project that include an area of approximately 3,245 acres located within the Carolina Tin-Spodumene Belt situated to the northwest of Charlotte, North Carolina in the United States. It also owns a real property of ... As of Date: 5/9/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
	Trend	6/30/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	181,349	350,182
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	93.1
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	56.74	63.75
EBIT Margin (%)		NA	NA	NA	68.03	96.61
Net Income Margin (%)		NA	NA	NA	42.96	53.79
Diluted EPS Excl. Extra Items		(0.01)	(0.02)	(0.01)	0.06	0.17
Diluted EPS Before Extra, 1 Year Growth (%)		(54.42)	NA	(67.93)	NA	NA

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	0.06	0.16	Period Ended	12/30/2022	12/30/2023
Price/ EPS (x)			Price/ EPS (x)	NM	6.34
TEV/ Total Revenue (x)			TEV/ Total Revenue (x)	NA	3.61
TEV/ EBITDA (x)			TEV/ EBITDA (x)	NM	6.37
Price/ Book (x)			Price/ Book (x)	2.45	1.31

Top Holders

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
BlackRock Inc.	132,066,300.00	6.88	48.6
State Street Global Advisors Inc.	115,190,100.00	6.00	42.4
LG Chem Ltd.	109,653,500.00	5.71	40.4
Vanguard Group Inc.	97,950,742.00	5.10	36.1
Van Eck Associates Corp.	55,389,100.00	2.89	20.4

Market Data ASX:PLL \$0.37 (2.50%) (\$0.01)

Last (Delayed)	0.37	Avg Daily Volume	1,578,106
VWAP (Delayed)	0.37	Avg 3M Daily Volume	1,136,859
Open	0.37	DR Units (3/1/2023)	39,789
Previous Close	0.38	Float (%)	85.88
Day High/Low	0.377644 / 0.368202	Inst. Ownership (%)	50.91
52 wk High/Low	0.682905 / 0.365055	Shares Sold Short	NA
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	706.8	Div. Yield (%)	NA
Total Enterprise Value (\$M)	623.9		



Status: Operating

Primary Industry (CIQ/GICS): Diversified Metals and Mining

Officers & Directors

Chairman of the Board	Jeffrey Thomas Armstrong
MD, CEO, President & Director	Keith Douglas Phillips
Executive VP & CFO	Michael D. White

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	0.37
Ordinary Shares Outstanding (actual)	1,919,588,900

Market Capitalization 706,797

Cash & Short Term Investments	89,219
Total Debt	1,603

Total Preferred Equity	NA
Total Minority Interest	NA

Total Enterprise Value (TEV) 623,940

Total Common Equity	325,435
Total Preferred Equity	NA

Total Minority Interest	NA
Total Debt	1,603

Total Capital 327,038

Stock Chart





Plus Therapeutics, Inc. (NASDAQCM:PSTV) | Public Company


4200 Marathon Boulevard | Suite 200 | Austin, TX 78756 | USA | (737) 255-7194 | plustherapeutics.com

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbameda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also dev...
As of Date: 3/23/2023


Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FY E 12/31/2023	2024FY E 12/31/2024
Total Revenue		303	NA	224	5,862	4,717
Total Revenues, 1 Year Growth (%)		(95.67)	NA	NA	NM	(19.54)
Gross Profit Margin (%)		NM	NA	NM	NA	NA
EBITDA Margin (%)		NM	NA	NM	(191.06)	(245.94)
EBIT Margin (%)		NM	NA	NM	(238.61)	NM
Net Income Margin (%)		NM	NA	NM	(240.48)	NM
Diluted EPS Excl. Extra Items		(27.92)	(16.65)	(11.58)	(5.46)	(3.89)
Diluted EPS Before Extra, 1 Year Growth (%)		(32.87)	(40.36)	(30.43)	(52.7)	(28.8)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(5.46)	(3.89)	Period Ended	12/30/2022	12/30/2023
RECOMMENDATION			Price/ EPS (x)	NM	NM
TEV/ Total Revenue (x)			TEV/ Total Revenue (x)	NM	NM
TEV/ EBITDA (x)			TEV/ EBITDA (x)	NM	0.21
Price/ Book (x)			Price/ Book (x)	0.43	NA

Revenue by Business and Geographic Segments




Stock Chart



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Central Nervous System, Chronic Diseases, Oncology, Cancer, Brain Cancer, Liver Cancer

Officers & Directors	
Chairman of the Board	Richard J. "Rick" Hawkins
President, CEO & Director	Marc H. Hedrick
VP & CFO	Andrew J. Sims

Debt Maturity



Capitalization	
Reported Currency Code	USD
Closing Price	1.23
Ordinary Shares Outstanding (actual)	2,879,620
Market Capitalization	3,542
Cash & Short Term Investments	10,895
Total Debt	4,955
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(2,398)
Total Common Equity	2,662
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	4,955
Total Capital	7,617

Top Holders

	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Vanguard Group Inc.	72,861.00	2.53	0.1
Gregory B. Petersen	24,166.00	0.84	0.0
Geode Capital Management LLC	17,007.00	0.59	0.0
Howard Clowes	11,693.00	0.41	0.0
BlackRock Inc.	6,960.00	0.24	0.0

Market Data NASDAQCM:PSTV \$1.24 0.92% \$0.01			
Last (Delayed)	1.24	Avg Daily Volume	12,895
VWAP (Delayed)	1.19	Avg 3M Daily Volume	413,330
Open	1.22	Shares Out. (8/14/2023)	2,879,620
Previous Close	1.23	Float (%)	98.46
Day High/Low	1.25 / 1.18	Inst. Ownership (%)	3.37
52 wk High/Low	10.95 / 1.12	Shares Sold Short (%)	140,457
Beta 3Y	1.00	Short Int/ShOut (%)	4.88
Market Cap. (\$M)	3.5	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(2.4)		



PodcastOne, Inc. (NASDAQCM:PODC) | Public Company


335 North Maple Drive | Suite 127 | Beverly Hills, CA 90210 | USA | (310) 858-0888 | www.podcastone.com

PodcastOne, Inc. operates as a podcast platform and publisher. The company offers its content to audiences through podcasting distribution platforms, including its website, Apple Podcasts, Spotify, Amazon Music, and others. It also produces vodcasts, branded podcasts, merchandise, and live events. In addition, the company builds, owns, and operates LaunchPadOne, a self-publishing podcast platform. The company was for...
As of Date: 9/28/2023

Key Statistics	Last 5 Yr Trend	2021 FY 3/31/2021	2022FY 3/31/2022	2023 FY 3/31/2023	2024FY E 3/31/2024	2025FY E 3/31/2025
Total Revenue		23,840	32,348	34,645	42,054	48,368
Total Revenues, 1 Year Growth (%)		NA	35.69	7.1	NA	15.01
Gross Profit Margin (%)		23.33	18.79	20.4	NA	NA
EBITDA Margin (%)		(11.12)	(12.58)	(4.36)	NA	NA
EBIT Margin (%)		(13.57)	(14.54)	(5.3)	2.06	5.04
Net Income Margin (%)		(13.69)	(11.14)	(20.11)	(2.47)	5.04
Diluted EPS Excl. Extra Items		(0.02)	(0.02)	(0.06)	(0.05)	0.11
Diluted EPS Before Extra, 1 Year Growth (%)		NA	10.41	158.16	NA	NA

Estimates	2023 FY	2024FY E	Multiples	2023 FY	2024FY E
Period Ended	03/30/2023	03/30/2024	Period Ended	03/30/2023	03/30/2024
Price/ EPS (x)	NM	NM	Price/ EPS (x)	NM	NM
TEV/ Total Revenue (x)	1.14	0.98	TEV/ Total Revenue (x)	1.14	0.98
TEV/ EBITDA (x)	NM	NA	TEV/ EBITDA (x)	NM	NA
Price/ Book (x)	5.06	NA	Price/ Book (x)	5.06	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
LiveOne Inc.	17,980,000.00	78.65	32.4
Robert S. Ellin	381,474.00	1.67	0.7
Jay Evan Krigsman	21,894.00	0.10	0.0
Kit Gray	4,731.00	0.02	0.0
Jacqueline Stone	4,221.00	0.02	0.0

Market Data NASDAQCM:PODC \$1.77 (1.67%) (\$0.03)			
Last (Delayed)	1.77	Avg Daily Volume	19,131
VWAP (Delayed)	1.79	Avg 3M Daily Volume	139,217
Open	1.77	Shares Out. (9/20/2023)	22,860,736
Previous Close	1.80	Float (%)	19.53
Day High/Low	1.8 / 1.77	Inst. Ownership (%)	0.00
52 wk High/Low	5.8 / 1.77	Shares Sold Short	NA
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	41.1	Div. Yield (%)	NA
Total Enterprise Value (\$M)	46.3		



Status: Operating Subsidiary
Primary Industry (CIQ/GICS): Movies and Entertainment
Topic Tags: Podcast, Podcast Platform

Officers & Directors	
Executive Chairman	Robert S. Ellin
Co-Founder & President	Kit Gray
Interim Chief Financial Officer	Aaron Sullivan

Debt Maturity

No data available

Capitalization	
Reported Currency Code	USD
Closing Price	1.80
Ordinary Shares Outstanding (actual)	22,860,736
Market Capitalization	36,000
Cash & Short Term Investments	468
Total Debt	5,630
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	41,162
Total Common Equity	6,993
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	5,630
Total Capital	12,623

Stock Chart





Presto Automation Inc. (NASDAQM:PRST) | Public Company


985 Industrial Road | Suite 205 | San Carlos, CA 94070 | USA | (650) 817-9012 | presto.com

Presto Automation Inc. operates as a labor automation technology provider in the hospitality industry. The company develops the Presto Smart Dining system (Presto Touch) that offers operations efficiency, guest self-service, and marketing benefits for casual dining operators. Its solution includes a portfolio of tabletop, handheld, and wearable devices supported by a suite of cloud-based services to enable guest orde... As of Date: 5/9/2023

Key Statistics	Last 5 Yr Trend	2020 FY 6/30/2020	2021 FY 6/30/2021	2022 FY 6/30/2022	2023 FY E 6/30/2023	2024 FY E 6/30/2024
Total Revenue		21,510	29,912	30,351	27,800	44,500
Total Revenues, 1 Year Growth (%)		NA	39.06	1.47	NA	60.07
Gross Profit Margin (%)		36.83	27.05	12.44	13	33
EBITDA Margin (%)		(75.71)	(46.18)	(95.96)	(126.26)	(55.73)
EBIT Margin (%)		(90.48)	(55.9)	(101.95)	(204.32)	(80)
Net Income Margin (%)		(110.69)	(166.5)	(185.54)	(242.09)	(111.69)
Diluted EPS Excl. Extra Items		(4.74)	(9.82)	(10.58)	(1.41)	(0.84)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	106.94	7.74	NA	(40.43)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023 FY E
EPS (\$)	(1.41)	(0.84)	Period Ended	06/29/2022	06/29/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	7.17	4.60
			TEV/ EBITDA (x)	NM	NM
			Price/ Book (x)	NM	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts


Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Romulus Capital Management LLC	14,350,390.00	25.28	24.0
Cleveland Avenue LLC	8,500,000.00	14.98	14.2
I2BF Global Ventures Ltd.	4,429,505.00	7.80	7.4
Susquehanna International Group LLP	2,468,070.00	4.35	4.1
Rajat Suri	2,240,762.00	3.95	3.7

Market Data NASDAQM:PRST \$1.76	5.39% \$0.09		
Last (Delayed)	1.76	Avg Daily Volume	120,752
VWAP (Delayed)	1.73	Avg 3M Daily Volume	249,347
Open	1.67	Shares Out. (6/23/2023)	56,758,174
Previous Close	1.67	Float (%)	44.74
Day High/Low	1.82 / 1.63	Inst. Ownership (%)	11.91
52 wk High/Low	5.74 / 1.23	Shares Sold Short	163,385
Beta 3Y	NA	Short Int/ShOut (%)	0.29
Market Cap. (\$M)	98.8	Div. Yield (%)	NA
Total Enterprise Value (\$M)	131.9		




Status: Operating
Primary Industry (CIQ/GICS): Electronic Equipment and Instruments
Topic Tags: Speech Recognition, Wearables, Artificial Intelligence, Machine Learning, Speech Recognition Techno...

Officers & Directors	
Chairman of the Board	Krishna K. Gupta
CEO & COO	Xavier Casanova
President	Daniel L. Mosher



Capitalization	
Reported Currency Code	USD
Closing Price	1.67
Ordinary Shares Outstanding (actual)	56,758,174
Market Capitalization	94,786
Cash & Short Term Investments	26,978
Total Debt	60,159
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	127,967
Total Common Equity	(22,232)
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	60,159
Total Capital	37,927



Processa Pharmaceuticals, Inc. (NASDAQM:PCSA) | Public Company

7380 Coca Cola Drive | Suite 106 | Hanover, MD 21076 | USA | (443) 776-3133 | www.processapharmaceuticals.com

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition.

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023 FY E 12/31/2023	2024 FY E 12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(2.54)	(0.75)	(1.7)	(0.46)	(0.39)
Diluted EPS Before Extra, 1 Year Growth (%)		262.97	(70.62)	128.22	(63.2)	(15.22)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023 FY E
EPS (\$)	(0.46)	(0.39)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NA	NA
			TEV/ EBITDA (x)	NM	NA
			Price/ Book (x)	0.43	NA

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Yuhan Corp.	1,250,000.00	5.08	0.3
CorLyst, LLC	1,129,331.00	4.59	0.2
David Young	847,404.00	3.44	0.2
Young Plaisance Revocable Trust	619,677.00	2.52	0.1
Richland Fund LLC	519,890.00	2.11	0.1

Market Data NASDAQM:PCSA \$0.19	(5.94%) (\$0.01)		
Last (Delayed)	0.19	Avg Daily Volume	60,546
VWAP (Delayed)	0.21	Avg 3M Daily Volume	102,429
Open	0.20	Shares Out. (9/25/2023)	24,606,474
Previous Close	0.20	Float (%)	75.97
Day High/Low	0.2275 / 0.19	Inst. Ownership (%)	5.61
52 wk High/Low	2.5686 / 0.1801	Shares Sold Short	128,925
Beta 3Y	0.83	Short Int/ShOut (%)	0.52
Market Cap. (\$M)	4.7	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(3.8)		



Status: Operating
Primary Industry (CIQ/GICS): Pharmaceuticals
Topic Tags: Chronic Diseases, Gastroenterology, Oncology, Pulmonology, Cancer, Irritable Bowel Syndrome, Consti...

Officers & Directors	
Chairman of the Board	Justin W. Yorke
CEO & Director	George K. Ng
Co-Founder and Chief Development & Reg...	Sian E. Bigora

Debt Maturity
 No data available

Capitalization	
Reported Currency Code	USD
Closing Price	0.20
Ordinary Shares Outstanding (actual)	24,606,474
Market Capitalization	4,971
Cash & Short Term Investments	8,677
Total Debt	191
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(3,515)
Total Common Equity	9,160
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	191
Total Capital	9,351





ProPhase Labs, Inc. (NASDAQCM:PRPH) | Public Company


711 Stewart Avenue | Suite 200 | Garden City, NY 11530 | USA | (215) 345-0919 | www.prophaselabs.com

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services. As of Date: 9/2/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FYE	2024FYE
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		14,514	79,042	122,647	61,427	80,640
Total Revenues, 1 Year Growth (%)		46.96	NM	55.17	(49.92)	31.28
Gross Profit Margin (%)		31.74	53.12	57.61	NA	NA
EBITDA Margin (%)		(24.28)	16.49	23.09	NA	NA
EBIT Margin (%)		(27.37)	12.4	19.24	(15.6)	(2.89)
Net Income Margin (%)		(14.64)	7.94	15.05	(14.54)	(3.71)
Diluted EPS Excl. Extra Items		(0.2)	0.4	1.02	(0.53)	(0.18)
Diluted EPS Before Extra, 1 Year Growth (%)		(25.31)	NM	158.93	NM	(66.67)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022FY	2023FY E
EPS (\$)	(0.53)	(0.18)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	4.26	NM
			TEV/ Total Revenue (x)	0.51	1.29
			TEV/ EBITDA (x)	2.16	NA
			Price/ Book (x)	1.11	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Ted William Karkus	3,572,350.00	21.21	15.6
Vanguard Group Inc.	601,840.00	3.57	2.6
Renaissance Technologies LLC	300,510.00	1.78	1.3
Louis Gleckel	273,840.00	1.63	1.2
Avidian Wealth Solutions LLC	156,024.00	0.93	0.7

Market Data NASDAQCM:PRPH \$4.38	0.46% \$0.02		
Last (Delayed)	4.38	Avg Daily Volume	1,812
VWAP (Delayed)	4.39	Avg 3M Daily Volume	42,243
Open	4.39	Shares Out. (8/11/2023)	16,845,029
Previous Close	4.36	Float (%)	76.41
Day High/Low	4.46 / 4.37	Inst. Ownership (%)	12.98
52 wk High/Low	12.69 / 4.05	Shares Sold Short	310,297
Beta 3Y	0.62	Short Int/ShOut (%)	1.84
Market Cap. (\$M)	73.4	Div. Yield (%)	NA
Total Enterprise Value (\$M)	79.5		



Status: Operating

Primary Industry (CIQ/GICS): Pharmaceuticals

Topic Tags: COVID-19, Infectious Diseases, Respiratory, Vaccines, Health Diagnostics, Mers, Diagnostic Service

Officers & Directors	
Chairman & CEO	Ted William Karkus
CFO, Principal Financial Officer & Pri...	Robert A. Morse Jr.
Chief Strategy Officer of Nebula Genomics	Sam A. Beeler

Capitalization	
Reported Currency Code	USD
Closing Price	4.36
Ordinary Shares Outstanding (actual)	16,845,029
Market Capitalization	73,444
Cash & Short Term Investments	10,404
Total Debt	16,493
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	79,533
Total Common Equity	59,257
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	16,493
Total Capital	75,750



Pyxis Tankers Inc. (NASDAQCM:PXS) | Public Company

59 K. Karamanli Street | 15125 Marousi | Greece | 30 210 63 80 200 | www.pyxistankers.com

Pyxis Tankers Inc. operates as a maritime transportation company with a focus on the tanker sector in the United States. Its fleet transports refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, and fuel oil, as well as other liquid bulk items, including vegetable oils and organic chemicals. As of March 31, 2023, the company operated a fleet of four tankers. Pyxis Tankers Inc. was incorp... As of Date: 4/13/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022FY	2023FYE
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023
Total Revenue		21,711	25,341	58,344	35,116
Total Revenues, 1 Year Growth (%)		(21.77)	16.72	130.24	(39.81)
Gross Profit Margin (%)		29.06	11.41	48.2	NA
EBITDA Margin (%)		11.4	(4.83)	40.93	NA
EBIT Margin (%)		(8.95)	(24.16)	30.47	17.53
Net Income Margin (%)		(31.78)	(48.69)	22.95	NA
Diluted EPS Excl. Extra Items		(1.3)	(1.43)	1.06	NA
Diluted EPS Before Extra, 1 Year Growth (%)		(17.44)	10.26	NM	NA

Estimates	Multiples	2022FY	2023FY E
Period Ended		12/30/2022	12/30/2023
Price/ EPS (x)		3.52	NA
TEV/ Total Revenue (x)		1.78	1.91
TEV/ EBITDA (x)		4.34	NA
Price/ Book (x)		0.65	NA

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Valentios Valentis	5,731,942.00	53.10	21.4
Renaissance Technologies LLC	105,707.00	0.98	0.4
Navellier & Associates Inc.	85,370.00	0.79	0.3
Squarepoint OPS LLC	74,262.00	0.69	0.3
Acadian Asset Management LLC	65,053.00	0.60	0.2

Market Data NASDAQCM:PXS \$3.72		(0.40%) (\$0.01)	
Last (Delayed)	3.72	Avg Daily Volume	7,966
VWAP (Delayed)	3.71	Avg 3M Daily Volume	50,067
Open	3.73	Shares Out. (8/7/2023)	10,794,812
Previous Close	3.73	Float (%)	46.34
Day High/Low	3.74 / 3.6328	Inst. Ownership (%)	4.94
52 wk High/Low	6.26 / 3.25	Shares Sold Short	54,334
Beta 3Y	0.18	Short Int/ShOut (%)	0.50
Market Cap. (\$M)	40.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	67.2		




Status: Operating Subsidiary

Primary Industry (CIQ/GICS): Marine Transportation

Officers & Directors	
Chairman & CEO	Valentios "Eddie" Valentis
CFO & Treasurer	Henry P. Williams
COO & Company Secretary	Konstantinos Lytras

Capitalization	
Reported Currency Code	USD
Closing Price	3.73
Ordinary Shares Outstanding (actual)	10,794,812
Market Capitalization	40,265
Cash & Short Term Investments	32,048
Total Debt	58,945
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	67,162
Total Common Equity	72,793
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	58,945
Total Capital	131,738



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts




Red Cat Holdings, Inc. (NASDAQCM:RCAT) | Public Company

15 Avenue Munoz Rivera | Suite 2200 | San Juan, PR 00901 | USA | (833) 373-3228 | www.redcat holdings.com

Red Cat Holdings, Inc. engages in the provision of various products, services, and solutions to the drone industry. The company operates through two segments: Enterprise and Consumer. It built infrastructure to manages drone fleets and fly, and provide services remotely, navigate confined industrial interior spaces and dangerous military environment. Red Cat Holdings, Inc. is based in San Juan, Puerto Rico. *As of Date: 8/2/2023*

Estimates	Multiples	2023 FY	2024 FY E
Period Ended		04/29/2023	04/29/2024
Price/ EPS (x)		NM	NA
TEV/ Total Revenue (x)		3.89	2.44
TEV/ EBITDA (x)		NM	NA
Price/ Book (x)		0.94	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Jeffrey M. Thompson	12,292,057.00	22.09	11.6
Gregory Ralph French	4,815,533.00	8.65	4.5
Allan Thomas Evans	1,443,945.00	2.60	1.4
Vanguard Group Inc.	1,276,730.00	2.29	1.2
Nicholas R. Liuzza Jr.	975,309.00	1.75	0.9

Market Data NASDAQCM:RCAT \$0.93 (1.64%) (\$0.02)			
Last (Delayed)	0.93	Avg Daily Volume	26,599
VWAP (Delayed)	0.93	Avg 3M Daily Volume	144,132
Open	0.93	Shares Out. (9/19/2023)	55,642,006
Previous Close	0.94	Float (%)	63.12
Day High/Low	0.95 / 0.925	Inst. Ownership (%)	7.52
52 wk High/Low	1.81 / 0.7676	Shares Sold Short	944,542
Beta 3Y	0.89	Short Int/ShOut (%)	1.70
Market Cap. (\$M)	51.7	Div. Yield (%)	NA
Total Enterprise Value (\$M)	44.7		

Status: Operating

Primary Industry (CIQ/GICS): Electronic Equipment and Instruments

Topic Tags: Drone Management, Drone Industry

Officers & Directors

Founder, Chairman, President & CEO	Jeffrey M. Thompson
CFO, Secretary & Treasurer	Joseph P. "Joe" Hernon
Chief Operating Officer	Allan Thomas Evans

Capitalization

Reported Currency Code	USD
Closing Price	0.94
Ordinary Shares Outstanding (actual)	55,642,006
Market Capitalization	52,537
Cash & Short Term Investments	8,860
Total Debt	1,780
Total Preferred Equity	0
Total Minority Interest	NA
Total Enterprise Value (TEV)	45,457
Total Common Equity	49,993
Total Preferred Equity	0
Total Minority Interest	NA
Total Debt	1,780
Total Capital	51,774

Stock Chart



Snow Lake Resources Ltd. (NASDAQCM:LITM) | Public Company

242 Hargrave Street | Suite 1700 | Winnipeg, Manitoba R3C 0V1 | Canada | snowlakelithium.com

Snow Lake Resources Ltd., a natural resource exploration company, engages in the exploration and development of mineral resources in Canada. The company explores for lithium mineral resources. It holds interest in the Thompson Brothers Lithium property covering an area of 55,318 acres; and a 100% interest in Snow Lake Lithium property comprising 122 mineral claims covering an area of 22,386.30 hectares located in nor... *As of Date: 11/4/2022*

Key Statistics	Last 5 Yr Trend	2020 FY 6/30/2020	2021 FY 6/30/2021	2022 FY 6/30/2022
Total Revenue		NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA
EBITDA Margin (%)		NA	NA	NA
EBIT Margin (%)		NA	NA	NA
Net Income Margin (%)		NA	NA	NA
Diluted EPS Excl. Extra Items		(0.01)	(0.03)	(0.47)
Diluted EPS Before Extra, 1 Year Growth (%)		(97.92)	203.33	NM

Multiples	2022 FY
Period Ended	06/29/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	NA
TEV/ EBITDA (x)	NA
Price/ Book (x)	0.84

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Nova Minerals Ltd.	6,600,000.00	32.48	8.0
Chaim D. Berger	1,333,333.00	6.56	1.6
Derek Knight	683,539.00	3.36	0.8
Philip Gross	637,658.00	3.14	0.8
Dale J. Schultz	400,489.00	1.97	0.5

Market Data NASDAQCM:LITM \$1.26 3.72% \$0.05			
Last (Delayed)	1.26	Avg Daily Volume	23,737
VWAP (Delayed)	1.22	Avg 3M Daily Volume	75,529
Open	1.22	Shares Out. (9/18/2023)	20,319,789
Previous Close	1.21	Float (%)	46.54
Day High/Low	1.255 / 1.2	Inst. Ownership (%)	2.63
52 wk High/Low	3.79 / 1	Shares Sold Short	66,457
Beta 3Y	NA	Short Int/ShOut (%)	0.37
Market Cap. (\$M)	24.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	14.9		

Status: Operating

Primary Industry (CIQ/GICS): Diversified Metals and Mining

Topic Tags: Mining Technology, Mineral Resource

Officers & Directors

Chairman of the Board	Nochum Labkowski
Chief Executive Officer	Frank David Wheatley
Chief Financial Officer	Keith Li

Capitalization

Reported Currency Code	CAD
Closing Price	1.21
Ordinary Shares Outstanding (actual)	20,319,789
Market Capitalization	24,587
Cash & Short Term Investments	9,660
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	14,927
Total Common Equity	22,365
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	22,365

Stock Chart





Sologenix Ltd. | Private Company
151 West Green Road London N15 5EA | United Kingdom



Corporate Data **Financial Highlights**

Company Data

Status	Operating
Local Registry ID	12746760
Date of Incorporation	07/16/2020
NACE Code	58.29 - Other software publishing
UK SIC Code	58.29/0 - Other software publishing
Activity Code	58.29/0 - Other software publishing

Company Description

Sologenix Ltd was incorporated in 2020 and is based in London, United Kingdom.
As of Date: 8/10/2023

Officers & Directors

Director	Mr. Muhammed Faruk Aziz
----------	-------------------------

Source: Third Party Private

Period Ended	5/31/2023
Total Assets (\$000)	125
Total Liabilities (\$000)	38
Total Equity (\$000)	87
Net Debt (\$000)	(114)



Strong Global Entertainment, Inc. (NYSEAM:SGE) | Public Company
5960 Fairview Road | Suite 275 | Charlotte, NC 28210 | USA | (704) 471-6784 | www.strong-entertainment.com




Strong Global Entertainment, Inc. manufactures and distributes projection screens and customized screen support systems in North America, South America, Asia, and internationally. It also distributes digital cinema equipment and provides technical support services to the entertainment industry. In addition, the company offers eclipse curvilinear screens for use in theme parks and immersive exhibitions, and military s... As of Date: 5/16/2023

Status: Operating Subsidiary
Primary Industry (CIQ/GICS): Electronic Equipment and Instruments
Topic Tags: Simulation, Military Simulation

Key Statistics				
	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022
Total Revenue		20,820	25,972	39,867
Total Revenues, 1 Year Growth (%)		(44.29)	24.75	53.5
Gross Profit Margin (%)		22.32	23.36	20.68
EBITDA Margin (%)		(2.17)	8.11	3.05
EBIT Margin (%)		(6.35)	4.62	1.3
Net Income Margin (%)		6.94	3.16	4.26
Diluted EPS Excl. Extra Items		NA	NA	NA
Diluted EPS Before Extra, 1 Year Growth (%)		NA	NA	NA

Revenue by Business and Geographic Segments




* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
FG Group Holdings Inc.	6,000,000.00	77.48	12.8
Daniel Kyle Cerminara	30,000.00	0.39	0.1
John W. Struble	20,000.00	0.26	0.0
Marsha G. King	20,000.00	0.26	0.0
Richard Edward Govignon Jr.	20,000.00	0.26	0.0

Market Data NYSEAM:SGE \$1.95 (8.87%) (\$0.19)			
Last (Delayed)	1.95	Avg Daily Volume	2,162
VWAP (Delayed)	1.96	Avg 3M Daily Volume	14,929
Open	2.15	Shares Out. (9/13/2023)	7,743,823
Previous Close	2.14	Float (%)	20.66
Day High/Low	2.15 / 1.95	Inst. Ownership (%)	0.24
52 wk High/Low	4.35 / 1.64	Shares Sold Short	3,813
Beta 3Y	NA	Short Int/ShOut (%)	0.05
Market Cap. (\$M)	16.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	30.3		

Officers & Directors	
Chairman of the Board	Daniel Kyle Cerminara
CEO & Director	Mark D. Roberson
President	Ray F. Boegner

Debt Maturity



Capitalization	
Reported Currency Code	USD
Closing Price	2.14
Ordinary Shares Outstanding (actual)	7,743,823
Market Capitalization	16,571
Cash & Short Term Investments	4,371
Total Debt	18,090
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	30,290
Total Common Equity	8,872
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	18,090
Total Capital	26,962

Stock Chart



Multiples	
Period Ended	12/30/2022
Price/ EPS (x)	NA
TEV/ Total Revenue (x)	0.41
TEV/ EBITDA (x)	12.11
Price/ Book (x)	NA



SYLA Technologies Co., Ltd. - 株式会社シーラホールディングス (NASDAQCM:SYT) | Public Company


Ebisu Prime Square Tower, 7th Floor, 1-1-39 Hiro, Shibuya-ku | Tokyo, Japan | 81 3 4560 0650 | www.syla-tech.jp

SYLA Technologies Co., Ltd., through its subsidiaries, primarily develops, constructs, sells, and manages apartments in Japan. The company engages in the land purchase, design, construction, operation, and maintenance of solar power plants. It also provides real estate leasing, brokerage, and management services; and real estate crowdfunding services on the Rimawari-kun platform. In addition, the company designs, dev... *As of Date: 8/14/2023*

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY
	Trend	12/31/2020	12/31/2021	12/31/2022
Total Revenue		123,115	151,825	168,824
Total Revenues, 1 Year Growth (%)		NA	26.83	32.35
Gross Profit Margin (%)		21.42	18.9	16.34
EBITDA Margin (%)		7.85	5	4.93
EBIT Margin (%)		6.76	4.09	3.53
Net Income Margin (%)		3.32	1.67	1.79
Diluted EPS Excl. Extra Items		0.15	0.09	0.09
Diluted EPS Before Extra, 1 Year Growth (%)		NA	(37.78)	9.19

Multiples	2022 FY
Period Ended	12/30/2022
Price/ EPS (x)	87.34
TEV/ Total Revenue (x)	2.00
TEV/ EBITDA (x)	26.51
Price/ Book (x)	3.95

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts



Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Sy Co. Ltd.	113,620.00	0.44	0.7
Hiroiyuki Sugimoto	25,815.00	0.10	0.2
Yoshiyuki Yuto	24,783.00	0.10	0.2
Right Now Co. Ltd.	20,250.00	0.08	0.1
Tianqi Li	5,389.00	0.02	0.0

Market Data NASDAQCM:SYT \$6.51			
Last (Delayed)	6.51	Avg Daily Volume	118
VWAP (Delayed)	6.33	Avg 3M Daily Volume	1,892
Open	NA	DR Units	NA
Previous Close	6.51	Float (%)	99.26
Day High/Low	NA / 6.51	Inst. Ownership (%)	0.00
52 wk High/Low	8.3999 / 5.28	Shares Sold Short	329
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	168.1	Div. Yield (%)	0.07
Total Enterprise Value (\$M)	311.2		

Status: Operating
Primary Industry (CIQ/GICS): Real Estate Services
Topic Tags: Artificial Intelligence, Machine Learning, Biomass Energy, Crowdfunding, Fintech, Learning Algorith...

Officers & Directors	
Chairman, Co-President & COO	Yoshiyuki Yuto
CEO, Co-President & Director	Hiroiyuki Sugimoto
CFO & Group Executive Officer	Nobuo Higuchi

Debt Maturity



TECO 2030 ASA (OB:TECO) | Public Company


Lysaker Torg 45 | 1366 Lysaker | Norway | 47 67 20 03 00 | teco2030.no

TECO 2030 ASA, together with its subsidiaries, operates as an engineering and equipment development company for the maritime industry in the United States, Asia, South America, and Europe. The company offers TECO Marine Fuel Cell, a modular hydrogen proton exchange membrane fuel cell system primarily designed for heavy-duty marine applications; TECO Future Funnel; TECO Ballast Water Treatment System, which is used to... *As of Date: 5/10/2023*

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FYE	2024FYE
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		233	1,491	1,312	4,719	48,511
Total Revenues, 1 Year Growth (%)		NA	NM	(1.85)	297.74	NM
Gross Profit Margin (%)		68.35	29.72	36.38	12	20
EBITDA Margin (%)		NM	NM	NM	(142)	(2.72)
EBIT Margin (%)		NM	NM	NM	(164)	(8.56)
Net Income Margin (%)		NM	NM	NM	(206)	(9.47)
Diluted EPS Excl. Extra Items		(0.06)	(0.05)	(0.07)	(0.06)	(0.03)
Diluted EPS Before Extra, 1 Year Growth (%)		(40.18)	(25.62)	54.76	NM	(55.56)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(0.06)	(0.02)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	94.71	25.45
			TEV/ EBITDA (x)	NM	NM
			Price/ Book (x)	9.91	4.25

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Teco Group AS	52,041,430.00	32.44	30.2
Nikko Asset Management Co. Ltd.	28,149,442.00	17.55	16.3
Citigroup Inc.	16,186,688.00	10.09	9.4
BNY Mellon Advisors Inc.	13,497,841.00	8.41	7.8
Bettina Nowak	8,007,430.00	4.99	4.6

Market Data OB:TECO \$0.58 (4.20%) (\$0.03)			
Last (Delayed)	0.58	Avg Daily Volume	23,681
VWAP (Delayed)	0.55	Avg 3M Daily Volume	38,212
Open	0.61	Shares Out. (9/1/2023)	160,420,204
Previous Close	0.61	Float (%)	47.16
Day High/Low	0.609705 / 0.580585	Inst. Ownership (%)	41.70
52 wk High/Low	1.25217 / 0.420878	Shares Sold Short	NA
Beta 3Y	0.65	Short Int/ShOut (%)	NA
Market Cap. (\$M)	97.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	115.8		

Status: Operating
Primary Industry (CIQ/GICS): Industrial Machinery and Supplies and Components
Topic Tags: Fuel Cells, ClimateTech, Water Purification, Proton Exchange, Water Treatment

Officers & Directors	
Chairman of the Board	Sigurd Gaarder Lange
Group Chief Executive Officer	Tore Enger
Chief Financial Officer	Pal Christian Johnsen

Capitalization	
Reported Currency Code	NOK
Closing Price	0.61
Ordinary Shares Outstanding (actual)	160,420,204
Market Capitalization	97,225
Cash & Short Term Investments	269
Total Debt	19,312
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	115,801
Total Common Equity	4,627
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	19,312
Total Capital	23,939



Tharimmune, Inc. (NASDAQCM:THAR) | Public Company

1200 Route 22 East | Suite 2000 | Bridgewater, NJ 08807 | USA | (908) 955-3140 | www.hillstreambio.com

Tharimmune, Inc., a biotechnology company, engages in developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. Its early-stage immuno-oncology pipeline includes antibodies targeting epitopes against validated targets in various solid tumors. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune... As of Date: 9/25/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY
	Trend	12/31/2020	12/31/2021	12/31/2022
Total Revenue		NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA
EBITDA Margin (%)		NA	NA	NA
EBIT Margin (%)		NA	NA	NA
Net Income Margin (%)		NA	NA	NA
Diluted EPS Excl. Extra Items		(0.38)	(0.35)	(0.75)
Diluted EPS Before Extra, 1 Year Growth (%)		2.71	(8.86)	115.71

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Randy D. Milby	2,937,940.00	16.69	0.6
Sabby Management LLC	1,325,219.00	7.53	0.3
Sireesh Appajosyula	1,256,312.00	7.14	0.2
Veronica Todd	431,818.00	2.45	0.1
Leonard L. Mazur	123,733.00	0.70	0.0

Market Data NASDAQCM:THAR \$0.18 (2.79%) (\$0.01)			
Last (Delayed)	0.18	Avg Daily Volume	112,612
VWAP (Delayed)	0.19	Avg 3M Daily Volume	681,552
Open	0.20	Shares Out. (8/30/2023)	17,602,665
Previous Close	0.19	Float (%)	65.35
Day High/Low	0.199 / 0.18	Inst. Ownership (%)	1.14
52 wk High/Low	2.65 / 0.1723	Shares Sold Short	52,743
Beta 3Y	NA	Short Int/ShOut (%)	0.30
Market Cap. (\$M)	3.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(0.7)		

Multiples	2022 FY
Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	NA
TEV/ EBITDA (x)	NA
Price/ Book (x)	0.40

Status: Operating
 Primary Industry (CIQ/GICS): Biotechnology
 Topic Tags: Oncology, Tumor

Officers & Directors
 President, Chairman & CEO Randy D. Milby
 Chief Financial Officer Thomas P. "Tom" Hess
 COO & Director Sireesh Appajosyula

Debt Maturity
 No data available

Capitalization	
Reported Currency Code	USD
Closing Price	0.19
Ordinary Shares Outstanding (actual)	17,602,665
Market Capitalization	3,348
Cash & Short Term Investments	3,904
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(556)
Total Common Equity	3,069
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	3,069



TMC the metals company Inc. (NASDAQGS:TMC) | Public Company

595 Howe Street | 10th Floor | Vancouver, British Columbia V6C 2T5 | Canada | (574) 252-9333 | metals.co

TMC the metals company Inc., a deep-sea minerals exploration company, focuses on the collection, processing, and refining of polymetallic nodules found on the seafloor in the Clarion Clipperton Zone (CCZ) in the south-west of San Diego, California. It primarily explores for nickel, cobalt, copper, and manganese products. The company holds exploration and commercial rights in three polymetallic nodule contract areas i... As of Date: 3/28/2023

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	NA	78,975
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	(83.57)
EBIT Margin (%)		NA	NA	NA	NA	(63.98)
Net Income Margin (%)		NA	NA	NA	NA	(60.82)
Diluted EPS Excl. Extra Items		(0.32)	(0.69)	(0.71)	(0.25)	(0.14)
Diluted EPS Before Extra, 1 Year Growth (%)		(3.32)	117.57	3.3	(65.1)	(44.96)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(0.25)	(0.14)	Period Ended	12/30/2022	12/30/2023
RECOMMENDATION			Price/ EPS (x)	NM	NM
1.67 - Outperform			TEV/ Total Revenue (x)	NA	NA
Target: 4.40			TEV/ EBITDA (x)	NM	NM
10/19/2023			Price/ Book (x)	5.93	4.62

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
ERAS Capital LLC	56,453,495.00	18.10	52.2
Allseas Group SA	53,780,268.00	17.24	49.7
Gerard Barron	15,459,563.00	4.96	14.3
First Manhattan Co. LLC	7,066,000.00	2.27	6.5
Andrew Carlyle Greig	4,095,827.00	1.31	3.8

Market Data NASDAQGS:TMC \$0.93 1.08% \$0.01			
Last (Delayed)	0.93	Avg Daily Volume	496,455
VWAP (Delayed)	0.91	Avg 3M Daily Volume	3,785,859
Open	0.92	Shares Out. (8/14/2023)	311,883,210
Previous Close	0.92	Float (%)	56.06
Day High/Low	0.935 / 0.8902	Inst. Ownership (%)	4.36
52 wk High/Low	3.2 / 0.511	Shares Sold Short	9,290,799
Beta 3Y	1.00	Short Int/ShOut (%)	2.98
Market Cap. (\$M)	285.9	Div. Yield (%)	NA
Total Enterprise Value (\$M)	265.9		

Status: Operating
 Primary Industry (CIQ/GICS): Diversified Metals and Mining
 Topic Tags: Energy Management, Smart Energy, ClimateTech, Electric Vehicle, Energy Storage, Energy Storage Mark...

Officers & Directors
 CEO & Chairman of the Board Gerard Barron
 Chief Financial Officer Craig Shesky
 Chief Accounting Officer Arthur Chen

Capitalization	
Reported Currency Code	USD
Closing Price	0.92
Ordinary Shares Outstanding (actual)	311,883,210
Market Capitalization	288,461
Cash & Short Term Investments	20,006
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	268,455
Total Common Equity	44,055
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	44,055





Tonix Pharmaceuticals Holding Corp. (NASDAQCM:TNXP) | Public Company

26 Main Street | Suite 101 | Chatham, NJ 07928 | USA | (862) 799-8599 | www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, develops therapeutics and vaccines to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, inc... *As of Date: 5/10/2023*

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	11,267	24,467
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	117.16
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NM	NM
Net Income Margin (%)		NA	NA	NA	NM	(248.94)
Diluted EPS Excl. Extra Items		(110.31)	(50.65)	(20.44)	(7.46)	(4.04)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	(54.08)	(59.65)	NA	NA

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022FY	2023FYE
EPS (\$)	(7.46)	(4.04)	Period Ended	12/30/2022	12/30/2023
RECOMMENDATION			Price/ EPS (x)	NM	NM
TEV/ Total Revenue (x)			TEV/ Total Revenue (x)	NA	NM
TEV/ EBITDA (x)			TEV/ EBITDA (x)	NM	NA
Price/ Book (x)			Price/ Book (x)	0.03	NA

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Vanguard Group Inc.	398,754.00	1.83	0.2
Renaissance Technologies LLC	211,421.00	0.97	0.1
Geode Capital Management LLC	85,365.00	0.39	0.0
Acadian Asset Management LLC	68,743.00	0.32	0.0
BlackRock Inc.	48,344.00	0.22	0.0

Market Data NASDAQCM:TNXP \$0.54 2.00% \$0.01			
Last (Delayed)	0.54	Avg Daily Volume	173,828
VWAP (Delayed)	0.55	Avg 3M Daily Volume	440,862
Open	0.55	Shares Out. (9/29/2023)	21,812,341
Previous Close	0.53	Float (%)	99.98
Day High/Low	0.55 / 0.54	Inst. Ownership (%)	4.84
52 wk High/Low	9.8125 / 0.4925	Shares Sold Short	305,547
Beta 3Y	1.31	Short Int/ShOut (%)	1.72
Market Cap. (\$M)	11.6	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(12.7)		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: COVID-19, Central Nervous System, Chronic Diseases, Immunology, Infectious Diseases, Neurology, Onc...

Officers & Directors	
Co-Founder, President, CEO & Chairman	Seth Lederman
CFO & Treasurer	Bradley Saenger
Chief Operating Officer	Jessica Edgar Morris

Capitalization	
Reported Currency Code	USD
Closing Price	0.53
Ordinary Shares Outstanding (actual)	21,812,341
Market Capitalization	11,648
Cash & Short Term Investments	25,617
Total Debt	1,267
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(12,702)
Total Common Equity	140,463
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	1,267
Total Capital	141,730



TransCode Therapeutics, Inc. (NASDAQCM:RNAZ) | Public Company

6 Liberty Square | Suite 2382 | Boston, MA 02109 | USA | (857) 837-3099 | www.transcodetherapeutics.com

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The c... *As of Date: 5/3/2023*

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(10.11)	(16.24)	(27.07)	(5.65)	(1.25)
Diluted EPS Before Extra, 1 Year Growth (%)		286.01	60.65	66.65	(79.07)	(77.88)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022FY	2023FYE
EPS (\$)	(5.65)	(1.25)	Period Ended	12/30/2022	12/30/2023
RECOMMENDATION			Price/ EPS (x)	NM	NM
TEV/ Total Revenue (x)			TEV/ Total Revenue (x)	NA	NA
TEV/ EBITDA (x)			TEV/ EBITDA (x)	NM	NA
Price/ Book (x)			Price/ Book (x)	0.10	NA

Top Holders			
Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Tang Capital Management, LLC	354,700.00	12.23	0.2
Sabby Management LLC	188,437.00	6.50	0.1
Robert Michael Dudley	180,262.00	6.21	0.1
Anna Moore	77,639.00	2.68	0.0
Zdravka Medarova	77,639.00	2.68	0.0


Market Data NASDAQCM:RNAZ \$0.48 (4.73%) (\$0.02)			
Last (Delayed)	0.48	Avg Daily Volume	750,664
VWAP (Delayed)	0.47	Avg 3M Daily Volume	2,759,207
Open	0.50	Shares Out. (8/14/2023)	2,025,674
Previous Close	0.50	Float (%)	67.37
Day High/Low	0.5 / 0.45	Inst. Ownership (%)	0.60
52 wk High/Low	31 / 0.4505	Shares Sold Short	24,365
Beta 3Y	NA	Short Int/ShOut (%)	1.20
Market Cap. (\$M)	1.4	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(2.1)		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Chronic Diseases, Oncology, Vaccines, Cancer, Tumor

Officers & Directors	
Chairman of the Board	Philippe P. Calais
Co-Founder, CEO, President & Director	Robert Michael Dudley
Co-Founder & CTO	Zdravka Medarova

Capitalization	
Reported Currency Code	USD
Closing Price	0.50
Ordinary Shares Outstanding (actual)	2,900,674
Market Capitalization	1,446
Cash & Short Term Investments	3,572
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	(2,126)
Total Common Equity	2,092
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	2,092





Ur-Energy Inc. (TSX:URE) | Public Company


10758 West Centennial Road | Suite 200 | Littleton, CO 80127 | USA | (720) 981-4588 | www.ur-energy.com

Ur-Energy Inc. engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. Its flagship property is the Lost Creek project comprising a total of approximately 1,800 unpatented mining claims and three Wyoming mineral leases covering an area of approximately 35,400 acres located in the Great Divide Basin, Wyo... As of Date: 5/28/2023

Key Statistics	Last 5 Yr Trend	2020 FY	2021 FY	2022 FY	2023FY E	2024FY E
		12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		8,316	16	19	26,535	60,100
Total Revenues, 1 Year Growth (%)		(74.22)	(99.81)	18.75	NM	126.49
Gross Profit Margin (%)		(69.13)	NM	NM	NA	NA
EBITDA Margin (%)		(102.24)	NM	NM	NA	NA
EBIT Margin (%)		(160.43)	NM	NM	17.75	41.76
Net Income Margin (%)		(177.79)	NM	NM	(34.06)	28.12
Diluted EPS Excl. Extra Items		(0.09)	(0.12)	(0.08)	(0.02)	0.17
Diluted EPS Before Extra, 1 Year Growth (%)		70.98	33.32	(33.33)	(78.13)	NM

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023FY E
EPS (\$)	(0.02)	0.17	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NM	11.89
			TEV/ EBITDA (x)	NM	NA
			Price/ Book (x)	5.06	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
MM Asset Management Inc	25,938,331.00	9.79	36.5
ALPS Advisors Inc.	15,230,661.00	5.75	21.4
CQS Management Ltd.	13,006,553.00	4.91	18.3
Azarias Capital Management LP	12,347,158.00	4.66	17.4
Mirae Asset Global Investments Co. Ltd.	11,297,505.00	4.26	15.9

Market Data TSX:URE \$1.38 (2.07%) (\$0.03)			
Last (Delayed)	1.38	Avg Daily Volume	32,425
VWAP (Delayed)	1.38	Avg 3M Daily Volume	82,672
Open	1.39	Shares Out. (8/24/2023)	264,900,249
Previous Close	1.41	Float (%)	88.48
Day High/Low	1.40622 / 1.36251	Inst. Ownership (%)	35.29
52 wk High/Low	1.66124 / 0.81969	Shares Sold Short	NA
Beta 3Y	1.53	Short Int/ShOut (%)	NA
Market Cap. (\$M)	372.5	Div. Yield (%)	NA
Total Enterprise Value (\$M)	315.5		



Status: Operating

Primary Industry (CIQ/GICS): Coal and Consumable Fuels

Officers & Directors

CEO, President & Non-Independent Chairman	John W. Cash
CFO & Chief Administrative Officer	Roger L. Smith
Chief Operating Officer	Steven M. Hatten

Capitalization

Reported Currency Code	USD
Closing Price	1.41
Ordinary Shares Outstanding (actual)	264,900,249
Market Capitalization	372,509
Cash & Short Term Investments	67,958
Total Debt	8,822
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	315,453
Total Common Equity	89,411
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	8,822
Total Capital	98,233

Stock Chart



Verde Bioresins, Inc. | Private Company

TLGY Acquisition Corporation (NASDAQM:TLGY) | Public Company

Verde Bioresins, Inc. manufactures plant based PolyEthylene resins. Verde Bioresins, Inc. was formerly known as Ezonix Bio Technologies, Inc. and changed its name to Verde Bioresins, Inc. in April 2021. The company was incorporated in 2020 and is based in Los Angeles, California.

Latest Activity

Key Developments

Verde Bioresins, Inc. Announces Board Changes	Other Executive or Board Change	6/22/2023
Verde Bioresins, Inc. entered into a definitive business combination agreement to acquire TLGY Acquisition Corporation (NasdaqGM:TLGY) from TLGY Sponsors LLC and other for approximately \$780 million in a reverse merger transaction.	M&A: Transaction Announcement	6/22/2023

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Jin-Goon Kim	5,344,700.00	40.90	58.6
Westchester Capital Management LLC	633,325.00	4.85	6.9
Fir Tree Capital Management LP	562,761.00	4.31	6.2
Karpus Management Inc	506,650.00	3.88	5.6
Castle Creek Arbitrage LLC	500,000.00	3.83	5.5

Market Data NASDAQM:TLGY \$10.97

Last (Delayed)	10.97	Avg Daily Volume	2
VWAP (Delayed)	11.00	Avg 3M Daily Volume	21,703
Open	NA	Shares Out. (9/25/2023)	7,318,182
Previous Close	10.97	Float (%)	56.00
Day High/Low	NA / 10.97	Inst. Ownership (%)	54.81
52 wk High/Low	11.35 / 10.05	Shares Sold Short	9
Beta 3Y	NA	Short Int/ShOut (%)	0.00
Market Cap. (\$M)	143.4	Div. Yield (%)	NA
Total Enterprise Value (\$M)	144.2		



Status: Operating

Primary Industry (CIQ/GICS): Asset Management and Custody Banks, Chemicals

Officers & Directors

Founder, Chairman & CEO	Jin-Goon Kim
President, CFO & Executive Director	Steven Norman
Board Director/Trustee	Hyun-Chan Cho

Capitalization

Reported Currency Code	USD
Closing Price	10.97
Ordinary Shares Outstanding (actual)	13,068,182
Market Capitalization	143,358
Cash & Short Term Investments	57
Total Debt	857
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	144,158
Total Common Equity	(13,248)
Total Minority Interest	NA
Total Debt	857
Total Capital	(12,390)

Stock Chart





VERSES AI Inc. (NEOE:VERS) | Public Company


810 Quayside Drive | Suite 205 | New Westminster, British Columbia V3M 6B9 | Canada | (323) 868-0514 | www.verses.ai

Verses Labs, Inc develops suite of integrated technologies that offer spatial rights management capabilities to enable dynamic workflows, verifiable traceability, intelligent automation and collaborative ecosystems that address the need for multi-party privacy, security, and interoperability by design. The company offers technologies such as KOSM, network operating system for distributed intelligence and WAYFINDER, O... As of Date: 11/23/2022

Status: Operating
Primary Industry (CIQ/GICS): Systems Software

Officers & Directors

Chairman of the Board	Jay Alan Samit
Founder, CEO & Director	Gabriel Rene
Founder, President & Director	Dan Mapes



Capitalization

Reported Currency Code	USD
Closing Price	0.98
Ordinary Shares Outstanding (actual)	139,466,075
Market Capitalization	136,167
Cash & Short Term Investments	6,278
Total Debt	220
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	130,322
Total Common Equity	1,855
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	220
Total Capital	2,075




Multiples 2023 FY

Period Ended	03/30/2023
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	85.27
TEV/ EBITDA (x)	NM
Price/ Book (x)	139.48

Key Statistics

	Last 5 Yr Trend	2021 FY 3/31/2021	2022 FY 3/31/2022	2023 FY 3/31/2023
Total Revenue		97	2,774	1,605
Total Revenues, 1 Year Growth (%)		(22.24)	NM	(42.13)
Gross Profit Margin (%)		NM	14.05	29.25
EBITDA Margin (%)		NA	(157.25)	NM
EBIT Margin (%)		NM	(157.97)	NM
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(0.04)	(0.11)	(0.17)
Diluted EPS Before Extra, 1 Year Growth (%)		NA	181.77	51.98



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Dan Mapes	31,275,001.00	22.42	30.5
Gabriel Rene	31,275,001.00	22.42	30.5
Scott Paterson	375,000.00	0.27	0.4
Gordon Scott Paterson	375,000.00	0.27	0.4
Jon DeVos	195,600.00	0.14	0.2

Market Data NEOE:VERS \$0.98 (0.74%) (\$0.01)

Last (Delayed)	0.98	Avg Daily Volume	76,695
VWAP (Delayed)	0.99	Avg 3M Daily Volume	267,253
Open	0.98	Shares Out. (9/8/2023)	76,966,075
Previous Close	0.98	Float (%)	54.44
Day High/Low	1.01277 / 0.976342	Inst. Ownership (%)	NA
52 wk High/Low	2.71044 / 0.327876	Shares Sold Short	NA
Beta 3Y	NA	Short Int/ShOut (%)	NA
Market Cap. (\$M)	136.2	Div. Yield (%)	NA
Total Enterprise Value (\$M)	130.3		



Viomi Technology Co., Ltd (NASDAQ:VIOT) | Public Company

Tower C, Xingang East Road, Room 1302, Wansheng Square, Haizhu District | Guangzhou , Guangdong 510220 | China | 86 20 8930 9496 | ir.viomi.com


Viomi Technology Co., Ltd, through its subsidiaries, develops and sells Internet-of-things-enabled (IoT-enabled) smart home products in the People's Republic of China. The company offers IoT-enabled smart home products, including smart water purification systems; smart kitchen products, such as refrigerators, oven steamers, dishwashers, range hoods, and gas stoves; and other smart products comprising air conditioning... As of Date: 4/28/2023

Status: Operating
Primary Industry (CIQ/GICS): Household Appliances

Topic Tags: Physical Security, Water Purification, Smart Locks, Water Filter

Key Statistics

	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022
Total Revenue		844,902	822,278	481,165
Total Revenues, 1 Year Growth (%)		25.35	(8.96)	(39.05)
Gross Profit Margin (%)		18.59	22.59	22.8
EBITDA Margin (%)		4.09	2.58	(5.84)
EBIT Margin (%)		3.16	1.22	(8.58)
Net Income Margin (%)		2.98	1.67	(8.52)
Diluted EPS Excl. Extra Items		0.35	0.19	(0.59)
Diluted EPS Before Extra, 1 Year Growth (%)		(40.74)	(50)	NM



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Holder	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Xiaoping Chen	23,476,440.00	33.98	21.2
Xiaomi Corp.	11,381,600.00	16.47	10.3
Shunwei Inc.	10,703,788.00	15.49	9.6
Guolao Investments	801,782.00	1.16	0.7
Acadian Asset Management LLC	712,122.00	1.03	0.6

Market Data NASDAQ:VIOT \$0.90 (0.63%) (\$0.01)

Last (Delayed)	0.90	Avg Daily Volume	33,184
VWAP (Delayed)	0.90	Avg 3M Daily Volume	50,127
Open	0.90	DR Units (3/31/2019)	11,400,000
Previous Close	0.90	Float (%)	32.03
Day High/Low	0.9001 / 0.8952	Inst. Ownership (%)	1.75
52 wk High/Low	1.6 / 0.7021	Shares Sold Short	8,893
Beta 3Y	1.50	Short Int/ShOut (%)	0.08
Market Cap. (\$M)	62.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	(42.6)		

Officers & Directors

Founder, Chairman & CEO	Xiaoping Chen
IR Director	Zhi Hong "Cecilia" Li
Board Director/Trustee	Jun Li

Capitalization

Reported Currency Code	CNY
Closing Price	0.90
Ordinary Shares Outstanding (actual)	69,100,439
Market Capitalization	62,260
Cash & Short Term Investments	140,084
Total Debt	36,076
Total Preferred Equity	NA
Total Minority Interest	(821)
Total Enterprise Value (TEV)	(42,568)
Total Common Equity	192,600
Total Preferred Equity	NA
Total Minority Interest	(821)
Total Debt	36,076
Total Capital	227,856



Multiples 2022 FY

Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	NM
TEV/ EBITDA (x)	NM
Price/ Book (x)	0.31




Virios Therapeutics, Inc. (NASDAQM:VIRI) | Public Company

44 Milton Avenue | Alpharetta, GA 30009 | USA | (866) 620-8655 | www.virios.com

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of man... *As of Date: 4/11/2023*

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023 FY E	2024 FY E
	Trend	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Revenue		NA	NA	NA	NA	NA
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NA
Net Income Margin (%)		NA	NA	NA	NA	NA
Diluted EPS Excl. Extra Items		(2.1)	(1.92)	(1.11)	(0.34)	(0.28)
Diluted EPS Before Extra, 1 Year Growth (%)		NM	(8.57)	(42.19)	(69.37)	(17.65)



Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023 FY E
EPS (\$)	(0.34)	(0.28)	Period Ended	12/30/2022	12/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NA	NA
			TEV/ EBITDA (x)	NA	NA
			Price/ Book (x)	2.11	NA

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Brian Corday	1,327,051.00	6.89	1.1
William L. Pridgen	761,279.00	3.96	0.6
Ionic Ventures LLC	697,292.00	3.62	0.6
Vanguard Group Inc.	210,996.00	1.10	0.2
Richard Alan Burch	147,681.00	0.77	0.1


Market Data NASDAQM:VIRI \$0.82	(3.42%) (\$0.03)		
Last (Delayed)	0.82	Avg Daily Volume	41,575
VWAP (Delayed)	0.83	Avg 3M Daily Volume	562,869
Open	0.85	Shares Out. (8/11/2023)	19,247,437
Previous Close	0.85	Float (%)	84.34
Day High/Low	0.8871 / 0.814	Inst. Ownership (%)	4.05
52 wk High/Low	2.42 / 0.218951	Shares Sold Short	465,066
Beta 3Y	NA	Short Int/ShOut (%)	2.42
Market Cap. (\$M)	16.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	11.7		



Status: Operating
Primary Industry (CIQ/GICS): Biotechnology
Topic Tags: Pain Management, Rheumatology, Fibromyalgia

Officers & Directors	
Chairman & CEO	Gregory Duncan
Founder & Director	William L. "Skip" Pridgen
CFO, SVP of Finance, Corporate Secreta...	Angela Walsh

Capitalization	
Reported Currency Code	USD
Closing Price	0.85
Ordinary Shares Outstanding (actual)	19,247,437
Market Capitalization	16,279
Cash & Short Term Investments	4,590
Total Debt	0
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	11,689
Total Common Equity	4,692
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	0
Total Capital	4,692




Vision Marine Technologies Inc. (NASDAQM:VMAR) | Public Company

730 Boulevard du CurE-Boivin | Boisbriand, Quebec J7G 2A7 | Canada | www.visionmarinetechnologies.com

Vision Marine Technologies Inc. designs, develops, and manufactures electric outboard powertrain systems and electric boats in Canada, the United States, and internationally. It operates in two segments, Sale of Electric Boats and Rental of Electric Boats. The company offers outboard motors, boat parts, and related maintenance services. In addition, it provides its products through retail e-commerce website, as well ... *As of Date: 12/1/2022*

Key Statistics	Last 5 Yr	2020 FY	2021 FY	2022 FY	2023 FY E	2024 FY E
	Trend	8/31/2020	8/31/2021	8/31/2022	8/31/2023	8/31/2024
Total Revenue		1,798	2,771	5,780	5,057	15,600
Total Revenues, 1 Year Growth (%)		(15.76)	45.37	109.2	NA	208.82
Gross Profit Margin (%)		25	45.65	44.7	14	28
EBITDA Margin (%)		(82.15)	NM	(169.9)	(235.29)	(31.43)
EBIT Margin (%)		(89.19)	NM	(173.77)	(267.65)	(48.1)
Net Income Margin (%)		(94.14)	NM	(178.37)	(207.35)	(45.71)
Diluted EPS Excl. Extra Items		(0.41)	(1.61)	(1.24)	(1.12)	(0.45)
Diluted EPS Before Extra, 1 Year Growth (%)		NM	274.44	(22.69)	NA	(60)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY	2023 FY E
EPS (\$)	(1.11)	(0.44)	Period Ended	08/30/2022	08/30/2023
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	4.18	5.27
			TEV/ EBITDA (x)	NM	NM
			Price/ Book (x)	1.06	NA



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
9134-0489 Quebec Inc.	2,140,506.00	19.15	4.7
Robert Ghetti	1,066,895.00	9.54	2.4
James Stafford	547,297.00	4.90	1.2
Michel Amyot	536,805.00	4.80	1.2
Alexandre Mongeon	296,602.00	2.65	0.7

Market Data NASDAQM:VMAR \$2.18	(1.36%) (\$0.03)		
Last (Delayed)	2.18	Avg Daily Volume	8,763
VWAP (Delayed)	2.24	Avg 3M Daily Volume	104,978
Open	2.22	Shares Out. (9/20/2023)	11,178,234
Previous Close	2.21	Float (%)	54.55
Day High/Low	2.356 / 2.18	Inst. Ownership (%)	1.38
52 wk High/Low	5.65 / 2.15	Shares Sold Short	97,644
Beta 3Y	NA	Short Int/ShOut (%)	0.88
Market Cap. (\$M)	24.7	Div. Yield (%)	NA
Total Enterprise Value (\$M)	26.1		



Status: Operating Subsidiary
Primary Industry (CIQ/GICS): Leisure Products

Officers & Directors	
Chairman of the Board	Carter Murray
Co-Founder, CEO & Director	Alexandre Mongeon
Chief Financial Officer	Kulwant Sandher



Capitalization	
Reported Currency Code	CAD
Closing Price	2.21
Ordinary Shares Outstanding (actual)	11,178,234
Market Capitalization	24,704
Cash & Short Term Investments	1,130
Total Debt	2,540
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	26,113
Total Common Equity	9,045
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	2,540
Total Capital	11,585






Wearable Devices Ltd. (NASDAQM:WLDS) | Public Company

5 Ha-Tnufa Street | Yokneam Illit, Northern 2066736 | Israel | 972 4 618 5670 | wearabledevices.co.il

Wearable Devices Ltd. engages in the development of a non-invasive neural input interface for controlling digital devices using subtle touchless finger movements. The company offers Mudra Inspire development kits that enable users to control digital devices, including consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, personal computers and laptop computers, drones, robots, and ot... As of Date: 4/18/2023

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022
Total Revenue		57	142	45
Total Revenues, 1 Year Growth (%)		(76.45)	149.12	(68.31)
Gross Profit Margin (%)		84.21	92.96	77.78
EBITDA Margin (%)		NM	NM	NM
EBIT Margin (%)		NM	NM	NM
Net Income Margin (%)		NM	NM	NM
Diluted EPS Excl. Extra Items		(0.2)	(0.27)	(0.53)
Diluted EPS Before Extra, 1 Year Growth (%)		28.67	38.25	96.54

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Guy Wagner	1,800,000.00	11.29	1.4
Leeor Langer	1,350,000.00	8.47	1.0
Asher Dahan	1,350,000.00	8.47	1.0
OurCrowd Ltd.	1,226,442.00	7.69	0.9
Alumot	1,198,774.00	7.52	0.9

Market Data NASDAQM:WLDS \$0.79		2.60% \$0.02	
Last (Delayed)	0.79	Avg Daily Volume	9,947
VWAP (Delayed)	0.80	Avg 3M Daily Volume	363,146
Open	0.78	Shares Out. (8/30/2023)	15,942,984
Previous Close	0.77	Float (%)	49.11
Day High/Low	0.8463 / 0.78	Inst. Ownership (%)	0.32
52 wk High/Low	2.56 / 0.39	Shares Sold Short	70,718
Beta 3Y	NA	Short Int/ShOut (%)	0.44
Market Cap. (\$M)	12.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	4.8		



Status: Operating

Primary Industry (CIQ/GICS): Technology Hardware, Storage and Peripherals

Topic Tags: Mobile Development Tools, Software Development, Wearables, Human Computer Interaction, Development ...

Officers & Directors

Co-Founder, Chairman & CEO	Asher Dahan
Co-Founder, Chief Scientific Officer, ...	Guy Wagner
Co-Founder & CTO	Leeor Langer

Debt Maturity

No data available

Capitalization

Reported Currency Code	USD
Closing Price	0.77
Ordinary Shares Outstanding (actual)	15,942,984
Market Capitalization	12,276
Cash & Short Term Investments	7,957
Total Debt	473
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	4,792
Total Common Equity	7,641
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	473
Total Capital	8,114

Stock Chart



Multiples	2022 FY
Period Ended	12/30/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	45.89
TEV/ EBITDA (x)	NM
Price/ Book (x)	1.16



Windtree Therapeutics, Inc. (NASDAQM:WINT) | Public Company


2600 Kelly Road | Suite 100 | Warrington, PA 18976 | USA | (215) 488-9300 | windtreex.com

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aer... As of Date: 4/7/2023

Key Statistics	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022	2023FY E 12/31/2023	2024FY E 12/31/2024
Total Revenue		NA	NA	NA	NA	2,000
Total Revenues, 1 Year Growth (%)		NA	NA	NA	NA	NA
Gross Profit Margin (%)		NA	NA	NA	NA	NA
EBITDA Margin (%)		NA	NA	NA	NA	NA
EBIT Margin (%)		NA	NA	NA	NA	NM
Net Income Margin (%)		NA	NA	NA	NA	NM
Diluted EPS Excl. Extra Items		(104.02)	(136.64)	(62.24)	(3.4)	(1.81)
Diluted EPS Before Extra, 1 Year Growth (%)		(17.26)	31.36	(54.45)	NA	(46.76)

Estimates	Current Year ('23)	Next Year ('24)	Multiples	2022 FY 12/30/2022	2023FY E 12/30/2023
EPS (\$)	(3.40)	(1.81)	Period Ended		
			Price/ EPS (x)	NM	NM
			TEV/ Total Revenue (x)	NA	NA
			TEV/ EBITDA (x)	NM	NA
			Price/ Book (x)	0.08	NA

Revenue by Business and Geographic Segments



* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Lincoln Park Capital LLC	307,167.00	5.97	0.3
The Lind Partners, LLC	290,102.00	5.63	0.3
Lee's Pharmaceutical Holdings Ltd.	96,337.00	1.87	0.1
Panacea Venture Management Co. Ltd.	68,984.00	1.34	0.1
Virtu Financial Inc.	42,667.00	0.83	0.0

Market Data NASDAQM:WINT \$1.02		(0.96%) (\$0.01)	
Last (Delayed)	1.02	Avg Daily Volume	42,659
VWAP (Delayed)	1.03	Avg 3M Daily Volume	118,818
Open	1.05	Shares Out. (8/7/2023)	5,148,219
Previous Close	1.03	Float (%)	91.48
Day High/Low	1.05 / 1.02	Inst. Ownership (%)	10.04
52 wk High/Low	19.055 / 0.86	Shares Sold Short	16,323
Beta 3Y	0.67	Short Int/ShOut (%)	0.32
Market Cap. (\$M)	5.3	Div. Yield (%)	NA
Total Enterprise Value (\$M)	11.3		



Status: Operating Subsidiary


Primary Industry (CIQ/GICS): Biotechnology

Topic Tags: COVID-19, Cardiovascular, Infectious Diseases, Internal Diseases, Nephrology, Respiratory, Vaccines

Officers & Directors

Chairman, President, CEO & Director	Craig E. Fraser
Interim Chief Financial Officer	John A. Tattory
Senior VP & COO	Eric L. Curtis

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	1.03
Ordinary Shares Outstanding (actual)	5,148,219
Market Capitalization	5,303
Cash & Short Term Investments	11,467
Total Debt	17,496
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	11,332
Total Common Equity	11,604
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	17,496
Total Capital	29,100

Stock Chart



Innovative International Acquisition Corp. (NASDAQCM:IOAC) | Public Company
 ZoomCar, Inc. | Private Company
 7th Floor, Tower-B, Diamond District 150, Hal Airport Road, Kodihalli Bengaluru 560 008 Karnataka India

ZoomCar, Inc. is a holding company, which through its subsidiary ZoomCar India Private Ltd. provides a self-drive car rental service that allows a client to rent cars by the hour, day, week, or month. ZoomCar, Inc. was incorporated in 2012 and is based in Bengaluru, India.


Corporate Data Latest Rounds of Funding

Company Data

Status	Operating
Primary Industry (CIQ/GICS)	Passenger Ground Transportation
Topic Tags	Car Sharing, Rent Cars, Rent Car
Date of Incorporation	04/18/2012
SIC Code	7514
NACE Code	77.1 - Renting and leasing of motor vehicles
NAICS Code	532111 - Passenger Car Rental

Officers & Directors

Co-Founder, CEO, President & Director	Gregory Moran
Chief Financial Officer	Geiv Dubash
Chief Operating Officer	Sudhindra Reddy



Funding Overview

Summary	8.89 (\$M) Disclosed	0.24 (\$B)	8.89 (\$M)* Raised in 2 Rounds by 1 Investor.
Total Funding	Latest Available Post-Money Valuation		It has been 6 Months since the last funding round.

Overview

Announced Date	Round Type Post-Money (\$M)	Round Number	Size (\$000)	Pre-Money (\$M)
4/6/2023	Mature NA	3	NA	NA
9/1/2021	Mature NA	2	7,890	NA
4/16/2021 E	Series 1	1,000	242	243

*This number reflects the estimated value of the total new money raised through private placement rounds.

Current/Pending Investors

INVESTOR	INITIAL INVESTMENT DATE	LAST INVESTMENT DATE	STAKE TYPE	AGGREGATE LATES AMOUNT INVESTED(\$000)
Altnet Systems, Inc.	Apr-16-2021	Apr-16-2021	Unknown	1,000 Series
Ford Next LLC	NA	NA	Minority	NA


Zomedica Corp. (NYSEAM:ZOM) | Public Company
 100 Phoenix Drive | Suite 125 | Ann Arbor, MI 48108 | USA | (734) 369-2555 | www.zomedica.com

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for... As of Date: 9/12/2023

Key Statistics

	Last 5 Yr Trend	2020 FY 12/31/2020	2021 FY 12/31/2021	2022 FY 12/31/2022
Total Revenue		NA	4,133	18,930
Total Revenues, 1 Year Growth (%)		NA	NA	NM
Gross Profit Margin (%)		NA	73.89	72.12
EBITDA Margin (%)		NA	NM	(94.46)
EBIT Margin (%)		NA	NM	(115.81)
Net Income Margin (%)		NA	NM	(89.88)
Diluted EPS Excl. Extra Items		(0.05)	(0.05)	(0.02)
Diluted EPS Before Extra, 1 Year Growth (%)		(73.68)	5.43	(67.06)

Revenue by Business and Geographic Segments



Multiples	2022 FY 12/31/2022
Period Ended	12/31/2022
Price/ EPS (x)	NM
TEV/ Total Revenue (x)	2.39
TEV/ EBITDA (x)	NM
Price/ Book (x)	0.59

* Segments with negative values are excluded from the total and percentage calculations and do not appear on the charts

Top Holders

Top Holders	Common Stock Equivalent Held	% of Total Shares Outstanding	Market Value (mm)
Vanguard Group Inc.	48,807,989.00	4.98	7.9
BlackRock Inc.	11,511,024.00	1.17	1.9
Cambridge Investment Research Advisors Inc.	11,257,560.00	1.15	1.8
Rowe Family Gst Trust	11,120,000.00	1.13	1.8
Geode Capital Management LLC	9,332,490.00	0.95	1.5

Market Data NYSEAM:ZOM \$0.16 0.06% \$0.00


Last (Delayed)	0.16	Avg Daily Volume	456,961
VWAP (Delayed)	0.16	Avg 3M Daily Volume	3,933,960
Open	0.16	Shares Out. (8/10/2023)	979,949,668
Previous Close	0.16	Float (%)	98.56
Day High/Low	0.1625 / 0.162	Inst. Ownership (%)	9.88
52 wk High/Low	0.335 / 0.15	Shares Sold Short	66,590,291
Beta 3Y	1.31	Short Int/ShOut (%)	6.80
Market Cap. (\$M)	158.7	Div. Yield (%)	NA
Total Enterprise Value (\$M)	29.6		

Status: Operating
Primary Industry (CIQ/GICS): Health Care Equipment
Topic Tags: Sensors, Chronic Diseases, Immunology, Inflammation, Oncology, Rheumatology, Health Diagnostics

Officers & Directors

Chairman of the Board	Jeffrey Michael Rowe
President, CEO & Director	Larry C. Heaton II
Chief Financial Officer	Peter L. Donato

Debt Maturity



Capitalization

Reported Currency Code	USD
Closing Price	0.16
Ordinary Shares Outstanding (actual)	979,949,668
Market Capitalization	158,654
Cash & Short Term Investments	130,473
Total Debt	1,422
Total Preferred Equity	NA
Total Minority Interest	NA
Total Enterprise Value (TEV)	29,603
Total Common Equity	259,479
Total Preferred Equity	NA
Total Minority Interest	NA
Total Debt	1,422
Total Capital	260,901

Stock Chart



ThinkEquity®



A Boutique Investment Bank

Built Around Client's Needs

ThinkEquity was created by experienced professionals who have worked together for more than a decade, collectively financing over \$50 billion of public and private capital raises, restructurings, and mergers and acquisitions.

- ✓ Around The Clock Attention
- ✓ Identifying Solutions That Create Investor Value
- ✓ Dedicated to A Team Effort Approach



Member of:
NYSE, FINRA, &
SIPC



What We Do

Specialized & Competent

We are among the industry's best in Investment Banking and Institutional Sales, with teams dedicated to IPOs, Follow-On Offerings, Registered Direct Placements, PIPEs, select private placements and SPACs.

We also excel in Debt Capital Markets capabilities to facilitate non-dilutive financing for private and public companies.



Investment Banking

Creating Capital



Mergers & Acquisitions

Targeting & Advising



Trading

Capitalizing on Market Events



Equity Capital Markets

Issuing Shares to Fund Growth



Debt Capital Markets

Sourcing & Structuring Debt Financings



Investment Banking

- > Initial Public Offerings (IPOs)
- > Secondary/Follow-On Offerings
- > Confidentially Marketed Public Offerings (CMPOs)
- > Registered Direct Placement & PIPEs
- > At-The-Market Offerings (ATMs)
- > Dual Listings (Foreign Exchanges to NASDAQ & NYSE)
- > Up-Listings (OTC to NASDAQ & NYSE)


Investment Banking

Advisory Services



01 02 03

- > Initial Public Offering Preparation
- > Up-Listing and Dual Listing Consultation (NASDAQ or NYSE American)
- > ADR overview
- > Mergers and Acquisitions (M&A) Advisory
- > SPAC, IPOs, and MSA
- > Fairness Opinions
- > Comparable company and precedent transaction analysis
- > Develop short and long-term goals focused on value creation



5

Investment Banking


Equity Syndicate

- > ThinkEquity's Equity Syndicate Department coordinates the marketing and distribution of its equity offerings.
- > The group builds institutional and retail syndicates for ThinkEquity's proprietary IPOs, Secondary/Follow-on and Up-Listing Offerings.
- > ThinkEquity regularly participates in public offerings managed by leading Wall Street investment banks, giving its investors access to equity, preferred and SPAC offerings.
- > Our equity, preferred and SPAC participations include co-manager, underwriter and selling group roles.



01 02 03

Our Syndicate network includes relationships developed over decades with dozens of banks & broker dealers.




6



Mergers & Acquisitions

- > Fairness Opinions
- > Valuation Analysis
- > Recapitalizations & Restructuring



Equity Capital Markets & Institutional Sales

- > Our investing client base consist of Mutual Funds, Hedge Funds, Family office accounts and High Net Worth
- > Corporate Access & Non-Deal Roadshows
- > ThinkEquity Conference & Equity Syndicate
- > Institutional Sales team dedicated to equity transactions, including IPOs, Follow-On Offerings, Registered Direct Placements, PIPEs, select private placements and SPACs
- > Access to over 10,000 institutions of all sizes throughout the U.S., Europe, Israel, Asia and South America
- > Extensive deal and non-deal roadshow capabilities in the U.S. and Europe
- > Ability to source and place large blocks of stock

2021 Non-Deal Roadshow Statistics

- > Number of Companies Marketed: 60
- > Number of Investor Accounts Introduced: 360
- > Total Meetings: 1,370

Including International Issuers & Investors Based In:

- > Belgium
- > Denmark
- > Germany
- > Netherlands
- > Sweden
- > United Kingdom
- > Canada
- > France
- > Israel
- > Norway
- > Switzerland
- > United States



Non-Deal Roadshows & Corporate Access

- > Introducing active investors and emerging growth companies through one-on-one calls and meetings.
- > Investors include mutual funds, hedge funds, family offices and high net worth accounts in the U.S. and abroad.
- > Companies include both under-the-radar growth stories and recently financed issuers.
- > Opportunity for companies to build a knowledgeable investor base and for investors to consistently generate new investment ideas.

9

Debt Capital Markets

- > Loans to both Public and Private Companies
- > Debt Placements
- > Senior Debt
- > Subordinated Debt
- > Unsecured Senior Debt
- > Acquisition Financing
- > Revolvers



ThinkEquity has structured over **\$1 billion** of debt financing for companies.

10

Debt Capital Markets

➤ ThinkEquity's Debt Capital Markets group sources and structures a wide variety of non-dilutive debt financings for both private & public companies.

➤ Working with its ever-growing network of lenders including national and regional banks, BDCs, private finance companies, hedge funds, family offices and other alternative lenders, ThinkEquity is your one-stop shop for working and growth capital needs, including acquisition financing, recapitalizations and bridge financings.


➤ The Debt Capital Markets group has structured over \$1 billion of debt financing for companies, with a strong focus on the technology, healthcare, industrials, cleantech, fintech, specialty finance and media & entertainment sectors.



Access to a diverse network of institutional lenders


ThinkEquity Reach

U.S. Public Issuers



International Reach

ThinkEquity has active relationships with Issuers and Investors globally



Trading

- > Trading & Sales Trading
- > Block Trading
- > 10b-5 Sales
- > Corporate Stock Buybacks
- > Risk Arbitrage & Event Driven Trading



Trading

NYSE Floor Trading Overview

In order to better serve our clients and provide the best possible access to liquidity, ThinkEquity has opened an NYSE Trading Floor Operation staffed by industry veterans.



ThinkEquity's NYSE floor trading operation provides clients with direct access to point of sale liquidity for IPOs and follow on offerings, as well as, Third Party Algo (TPA) access to the NYSE Parity order types (eQuote and dQuote).



Our Floor Brokers trade Initial Public Offerings (IPOs), Up-listings, At-the-Market Programs (ATM's), Follow-ons, Convertibles and Derivatives, Rights Offerings, Share Repurchases/10b-18 Company Buybacks, Risk Arbitrage and Special Situations.



ThinkEquity traders source liquidity using multiple algo strategies while having access to NYSE Parity allocation, which enables our Floor Brokers a share of incoming interest at the best price, regardless of order-entry time. Brokers can utilize multiple execution strategies simultaneously, combining algos with d-quote, reserve, darkpools, layering, etc.



Our trading professionals deliver both high and low-touch services to help our clients develop trading strategies to execute transactions across exchanges globally.

15

Equity Research

ThinkEquity's proprietary research platform focuses on discovering and analyzing exciting emerging growth companies in a variety of business sectors.



Our research team strives to be the "go to" source of information for each company under coverage and its particular industry.



Sector Focus

Technology

Media

Telecom

Healthcare

Industrials

Consumer

Energy

Financials

More



16

Private Client Group

Whether you are planning for retirement, to fund a college education, or you want to speculate or trade your account, we offer investors a wide range of financial products to meet your financial and strategic objectives. For the sophisticated, accredited investor we also provide access to proprietary investment opportunities, such as private placements of debt and equity securities. Each investor's goals are unique.

- > **Equities**
- > **Fixed-Income**
- > **Mutual Funds**
- > **Private Placements**

Products and Services for Unique Financial Needs



The ThinkEquity Standard

- > We only represent clients we believe in – people and businesses that we feel will make a difference.
- > Our goal is to identify opportunities that others can't see and create superior value.
- > We work intensely and endlessly for our clients no matter the difficulties at hand.
- > Our goal is to deliver superior returns and achievements for investors and issuers.
- > We stimulate and develop solutions in difficult situations, creating an atmosphere of optimism and pride in every aspect of our business.
- > We perform at the highest ethical standards in our work for our clients.
- > Our goal is to recognize the constantly changing environment ahead of the herd and evaluate and implement those changes rapidly and timely.
- > Our goal is to be the best.

ThinkEquity Conference

The Mandarin Oriental Hotel
New York, NY

October 26, 2022

Who Should Attend

- U.S. & International Public & Private Companies
- Industry Executives
- Institutional Investors
- Accredited Investors
- Private Equity & Venture Capital

Sectors:

AI/Big Data

Biotechnology

Metals & Mining

Oil & Gas

Technology

EV/ EV Infrastructure

Conference Overview:

70+

Company Presentations

700+

Attendees

500+

1-on-1 Investor Meetings



Premium Networking Opportunities



Ramnarain “Joe” Jaigobind

Chief Executive Officer

Joe Jaigobind has been in the financial services arena for over 30 years. He and his team have originated and raised in excess of \$60 billion in capital markets transactions as the Sole Book Runner, Joint, Co-Manager, or as a Syndicate Member. He began his career at Shearson Lehman American Express in the Private Client Group. He later served as Senior Vice President with Investec Ernst & Co, Head of Capital Markets for Rodman & Renshaw, and was an Executive Managing Director & Head of Capital Markets at Maxim Group. Over the past three decades, Mr. Jaigobind created and built investment banking, equity capital markets, and institutional sales departments at many boutique firms. Mr Jaigobind is currently a director of Empourus Limited, a quant trading technology company focused on Generative AI. Mr. Jaigobind was a Chairman's Circle Member of the US-India Business Council and was a Director on the Board of the US-Pakistan Business Council. He was also a member of the Susquehanna Investment Network based in Lewisburg, PA. Mr. Jaigobind has previously served on the Board of Directors of Care Management International.



William Baquet

President & COO

Mr. Baquet has more than thirty-five years of executive leadership and investment banking experience and has been involved in the successful financing of a broad range of public and private companies. He began his Wall Street career at Haas Securities Corporation, NYSE Member Firm and later served as President, Chief Executive Officer and Investment Banker at Berkeley Securities Corporation. Following Berkeley, Mr. Baquet joined Commonwealth Associates' investment banking team where he was instrumental in the financing and structuring of numerous highly successful telecommunications and technology projects. Since 1997, Mr. Baquet has served as President and Chief Executive Officer of Fordham Financial Management, Inc. where he developed, managed, and expanded all aspects of the full-service broker-dealer.

Chirag Choudhary

Head of Equity Capital Markets

Chirag's career on Wall Street spans over 17 years when he began his career at Merrill Lynch & Co. in the Private Client Group. Following Merrill Lynch, Chirag served as Vice President in the Private client division at Investec Ernst & Co., Senior Vice President in Global Syndicate at Maxim Group, & Senior Vice President, Institutional Sales at Rodman & Renshaw. Chirag has built and expanded several boutique investment banks' institutional sales desks. Chirag has Series 7, 66 & 24 licenses. Mr. Choudhary received a Master's degree in Business Administration (Finance) from Hawaii Pacific University and a degree in Commerce (Hons.) (Finance and Tax Planning) from University of Delhi. He was a member of Chairman's Circle of U.S.-India Chamber of Commerce (NY chapter). Mr. Choudhary is also a member of Asia Society, a leading international non-profit educational organization founded in 1956 with headquarters in New York and presence in 6 countries. He is also involved with charities like Hudson Union Society of New York, September 2001 Memorial Foundation, NY and RobinHood.

21

Eric Lord

Head of Investment Banking

Eric Lord has been on Wall Street for over 16 years. Mr. Lord began his career as Vice President of Equity Capital Markets at Maxim Group. Following Maxim, he joined Rodman & Renshaw as Senior Vice President of Global Equity Capital Markets. Over the past two decades Mr. Lord created and built banking departments & equity capital markets desks at many boutique investment banks. Mr. Lord has originated & executed hundreds of public offerings. Mr. Lord is a Series 7 licensed Registered Representative, Series 24 licensed General Securities Principal and passed the CFA Level 1 exam. Mr. Lord holds a B.S. in Business Administration with a concentration in Finance from the University of Richmond.

Craig M. Skop

Managing Director, Corporate & Executive Services

Mr. Skop has been a Wall Street professional for over 20 years. He is responsible for all Corporate Access at ThinkEquity. Prior to ThinkEquity, Mr. Skop was at Joseph Gunnar as a Senior Vice President in the Global Equity Capital Markets Group. Prior to joining Joseph Gunnar & Co., LLC, Mr. Skop spent 10 years at Aegis Capital Corp., most recently as a Senior Vice President of Global Equity Capital Markets and previously on the Equity Sales Desk. Mr. Skop spent the earlier part of his career on the Equity Sales Desks at Oppenheimer and Shearson Lehman, managing assets for institutional and high net-worth clients. Mr. Skop is a Series 7 and Series 63 licensed Registered Representative. Mr. Skop has received a Business Administration Degree from Florida Atlantic University.

22

Kevin Mangan

Managing Director, Head of Equity Syndicate

Mr. Mangan has more than 10 years of experience in the securities industry serving in management positions in Equity Capital Markets, Investment Banking and Equity Syndicate. As Managing Director and Head of Equity Syndicate at ThinkEquity, he is responsible for coordinating ThinkEquity's proprietary public and private offerings while maintaining relationships with leading investment banks to facilitate the firm's participation in syndicated offerings. Prior to ThinkEquity, Mr. Mangan was Senior Vice President of Investment Banking at Joseph Gunnar & Co., LLC. Kevin started his career as Syndicate Manager at Maxim Group LLC. During his time at Maxim, Kevin was involved in all aspects of the firm's syndicate business. Following Maxim, Kevin was Vice President, Syndicate Manager of Global Equity Capital Markets at Rodman & Renshaw, LLC. In over three years at Rodman, Mr. Mangan assisted in the origination, marketing and execution of nearly 100 public offerings, including over 25 lead-managed public offerings, as well as several lead-managed private placements. After Rodman, Mr. Mangan was Vice President, Syndicate Manager at Aegis Capital Corp and a founding member of the firm's Global Equity Capital Markets department. In four years with Aegis, the Global Equity Capital Markets department completed over 100 offerings as book-runner or co-manager, raising nearly \$3 billion in gross proceeds. Mr. Mangan is a Series 7 licensed Registered Representative and Series 24 licensed General Securities Principal. He holds a B.S. in Business Administration with a concentration in Management from the University of Miami.

Philip Quartuccio

Managing Director, Head of Global Trading

Mr. Quartuccio is Head of global trading operations for ThinkEquity, including the NYSE Trading Floor. Mr. Quartuccio has been on Wall Street for over 26 years. Phil was CEO of Ilustro Trading. He has held senior trading positions at Janney Montgomery Scott, Arnhold & S. Bleichroeder, Labranche, Brown Brothers Harriman and most recently, Tullet Prebon ICAP. Mr. Quartuccio has been part of development of the NYSE Third Party Algo (TPA) program that enables algorithmic access to the NYSE Parity order types for quantitative automated trading. Phil is member of the New York Stock Exchange Technology Committee. Mr. Quartuccio holds FINRA Series 7, 19, 24, 57, 99 and 63 registrations.

Jeffrey Singer

Head of Debt Capital Markets

Mr. Singer has been involved in the successful financing of a broad range of public and private companies across almost every industry with a strong focus on technology, energy, specialty finance/FinTech, IT services, digital commerce, ed-tech, healthcare services and consumer brands. Jeff specializes in structuring debt financings for emerging growth companies to maximize their funding availability while minimizing dilution to shareholders. Jeff works with a vast network of lenders including specialty banks, private finance companies, hedge funds, BDCs, venture lenders, family offices and other alternative lenders to structure and place debt financings of all sizes for his client base. Jeff works with company management teams to analyze their balance sheets and capital needs to determine the various options available and to find the most attractive and surest path to closing. Debt structures include cash flow financing, asset based loans, loans against IP, loans against contracts and purchase orders, enterprise value loans as well as other alternative structures.

Prior to joining ThinkEquity, Jeff served as Head of Debt Capital Markets at Joseph Gunnar & Co. for two years and as Managing Director of Dragonfly Capital Partners, where he ran the New York office of the firm for over 10 years. Jeff has structured over one billion dollars of debt financing proposals over the course of his career. Mr. Singer holds a BS from University of Wisconsin and his MBA from Fordham University Graduate School of Business.

Ashok Kumar

Head of Equity Research

Mr. Kumar joined ThinkEquity in 2018, continuing his distinguished 27 plus year career in equity research. Mr. Kumar has held senior research positions at Raymond James, Piper Jaffray, Prudential Securities and at a host of boutique firms. Prior to his career in research, specializing in the technology and healthcare sectors, Mr. Kumar worked in engineering and marketing at Intel Corporation. Having been cited in various publications such as The Wall Street Journal, The New York Times, USA Today, Business Week, and Fortune, as well as being regularly featured on CNBC and Bloomberg, Mr. Kumar was named one of Smart Magazine's 30 Most Influential People in Investing in 2000. Mr. Kumar received a Bachelor's Degree in Engineering from the Indian Institute of Technology, a Master's Degree in Electrical Engineering from Purdue University, and a Master's Degree in Business Administration from the Wharton School of the University of Pennsylvania.

Scott Rothbaum

Head of Institutional Sales

Scott has over 20 years of institutional and deal sales experience. He has extensive knowledge of IPO, Secondaries, PIPEs and Private Placements in equity capital markets. Scott began his career as a partner and Managing Director at Maxim Group, focused on equity sales of NASDAQ and NYSE new issues.

After Maxim, Scott was Director of Institutional Sales at Joseph Gunnar, he has spent the last 4 years building relationships with existing and new institutional clients, originating and executing public and private offerings. Over the last two decades, Scott has worked on hundreds of public offerings, specializing in tech & healthcare. Scott graduated Cum Laude from the State University of New York at Farmingdale with a degree in Business Administration and holds Series 7, 63 and 24 licenses.

Karim Rammal

Managing Director Global Corporate Advisory

Karim has spent over 12 years with WPP World Wide / Walter Thompson in the United States, Pakistan, and Afghanistan, as Senior Partner at JWT New York and as President WPP Marketing Communications / JWT, Pakistan. Post WPP, Karim founded Unicorn Consulting.

Karim works and focuses on marketing, communication and business development strategies for over 80 multinational and local clients. Past clients including Pepsi, Shell, Levi Strauss, Unilever, Philips, Kodak, HSBC, Swiss Airlines, Aga Khan Development Network, LG, Syngenta, DeBeers, Knorr, Bata, BMW, Rolls Royce, Hyundai, Habib Bank Limited, Cadbury, Roshan Telecom, and the Government of Pakistan.

Karim earned his undergraduate and graduate degrees from Boston University. Karim is a member of the Young Presidents Organization (YPO) since 2007 and has held various voluntary positions with the Aga Khan Development Network (AKDN.org) since the 1990s.

25

Recent Transactions

OMNIQ Corp.  \$3,000,000 Follow-On Offering October 5, 2023	Transcode Therapeutics, Inc.  \$8,500,000 Follow-On Offering September 25, 2023	Alarum Technologies Ltd.  \$4,250,000 Financial Advisor September 14, 2023	ICU Eyewear, Inc.  \$15,000,000 Senior Secured Debt Financing September 12, 2023	MAIA Biotechnology, Inc.  \$7,000,000 ATM Offering September 1, 2023	iCoreConnect Inc. and FG Merger Corp.  \$98,000,000 Business Combination August 25, 2023	Foremost Lithium Resource & Technology Ltd.  \$4,000,000 Follow-On Offering August 21, 2023	The Metals Company  \$27,000,000 Financial Advisor August 14, 2023
Red Cat Holdings, Inc.  \$17,000,000 ATM Offering August 6, 2023	Netcapital, Inc.  \$1,200,000 Follow-On Offering July 19, 2023	KWESST Micro Systems Inc.  \$5,600,000 Private Placement July 19, 2023	CEL-SCI Corporation  \$5,000,000 Follow-On Offering July 17, 2023	Alliance Entertainment Holding Corporation  \$4,000,000 Follow-On Offering June 29, 2023	Azitra Inc  \$7,500,000 Initial Public Offering June 15, 2023	Immix Biopharma, Inc.  \$5,000,000 ATM Offering June 14, 2023	Forza X1, Inc.  \$8,000,000 Follow-On Offering June 12, 2023
FG Financial Group, Inc.  \$1,600,000 Follow-On Offering May 30, 2023	Netcapital Inc.  \$1,700,000 Registered Direct May 23, 2023	Strong Global Entertainment, Inc.  \$4,000,000 Initial Public Offering May 15, 2023	Hillstream BioPharma  \$2,650,000 Follow-On Offering April 27, 2023	MAIA Biotechnology, Inc.  \$5,800,000 Follow-On Offering April 24, 2023	Marpai, Inc.  \$7,400,000 Follow-On Offering April 17, 2023	Annovis Bio, Inc.  \$50,000,000 ATM Offering March 31, 2023	G Medical Innovations Holdings Ltd.  \$9,600,000 Follow-On Offering March 31, 2023
Immix Biopharma, Inc.  \$5,000,000 ATM Offering March 22, 2023	Rittenhouse Media LLC  \$5,000,000 Debt Financing March 21, 2023	Beamr Imaging Ltd  \$7,800,000 Initial Public Offering February 27, 2023	Alliance Entertainment and Adara Acquisition Corp.  \$480,000,000 Business Combination February 10, 2023	Tivic Health Systems, Inc.  \$5,000,000 Follow-On Offering February 8, 2023	Lirum Therapeutics, Inc.  \$7,000,000 Private Placement February 8, 2023	Blink Charging Co.  \$100,000,000 Follow-On Offering February 6, 2023	BK Technologies Corporation  15,000,000 ATM Offering January 31, 2023

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

26

Recent Transactions

ProPhase Labs, Inc. ProPhase Labs, Inc. Asset Purchase from Stella Diagnostics, Inc. December 19, 2022	Nexcella, Inc. Immix Biopharma, Inc. Subsidiary Nexcella, Inc. In-Licensed NYC-201 December 14, 2022	Netcapital Inc. \$1,700,000 Follow-On Offering December 13, 2022	KWESST Micro Systems Inc. \$14,100,000 Follow-On Offering December 6, 2022	Alarum Technologies Ltd. \$5,000,000 ATM Offering November 25, 2022	FAT Brands Inc. \$21,400,000 ATM Offering November 14, 2022	TECO 2030 \$10,000,000 Joint Placement Agent November 14, 2022	FG Financial Group, Inc. \$2,576,000 ATM Offering November 3, 2022
Twin VEE Powercats Co. \$6,875,000 Follow-On Offering September 28, 2022	Virios Therapeutics, Inc. \$5,000,000 Follow-On Offering September 20, 2022	Blink Charging Co. \$250,000,000 ATM Offering September 2, 2022	Second Sight Medical Inc. and Nano Precision Medical, Inc. Business Combination August 30, 2022	Mobilicom Limited \$13,300,000 U.S. Initial Public Offering August 24, 2022	Save Foods, Inc. \$4,800,000 Follow-On Offering August 15, 2022	Forza X1, Inc. \$17,250,000 Initial Public Offering August 11, 2022	MAIA Biotechnology, Inc. \$11,500,000 Initial Public Offering July 27, 2022
Netcapital Inc. \$5,000,000 Follow-On Offering July 12, 2022	United Infrastructure Holdings, Inc. \$20,000,000 Debt Financing June 13, 2022	EZRaider \$880,000 Debt Financing June 10, 2022	CEA Industries Inc. \$24,000,000 Follow-On Offering February 10, 2022	SaverOne 2014 Ltd. \$13,010,000 U.S. Initial Public Offering June 2, 2022	OKYO Pharma Ltd. \$2,500,000 Follow-On Offering May 16, 2022	Snow Lake Resources Ltd. \$18,000,000 Follow-On Offering April 7, 2022	Permex Petroleum Corporation \$7,500,000 Private Placement March 28, 2022
OMNIQ Corp. \$8,500,000 Debt Financing March 25, 2022	FG Merger Corp. \$80,500,000 Initial Public Offering February 25, 2022	CEA Industries Inc. \$24,000,000 Follow-On Offering February 10, 2022	Hillstream BioPharma, Inc. \$15,000,000 Initial Public Offering January 11, 2022	Hillstream BioPharma, Inc. \$15,000,000 Initial Public Offering January 11, 2022	Immix Biopharma, Inc. \$24,150,000 Initial Public Offering December 15, 2021	Hagerty, Inc. and Aldel Financial Inc. \$3,130,000,000 Business Combination December 2, 2021	Context Therapeutics Inc. \$31,250,000 Private Placement December 1, 2021

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Recent Transactions

iSpecimen Inc. \$21,000,000 Private Placement November 29, 2021	Tivic Health Systems, Inc. \$17,250,000 Initial Public Offering November 10, 2021	Zoomcar, Inc. \$92,000,000 Private Placement November 8, 2021	TG Venture Acquisition Corp. \$115,000,000 Initial Public Offering November 2, 2021	FAT Brands Inc. \$18,000,000 8.25% Series B Cumulative Preferred Stock October 27, 2021	Marpai, Inc. \$28,750,000 Initial Public Offering October 26, 2021
FG Financial Group, Inc. \$2,600,000 Follow-On Offering October 25, 2021	Harbor Custom Development, Inc. \$41,400,000 8% Series A Cumulative Convertible Preferred Stock October 4, 2021	EzFill Holdings, Inc. \$28,750,000 Initial Public Offering September 14, 2021	Virpax Pharmaceuticals, Inc. \$40,000,000 Follow-On Offering September 14, 2021	ProPhase Labs, Inc. \$14,600,000 Acquisition of Nebula Genomics August 11, 2021	PetVivo Holdings, Inc. \$11,250,000 Follow-On Offering August 10, 2021
BioVie Inc. \$20,000,000 Follow-On Offering August 6, 2021	Opportunity Financial, LLC and FG New America Acquisition Corp. \$800,000,000 Business Combination July 20, 2021	Twin Vee PowerCats Co. \$18,000,000 Initial Public Offering July 20, 2021	Red Cat Holdings, Inc. \$60,000,000 Follow-On Offering July 18, 2021	EVmo, Inc. \$15,000,000 Debt Financing July 12, 2021	TransCode Therapeutics, Inc. \$28,750,000 Initial Public Offering July 8, 2021
OMNIQ Corp. \$15,000,000 Private Placement July 8, 2021	cbdMD, Inc. \$16,500,000 8% Series A Cumulative Convertible Preferred Stock June 28, 2021	Second Sight Medical Products, Inc. \$57,500,000 Follow-On Offering June 22, 2021	FAT Brands Inc. \$9,200,000 8.25% Series B Cumulative Preferred Stock June 17, 2021	Inhibikase Therapeutics, Inc. \$45,000,000 Follow-On Offering June 15, 2021	Harbor Custom Development, Inc. \$31,500,000 8% Series A Cumulative Convertible Preferred Stock June 9, 2021
Draganfly Inc. \$20,000,000 Follow-On Offering July 29, 2021	Kiromic BioPharma, Inc. \$40,000,000 Follow-On Offering June 29, 2021	Second Sight Medical Products, Inc. \$57,500,000 Follow-On Offering June 22, 2021	Pyxis Tankers, Inc. \$6,200,000 7.75% Series A Cumulative Convertible Preferred Stock July 14, 2021	iSpecimen Inc. \$20,700,000 Initial Public Offering June 16, 2021	Harbor Custom Development, Inc. \$31,500,000 8% Series A Cumulative Convertible Preferred Stock June 9, 2021

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Recent Transactions

BK Technologies Corporation  \$12,800,000 Follow-On Offering June 6, 2021	BriaCell Therapeutics Corp.  \$27,200,000 Private Placement June 3, 2021	1847 Goedecker Inc.  \$209,500,000 Follow-On Offering May 27, 2021	Annovis Bio, Inc.  \$50,000,000 Follow-On Offering May 23, 2021	Save Foods, Inc.  \$12,000,000 Follow-On Offering May 13, 2021
Red Cat Holdings, Inc.  \$16,000,000 Follow-On Offering April 29, 2021	Aldel Financial Inc.  \$115,000,000 Initial Public Offering April 8, 2021	Piedmont Lithium Limited  \$122,500,000 Follow-On Offering March 23, 2021	BriaCell Therapeutics Corp.  \$28,700,000 Follow-On Offering February 23, 2021	Pyxis Tankers, Inc.  \$25,000,000 Private Placement February 17, 2021
Virpax Pharmaceuticals Inc.  \$18,000,000 Initial Public Offering February 16, 2021	Nano Dimension Ltd.  \$500,000,000 Registered Direct February 15, 2021	Vallon Pharmaceuticals, Inc.  \$18,000,000 Initial Public Offering February 9, 2021	Polar Power, Inc.  \$13,500,000 Follow-On Offering February 7, 2021	Baillanthyne Strong, Inc.  \$7,600,000 Follow-On Offering February 3, 2021
OncoSec Medical Incorporated  \$42,000,000 Follow-On Offering January 21, 2021	Lantern Pharma Inc.  \$69,000,000 Follow-On Offering January 14, 2021	Harbor Custom Development, Inc.  \$27,600,000 Follow-On Offering January 12, 2021	United Infrastructure Holdings, Inc.  \$20,000,000 Preferred Equity & Senior Debt January 4, 2021	Nano Dimension Ltd.  \$250,000,000 Registered Direct December 27, 2020

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Recent Transactions

Inhibikase Therapeutics, Inc.  \$18,000,000 Initial Public Offering December 22, 2020	Virios Therapeutics, Inc.  \$34,500,000 Initial Public Offering December 16, 2020	cbdMD, Inc.  \$172,500,000 8% Series A Cumulative Convertible Preferred Stock December 8, 2020	Nano Dimension Ltd.  \$60,000,000 Registered Direct November 29, 2020	Vision Marine Technologies Inc.  \$27,600,000 Initial Public Offering November 23, 2020
Nano Dimension Ltd.  \$100,000,000 Registered Direct November 19, 2020	ENDRA Life Sciences Inc.  \$5,500,000 Follow-On Offering December 15, 2020	Kiromic BioPharma, Inc.  \$15,000,000 Initial Public Offering October 15, 2020	HEPION Pharmaceuticals, Inc.  \$34,500,000 Follow-On Offering November 24, 2020	BioVie Inc.  \$18,000,000 Follow-On Offering September 17, 2020
SG Blocks, Inc. and Clarity Diagnostics  Financial Advisor Joint Venture September 1, 2020	Piedmont Lithium Ltd.  \$57,500,000 Follow-On Offering October 21, 2020	Fortress Biotech, Inc.  \$13,200,000 Series A Cumulative Redeemable Preferred Stock August 26, 2020	FC New America Acquisition Corp.  \$238,000,000 Initial Public Offering September 29, 2020	1847 Goedecker Inc.  \$10,000,000 Initial Public Offering July 30, 2020
Fat Brands, Inc.  \$9,000,000 8.25% Series B Cumulative Preferred Stock July 13, 2020	GreenPower Motor Company, Inc.  \$37,200,000 U.S. Initial Public Offering August 28, 2020	Medigus Ltd.  \$5,000,000 Follow-On Offering May 19, 2020	Tiziana Life Sciences plc  \$57,300,000 Registered Direct August 3, 2020	SG Blocks, Inc. and OSANG Healthcare Co., Ltd.  Distribution Agreement May 5, 2020

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Recent Transactions

Second Sight Medical Products, Inc. SECONDSIGHT \$7,500,000 Follow-On Offering April 30, 2020	Nano Dimension Ltd. NANO DIMENSION \$13,300,000 Follow-On Offering April 22, 2020	Fortress Biotech, Inc. FORTRESS BIOTECH \$5,000,000 Series A Preferred Repurchase Program March 23, 2020	Tiziana Life Sciences plc TIZIANA LIFE SCIENCES \$20,000,000 ATM Offering April 10, 2020	Fortress Biotech, Inc. FORTRESS BIOTECH \$5,000,000 Series A Preferred Repurchase Program March 23, 2020	Tiziana Life Sciences plc TIZIANA LIFE SCIENCES \$10,000,000 Follow-On Offering March 12, 2020	Ampio Pharmaceuticals, Inc. AMPIO PHARMACEUTICALS \$50,000,000 ATM Offering February 21, 2020	Duos Technologies Group, Inc. DUOSTECH \$9,300,000 Follow-On Offering February 12, 2020	Fortress Biotech, Inc. FORTRESS BIOTECH \$14,400,000 9.375% Series A Cumulative Redeemable Preferred Stock February 11, 2020
LMP Automotive Holdings, Inc. LMP AUTOMOTIVE HOLDINGS \$19,200,000 Follow-On Offering February 11, 2020	OncoSec Medical, Inc. ONCOSEC \$30,000,000 Strategic Investment February 10, 2020	Annovis Bio, Inc. ANNOVIS \$13,800,000 Initial Public Offering January 31, 2020	Nano Dimension Ltd. NANO DIMENSION \$3,900,000 Follow-On Offering February 5, 2020	Annovis Bio, Inc. ANNOVIS \$13,800,000 Initial Public Offering January 31, 2020	cbdMD, Inc. CBDMD \$18,400,000 Follow-On Offering January 10, 2020	Better Choice Company HALO \$47,000,000 M&A December 20, 2019	SG Blocks, Inc. SG BLOCKS \$2,200,000 Follow-On Offering December 10, 2019	Drone Aviation Corp/COMSOVEREIGN DRONE AVIATION CORP \$76,000,000 Merger December 4, 2019
LMP Automotive Holdings, Inc. LMP AUTOMOTIVE HOLDINGS \$13,200,000 Initial Public Offering December 4, 2019	Fortress Biotech, Inc. FORTRESS BIOTECH \$6,000,000 Series A Cumulative Redeemable Preferred Stock November 25, 2019	BioXcel Therapeutics, Inc. BT \$19,000,000 Follow-On Offering September 26, 2019	cbdMD, Inc. CBDMD \$5,000,000 Series A Cumulative Convertible Preferred Stock October 10, 2019	BioXcel Therapeutics, Inc. BT \$19,000,000 Follow-On Offering September 26, 2019	Stemline Therapeutics, Inc. STEMLINE \$87,600,000 Follow-On Offering August 9, 2019	Ampio Pharmaceuticals, Inc. AMPIO PHARMACEUTICALS \$12,000,000 Registered Direct June 17, 2019	OncoSec Medical Incorporated ONCOSEC \$11,000,000 Follow-On Offering May 28, 2019	
Immuron Limited IMMURON \$2,000,000 Follow-On Offering May 23, 2019	cbdMD, Inc. CBDMD \$13,800,000 Follow-On Offering May 13, 2019	OMNIQ Corp. OMNIQ \$5,000,000 Private Placement April 4, 2019	GreenPower Motor Company GPM \$4,000,000 Private Placement May 3, 2019	OMNIQ Corp. OMNIQ \$5,000,000 Private Placement April 4, 2019	ElectraMeccanica Vehicules Corp. MECCANICA \$12,000,000 Registered Direct March 26, 2019	Bridgeline Digital BRIDGELINE DIGITAL \$10,000,000 Private Placement March 13, 2019	Staffing 360 Solutions, Inc. STAFFING 360 SOLUTIONS \$4,800,000 Follow-On Offering February 8, 2019	

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Recent Transactions

Stemline Therapeutics, Inc. STEMLINE \$92,000,000 Follow-On Offering January 15, 2019	Precision Opinion PRECISION OPINION \$4,800,000 Senior Secured Term Loan January 14, 2019	Level Brands, Inc. & cbdMD LB \$120,000,000 Fairness Opinion December 21, 2018	ReWalk Robotics Ltd. REWALK \$13,300,000 Follow-On Offering November 16, 2018	Cuentas Inc. CUENTAS \$4,000,000 Factoring Agreement November 9, 2018	ElectraMeccanica Vehicules Corp. MECCANICA \$8,500,000 Registered Direct November 7, 2018
Novumc Solutions, Inc. NOVUME \$3,300,000 Follow-On Offering October 29, 2018	Wize Pharma, Inc. WP \$4,500,000 Private Placement October 23, 2018	Spectrum Global Solutions, Inc. SPECTRUM \$5,000,000 Credit Facility October 12, 2018	Level Brands, Inc. LB \$6,900,000 Follow-On Offering September 28, 2018	FlexShopper, Inc. FLEX-SHOPPER \$10,000,000 Follow-On Offering September 25, 2018	ElectraMeccanica Vehicules Corp. MECCANICA \$10,000,000 Follow-On Offering August 8, 2018
HealthLynked Corp. HEALTHLYNKED \$2,000,000 Private Placement July 19, 2018	Matinas Biopharma MATINAS \$8,000,000 Registered Direct June 19, 2018	Shared Labs, Inc. SHARED LABS \$10,000,000 Senior Debt Financing April 10, 2018	Immuron Limited IMMURON \$5,100,000 Private Placement March 14, 2018	Aytu Biosciences, Inc. AYTU \$12,900,000 Follow-On Offering March 1, 2018	Spectrum Global Solutions, Inc. SPECTRUM \$6,200,000 Senior/Junior Acquisition Debt Financing February 27, 2018
Blink Charging Co. BLINK \$18,500,000 Follow-On Offering February 13, 2018	Shared Labs, Inc. SHARED LABS \$15,000,000 Working Capital Financing February 9, 2018	Stemline Therapeutics, Inc. STEMLINE \$51,800,000 Follow-On Offering January 24, 2018	Absolutdata Technologies, Inc. ABSOLUTDATA \$2,700,000 Debt Capital January 9, 2018	Teamtronics, Inc. TEAMTRONICS \$3,300,000 Acquisition Debt Financing January 9, 2018	Akers Biosciences, Inc. AKERS \$6,900,000 Follow-On Offering December 18, 2017

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Recent Transactions




















Akoustis Technologies, Inc.  \$14,600,000 Private Placement December 15, 2017	Pyxis Tankers Inc.  \$4,800,000 Private Placement December 6, 2017	Duos Technologies Group, Inc.  \$11,000,000 Private Placement November 21, 2017	Level Brands, Inc.  \$12,000,000 Initial Public Offering November 17, 2017	Sachem Capital Corp.  \$17,000,000 Follow-On Offering October 25, 2017	Ampio Pharmaceuticals, Inc.  \$6,800,000 Registered Direct October 16, 2017	Hamamatsu Photonics  \$42,000,000 M&A September 22, 2017	Precision Opinion, Inc.  \$4,300,000 Debt Capital September 19, 2017
BiondVax Pharmaceuticals Ltd.  \$10,000,000 Follow-On Offering September 14, 2017	China Cord Blood Corp.  \$30,000,000 1065 Stock Sale August 28, 2017	Aytu BioScience, Inc.  \$11,800,000 Private Placement August 15, 2017	Shared Labs, Inc.  \$12,000,000 Acquisition Debt Financing August 11, 2017	Meridian Waste Solutions  \$4,000,000 Follow-On Offering June 28, 2017	SG Blocks, Inc.  \$8,600,000 Initial Public Offering June 21, 2017	Immuron Limited  \$6,100,000 Initial Public Offering June 8, 2017	Ampio Pharmaceuticals  \$6,300,000 Private Placement June 2, 2017
MRI Interventions, Inc.  \$13,300,000 Private Placement May 25, 2017	Staffing 360 Solutions, Inc.  \$3,000,000 ATM Offering May 11, 2017	Arkados  \$15,000,000 M&A May 8, 2017	Arkados  \$4,000,000 Private Placement May 8, 2017	Ontrak, Inc. (fka CataSys, Inc.)  \$16,500,000 Follow-On Offering April 25, 2017	Sorrento Therapeutics  \$47,300,000 Follow-On Offering April 13, 2017	AVEO Pharmaceuticals, INC.  \$15,500,000 Follow-On Offering March 31, 2017	Akers Biosciences, Inc.  \$2,000,000 Private Placement March 30, 2017
Pareteum Corp.  \$3,500,000 Follow-On Offering March 10, 2017	Micronet  \$3,000,000 Senior Secured Credit Facility March 1, 2017	Sachem Capital Corp  \$13,000,000 Initial Public Offering February 10, 2017	Meridian Waste Solutions  \$12,400,000 Follow-On Offering January 24, 2017	Stemline Therapeutics, Inc.  \$45,000,000 Follow-On Offering January 20, 2017	Akoustis  \$10,000,000 Private Placement January 18, 2017	Akers Biosciences, Inc.  \$2,000,000 Follow-on Direct January 10, 2017	AMERI Holdings, Inc.  \$5,000,000 Capital Restructuring Consulting December 30, 2016

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

33

Recent Transactions

































Polar Power, Inc.  \$19,300,000 Initial Public Offering December 7, 2016	Delivery Agent  M&A November 18, 2016	Sysores  \$10,000,000 Senior Secured Credit Facility November 1, 2016	Aytu BioScience, Inc.  \$8,600,000 Secondary/Follow-On October 27, 2016	ToughBuilt Industries, Inc.  \$6,100,000 Private Placement October 17, 2016	Drone Company  \$1,500,000 Senior Term Loan October 14, 2016	Sorrento Therapeutics, Inc.  \$200,000,000 Fairness Opinion August 15, 2016
Sorrento Therapeutics, Inc.  \$70,000,000 Fairness Opinion August 8, 2016	Collect Biotechnology Ltd.  \$8,400,000 Initial Public Offering July 29, 2016	Aytu BioScience, Inc.  \$10,500,000 Common Stock Purchase Agreement July 28, 2016	Remnova Health, Inc.  \$8,600,000 Secondary/Follow-On July 14, 2016	Kitoy Pharmaceuticals Holdings Ltd.  \$12,000,000 Secondary/Follow-On June 29, 2016	Intellicheck Mobilisa, Inc.  \$2,100,000 Secondary/Follow-On June 15, 2016	Chalkable  \$3,000,000 Bank/Venture Debt Term Loan April 20, 2016
340B Technologies  \$2,000,000 Senior Secured Term Loan April 18, 2016	Staffing 360 Solutions, Inc.  \$2,000,000 Registered Direct April 3, 2016	DurioHealth Corp.  \$8,500,000 Secondary/Follow-On March 4, 2016				
					Optex Systems Holdings, Inc.  \$4,800,000 Follow-on Direct August 22, 2016	
						Aytu BioScience, Inc.  \$7,500,000 Secondary/Follow-On May 3, 2016

01 02 03 04 05 06 07 08 09

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

34





























Selected Past IPOs

Azitra Inc  \$7,500,000 Initial Public Offering June 15, 2023	Strong Global Entertainment, Inc.  \$4,000,000 Initial Public Offering May 15, 2023	Beamr Imaging Ltd  \$7,800,000 Initial Public Offering February 27, 2023	KWESST Micro Systems Inc.  \$14,100,000 U.S. Initial Public Offering December 6, 2022	Mobilicom Limited  \$11,800,000 U.S. Initial Public Offering August 24, 2022	Forza XI, Inc.  \$17,250,000 Initial Public Offering August 11, 2022	MAIA Biotechnology, Inc.  \$11,500,000 Initial Public Offering July 27, 2022	SaverOne 2014 Ltd.  \$13,010,000 U.S. Initial Public Offering June 2, 2022
FG Merger Corp.  \$80,500,000 Initial Public Offering February 25, 2022	Hillstream BioPharma, Inc.  \$15,000,000 Initial Public Offering January 11, 2021	Immix Biopharma, Inc.  \$24,150,000 Initial Public Offering December 15, 2021	Snow Lake Resources Ltd.  \$27,600,000 Initial Public Offering November 18, 2021	Tivic Health Systems, Inc.  \$17,250,000 Initial Public Offering November 10, 2021	TG Venture Acquisition Corp.  \$115,000,000 Initial Public Offering November 2, 2021	Marpai, Inc.  \$28,750,000 Initial Public Offering October 26, 2021	Context Therapeutics Inc.  \$28,750,000 Initial Public Offering October 19, 2021
EzFill Holdings, Inc.  \$28,750,000 Initial Public Offering September 14, 2021	Twin Vee PowerCats Co.  \$18,000,000 Initial Public Offering July 20, 2021	TransCode Therapeutics, Inc.  \$28,750,000 Initial Public Offering July 8, 2021	iSpecimen Inc.  \$20,700,000 Initial Public Offering June 16, 2021	Aldel Financial Inc.  \$115,000,000 Initial Public Offering April 8, 2021	Virpax Pharmaceuticals Inc.  \$18,000,000 Initial Public Offering February 16, 2021	Vallon Pharmaceuticals, Inc.  \$18,000,000 Initial Public Offering February 9, 2021	Adara Acquisition Corp.  \$115,000,000 Initial Public Offering February 8, 2021
Inhibikase Therapeutics, Inc.  \$18,000,000 Initial Public Offering December 22, 2020	Virios Therapeutics, Inc.  \$34,500,000 Initial Public Offering December 16, 2020	Vision Marine Technologies Inc.  \$27,600,000 Initial Public Offering November 23, 2020	Kiromic BioPharma, Inc.  \$15,000,000 Initial Public Offering October 15, 2020	FG New America Acquisition Corp.  \$238,000,000 Initial Public Offering September 29, 2020	Harbor Custom Development, Inc.  \$12,200,000 Initial Public Offering August 28, 2020	GreenPower Motor Company, Inc.  \$37,200,000 U.S. Initial Public Offering August 28, 2020	1847 Goedecker Inc.  \$10,000,000 Initial Public Offering July 30, 2020

01 02

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Selected Past IPOs


Lantern Pharma Inc.  \$26,300,000 Initial Public Offering June 10, 2020	Annovis Bio, Inc.  \$13,800,000 Initial Public Offering January 31, 2020	LMP Automotive Holdings, Inc.  \$13,200,000 Initial Public Offering December 4, 2019	SG Blocks, Inc.  \$8,600,000 Initial Public Offering June 21, 2017	Immuron  \$6,100,000 Initial Public Offering June 8, 2017	Sachem Capital Corp  \$13,000,000 Initial Public Offering February 10, 2017	Polar Power, Inc.  \$193,000,000 Initial Public Offering December 7, 2016
Ritter Pharmaceuticals, Inc.  \$20,000,000 Initial Public Offering June 24, 2015	Jaguar Animal Health, Inc.  \$20,000,000 Initial Public Offering May 13, 2015	BiondVax Pharmaceuticals Ltd.  \$9,600,000 Initial Public Offering May 11, 2015	EyeGate Pharmaceuticals, Inc.  \$4,100,000 Initial Public Offering February 12, 2015	GlobeImmune, Inc.  \$15,000,000 Initial Public Offering July 1, 2014	Signal Genetics, Inc.  \$8,500,000 Initial Public Offering June 17, 2014	Aldeyra Therapeutics, Inc.  \$12,000,000 Initial Public Offering May 1, 2014
1347 Property Insurance Holdings, Inc.  \$17,400,000 Initial Public Offering March 31, 2014	Reero Pharma, Inc.  \$34,500,000 Initial Public Offering March 6, 2014	Semler Scientific, Inc.  \$10,000,000 Initial Public Offering February 20, 2014	Biocept, Inc.  \$19,000,000 Initial Public Offering February 4, 2014	Evoked Biosciences, Inc.  \$15,000,000 Initial Public Offering January 23, 2014	Evoked Pharma, Inc.  \$29,000,000 Initial Public Offering September 25, 2013	Heat Biologics, Inc.  \$27,000,000 Initial Public Offering July 23, 2013
xG Technologies, Inc.  \$8,500,000 Initial Public Offering July 18, 2013	Cancer Genetics, Inc.  \$6,900,000 Initial Public Offering April 4, 2013	Professional Diversity Network, Inc.  \$21,000,000 Initial Public Offering March 5, 2013	Stemline Therapeutics, Inc.  \$38,200,000 Initial Public Offering January 29, 2013	Akers Biosciences, Inc.  \$15,000,000 Initial Public Offering January 23, 2014	Stemline Therapeutics, Inc.  \$38,200,000 Initial Public Offering January 29, 2013	Stemline Therapeutics, Inc.  \$38,200,000 Initial Public Offering January 29, 2013

01 02

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Transcode Therapeutics, Inc.

Nasdaq: RNAZ



\$8,500,000
Follow-On Offering
September 2023

\$28,750,000
Initial Public Offering
July 2021

- In July 2021, Transcode Therapeutics, Inc. (Nasdaq: RNAZ) raised \$28.75 million in an underwritten initial public offering of common stock which listed the Company onto the Nasdaq.
- The Company priced the initial public offering of 7,187,500 shares, including the full exercise of the over-allotment option, at a public offering price of \$4.00 per share. ThinkEquity acted as sole book-running manager for the offering.
- In September 2023, the Company raised approximately an additional \$8.5 million in a follow-on offering of common stock.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

OMNIQ Corp.

Nasdaq: OMQS



\$3,000,000
Follow-On Offering
October 5, 2023

\$8,500,000
Debt Financing
March 25, 2022

\$5,000,000
Private Placement
April 4, 2019

\$15,000,000
Private Placement
July 8, 2021

\$3,300,000
Acquisition Financing
January, 2018

- In January 2018, Teamtronics, Inc. acquired HTS-APR, a U.S. Based computerized vision image processing equipment maker for \$3.3 million and became HTS Image Processing, Inc.
- In October 2018, omniQ Corp. (Nasdaq: OMQS) acquired HTS Imaging Processing, Inc., a technological world leader in computer vision solutions for Security, Safe Cities, Traffic Management, Parking Management, Law Enforcement, and Surveillance for \$6.3 million.
- In April 2019, the Company raised \$5.0 million in a private placement of common stock and warrants.
- In July 2021, the Company raised \$15.0 million in a private placement of common stock and warrants.
- On September 2, 2021, the Company began trading on the Nasdaq under the ticker symbol "OMQS".
- In March 2022, the Company raised \$8.5 million in a debt financing. ThinkEquity acted as placement agent on the transaction.
- In October 2023, the Company raised approximately \$3.0 million in a follow-on offering of common stock.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

37

Alliance Entertainment LLC

Nasdaq: AENT



\$4,000,000
Follow-On Offering
June 29, 2023

\$480,000,000
Up-Listing
February 10, 2023

- In February 2023, Alliance Entertainment LLC and Adara Acquisition Corp. announced the merger agreement for Alliance Entertainment LLC to become a publicly traded company. The transaction valued Alliance Entertainment at a pro forma enterprise value of \$480 million.
- In June 2023, Alliance Entertainment Holding Corporation (Nasdaq: AENT) raised \$4.0 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company offered 1,335,000 shares of Class A Common Stock at a public offering price of \$3.00 per share. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Foremost Lithium Resources & Technology Ltd.

Nasdaq: FMST, FMSTW



\$4,000,000
Up-Listing
August 21, 2023

- In August 2023, Foremost Lithium Resources & Technology Ltd. raised \$4 million in an underwritten public offering which listed the company onto the Nasdaq.
- The company priced the public offering of 800,000 units consisting of one common share and one warrant at a public offering price of \$5.00 per unit. ThinkEquity acted as sole book-running manager for the offering.

38

KWESST Micro Systems Inc.

— *Nasdaq: KWE, KWESW*



\$5,600,000
Private Placement
July 19, 2023

\$14,100,000
Follow-On Offering
December 6, 2022

- In December 2022, KWESST Micro Systems Inc. (Nasdaq: KWE, KWESW | TSXV: KWE) raised \$14.1 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 2,500,000 units consisting of one share and one warrant at a public offering price of \$4.13 per unit. ThinkEquity acted as sole book-running manager for the offering.
- In July 2023, ThinkEquity acted as sole placement agent for a private placement for the Company raising approximately \$5.6 million at a price of \$2.26 per share and warrant.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

39

Mobilicom Limited

— *Nasdaq: MOB, MOBBW | ASX: MOB*



\$13,300,000
U.S. Initial Public Offering
August 24, 2022

- In August 2022, Mobilicom Limited (Nasdaq: MOB, MOBBW | ASX: MOB) raised \$13.3 million in an underwritten public offering which listed the company onto the Nasdaq.
- The company priced the public offering of 3,220,338 units consisting of one ADSs (or Pre-Funded Warrant in lieu thereof) and one warrant at a public offering price of \$4.13 per unit. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Netcapital Inc.

— *Nasdaq: NCPL, NCPLW*



\$1,200,000
Follow-On Offering
July 19, 2023

\$1,700,000
Registered Direct
May 25, 2023

\$1,745,000
Follow-On Offering
December 13, 2022

\$13,000,000
U.S. Initial Public Offering
June 2, 2022

- In July 2022, NetCapital (Nasdaq: NCPL, NCPLW) raised \$5.0 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 1,205,000 shares of its common stock and warrants to purchase up to 1,205,000 shares of the Company's common stock at a combined public offering price of \$4.15 per share and warrant. ThinkEquity acted as sole book-running manager for the offering.
- In December 2022, the Company raised approximately \$1.7 million in a follow-on offering of common stock at a price of \$1.40 per share.
- In May 2023, ThinkEquity acted as placement agent for a registered direct offering, raising \$1.7 million for the Company at a price of \$1.55 per share.
- In July 2023, the Company raised approximately \$1.2 million in a follow-on offering of common stock at a price of \$0.70 per share.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

40

SaverOne 2014 Ltd.

— *Nasdaq: SVRE, SVREW | TASE: SVRE*



\$13,000,000
U.S. Initial Public Offering
June 2, 2022

- In June 2022, SaverOne 2014 Ltd. (Nasdaq: SVRE, SVREW | TASE: SVRE) raised \$13.0 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 3,150,200 units consisting of one ADSs (or Pre-Funded Warrant in lieu thereof) and one warrant at a public offering price of \$4.13 per unit. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

OKYO Pharma Ltd.

Nasdaq: OKYO | LSE: OKYO



\$2,500,000
Follow-On Offering
May 16, 2022

- In May 2022, OKYO Pharma Ltd. (Nasdaq: OKYO | LSE: OKYO) raised \$2.5 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 625,000 ADSs at a public offering price of \$4.00 per ADS. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

41

CEA Industries Inc.

Nasdaq: CEAD, CEADW



\$24,000,000
Follow-On Offering
February 10, 2022

- In February 2022, CEA Industries Inc. (Nasdaq: CEAD, CEADW) raised \$24 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 5,811,138 shares of its common stock and warrants to purchase up to 5,811,138 shares of the Company's common stock at a combined public offering price of \$4.13 per share and warrant. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

authID.ai

Nasdaq: AUID



\$11,500,000
Follow-On Offering
August 23, 2021

- In August 2021, authID.ai (Nasdaq: AUID) raised \$11.50 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 1,642,856 shares of its common stock at a public offering price of \$7.00 per share. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

42

PetVivo Holdings, Inc.

Nasdaq: PETV, PETVW



\$11,250,000
Follow-On Offering
August 10, 2021

- In August 2021, PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) raised \$11.25 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 2,500,000 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of \$4.50. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Draganfly Inc.

Nasdaq: DPRO



\$20,000,000
Follow-On Offering
July 29, 2021

- In July 2021, Draganfly Inc. (Nasdaq: DPRO | GSE: DPRO) raised \$20 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 5,000,000 shares of its common stock at a public offering price of \$4.00 per share. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

43

Save Foods, Inc.

Nasdaq: SVFD



\$4,800,000
Follow-On Offering
August 15, 2022

\$12,000,000
Follow-On Offering
May 13, 2021

- Save Foods, Inc. (Nasdaq: SVFD) raised \$12 million in May 2021 in a public offering which listed the Company onto the Nasdaq.
- The Company sold 1,090,909 shares of the Company's common stock at a public offering price of \$11.00 per share.
- In August 2022, the Company raised an additional \$4.8 million in a follow-on offering of common stock at a price of \$3.00 per share.

Draganfly Inc.

Nasdaq: DPRO



\$20,000,000
Follow-On Offering
July 29, 2021

- In July 2021, Draganfly Inc. (Nasdaq: DPRO | GSE: DPRO) raised \$20 million in an underwritten public offering which listed the Company onto the Nasdaq.
- The Company priced the public offering of 5,000,000 shares of its common stock at a public offering price of \$4.00 per share. ThinkEquity acted as sole book-running manager for the offering.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

43

Red Cat Holdings, Inc.

Nasdaq: RCAT



\$60,000,000
Follow-On Offering
July 18, 2021

\$16,000,000
Follow-On Offering
April 29, 2021

- Red Cat Holdings, Inc. (Nasdaq: RCAT) raised \$16 million in April 2021 in a public offering which listed the Company onto the Nasdaq.
- The Company sold 4,000,000 shares of the Company's common stock at a public offering price of \$4.00 per share.
- Three months later, the Company raised an additional \$60 million in a follow-on offering of common stock priced at \$4.50 per share.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

44

BriaCell Therapeutics Corp.

Nasdaq: BCTX, BCTXW | TSXV: BCT



\$27,200,000
Private Placement
June 3, 2021

\$28,700,000
Follow-On Offering
February 23, 2021

- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW | TSXV: BCT) raised \$25 million in February 2021 in a public offering which listed the Company onto the Nasdaq.
- The Company sold 5,882,353 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of \$4.25 per unit.
- On April 12th 2021, BriaCell announced the closing of the over-allotment option in connection with February's offering. An additional 882,352 shares at the public offering price of \$4.24 per share for gross proceeds of \$3.7 million was raised.
- In June 2021, ThinkEquity acted as placement agent for a private placement for BriaCell, raising \$27.2 million at a price of \$5.26 per share and one warrant.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

44

urban-gro, Inc.

Nasdaq: UGRO



\$62,000,000
Follow-On Offering
February 11, 2021

- In February 2021, urban-gro, Inc. (Nasdaq: UGRO) raised \$62.1 million, including the underwriter's full exercise of over-allotment option, in a public offering which listed the Company onto the Nasdaq.
- The Company sold 6,210,000 shares of the Company's common stock at a public offering price of \$10.00 per share, which includes 810,000 shares sold upon full exercise of the underwriter's option to purchase additional shares.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

BioVie Inc.

Nasdaq: BIVI



\$20,000,000
Follow-On Offering
August 8, 2021

\$18,000,000
Follow-On Offering
September 17, 2020

- In September 2020, BioVie Inc. (Nasdaq: BIVI) raised \$15.7 million in a common stock public offering which listed the Company onto Nasdaq.
- The underwriters exercised the full over-allotment option, increasing the offering size to \$18 million.
- The net proceeds from the offering eliminated the Company's outstanding indebtedness and will fund clinical trials for its lead drug candidate, an orphan drug for the treatment of ascites due to advanced liver cirrhosis.
- In August 2021, ThinkEquity acted as the sole book-running manager in a follow-on public offering, raising \$20 million at a price of \$8.00 per share.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

45

GreenPower Motor Company Inc.

Nasdaq: GP | TSXV: GPV



\$37,200,000
US Initial Public Offering
August 28, 2020

\$4,000,000
Private Placement
May 3, 2019

- In May 2019, ThinkEquity acted as placement agent for GreenPower Motor Company Inc. (Nasdaq: GP | TSXV: GPV), then listed on the TSX-V and OTCQX, raising \$4.0 million in a private placement priced at \$2.14 per share and half warrant (split adjusted).
- In August 2020, GreenPower raised \$37.2 million in a common stock US initial public offering priced at \$20.00 per share which listed the company onto Nasdaq.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Duos Technologies Group, Inc.

Nasdaq: DUOT



\$9,300,000
Follow-On Offering
February 12, 2020

\$11,000,000
Private Placement
November 21, 2017

- In November 2017, Duos Technologies Group, Inc. (Nasdaq: DUOT) raised \$11.0 million in a private placement.
- In January 2020, Duos completed a reverse split of its shares of common stock at a ratio of 1-for-14 in connection with future up-listing.
- In February 2020, raised \$9.3 million in a common stock public offering which listed the company onto Nasdaq.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

46

Immuron Limited

Nasdaq: *IMRN*; *IMRNW* | ASE: *IMC*



\$1,360,000
Follow-On Offering
July 17, 2019

\$5,100,000
Private Placement
March 13, 2018

\$2,000,000
Follow-On Offering
May 23, 2019

\$6,100,000
US Initial Public Offering
June 8, 2017

- Immuron Limited (Nasdaq: *IMRN*, *IMRNW* | ASE: *IMC*) raised \$6.1 million of common stock in June 2017 for its US Initial Public Offering, listing the company's shares on Nasdaq.
- In March 2018, the company raised an additional \$5.1 million in a private placement of common stock and warrants.
- From May 2019 to July 2019, the company raised an aggregate of \$3.4 million in two public offerings of common stock without warrants to fund the advancement of additional drug candidates under a new CEO.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

47

Ontrak, Inc. (fka Catasys, Inc.)

Nasdaq: *OTRK*



\$48,900,000
Series A Cumulative Perpetual Preferred Stock Offering
August 26, 2020

\$16,458,000
Follow-On Offering
April 25, 2017

- Ontrak, Inc. (fka Catasys, Inc.) (Nasdaq: *OTRK*) raised \$16.5 million in April 2017 in a common stock public offering which listed the company on Nasdaq (no warrants).
- Converted approximately \$8 million of debt and liabilities to equity in connection with the offering, leaving the company debt free and increased total stockholders equity to \$9 million from a deficit of \$25 million pre-offering.
- Average daily trading volume increased from approximately 6,900 shares in the year prior to the offering to 56,000 shares in the year following the offering.
- Entered into a \$10 million debt financing agreement in June 2018, where: \$7.5 million came from Horizon Technology Finance Corporation (Nasdaq: *HRZN*) and \$2.5 million from Heritage Bank of Commerce.
- Expanded upon the June 2018 debt financing with Horizon Technology Finance Corporation by adding an additional \$7.5 million to the agreement.
- In August 2020, the Company raised \$48.9 million in a public offering of non-convertible preferred stock, including the full exercise of the overallotment option.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Cryoport, Inc.

Nasdaq: *CYRX*, *CYRXW*



\$11,000,000
Follow-on Offering
March 27, 2017

\$6,500,000
Follow-On Offering
July 23, 2015

- Cryoport, Inc. (Nasdaq: *CYRX*, *CYRXW*) raised \$6.5 million in July 2015 in a common stock and warrants public offering which listed the company on Nasdaq.
- Since the July 2015 up-Listing, the company has raised hundreds of millions through common stock offerings, debt financings, rights offerings and other financings.
- Cryoport's common stock has greatly appreciated from the up-listing price, with its market cap surpassing as high as \$3.0 billion.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

48

Abeona Therapeutics, Inc. (fka PlasmaTech Biopharmaceuticals, Inc.)

Nasdaq: *ABEO*, *ABEOW*



\$14,000,000
Follow-On Offering
December 18, 2014

- Abeona Therapeutics, Inc. (Nasdaq: *ABEO*, *ABEOW*) raised \$14 million in December 2014 in a common stock and warrants public offering which listed the company on Nasdaq.
- Nine months later, Abeona Therapeutics raised \$15 million in an offering of common stock and warrants at a 37.5% premium to the unit offering price.
- In October of 2016, the company raised \$42 million of common stock (no warrants).
- In October of 2017, the company raised \$80 million of common stock at \$16 (no warrants).
- The company has since raised approximately \$134 million in equity offerings

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Sorrento Therapeutics, Inc.

Nasdaq: SRNE



\$47,300,000 Follow-On Offering April 13, 2017	\$200,000,000 Fairness Opinion August 15, 2016	\$70,000,000 Fairness Opinion August 8, 2016
\$28,800,000 Follow-On Offering May 14, 2014	\$17,700,000 Block Trade December 19, 2013	\$34,600,625 Follow-On Offering October 24, 2013

- Sorrento Therapeutics, Inc. (Nasdaq: SRNE) raised \$34.6 million in October 2013 in a common stock public offering which listed the company on Nasdaq.
- The offering was originally marketed with 50% tradable warrants, but halfway through the roadshow, the warrant component of the offering was removed. The pricing date was also accelerated by four days.
- Two months later in December 2013, the our team led the sale of a block of \$17.7 million worth of common stock from OPKO Health, one of Sorrento's early investors, to institutional investors.
- Five months later in May 2014, Sorrento raised \$28 million in a common stock offering to institutional investors (no warrants).
- The company has since sold its drug candidate Cynviloq™ for up to \$1.3 billion to NantPharma, raised and additional \$47.3 million from the sale of common stock and made multiple acquisitions.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Advaxis, Inc.

Nasdaq: ADXS, ADXSW



\$14,100,000 Follow-On Offering March 26, 2014	\$26,450,000 Follow-On Offering October 16, 2013
------------------------------------------------------	--------------------------------------------------------

- Advaxis, Inc. (Nasdaq: ADXS, ADXSW) raised \$26.5 million in October 2013 in a common stock plus 50% tradable warrants public offering which listed the company on Nasdaq.
- Five months later in March 2014, Advaxis raised another \$12 million in a common stock offering (without warrants).
- Nine months later in December 2014, Advaxis raised \$17 million in a registered direct offering of common shares (without warrants) to institutional investors.
- Two months later in February 2015, Advaxis raised \$23 million in a registered direct offering of common shares (without warrants) to institutional investors.
- Two months later in April 2015, Advaxis raised \$53 million in an underwritten public offering of common stock (without warrants).
- Four months later in August 2015, Advaxis raised \$25 million from a strategic investor in a common stock sale (without warrants).

* ADXS prices shown on a pre-reverse split basis for comparison to the \$4.00 2013 public offering price

49

Xplore Technologies Corp.

Nasdaq: XPLR



\$10,000,000 Follow-On Offering October 26, 2012	\$17,250,000 Follow-On Offering December 1, 2011
--------------------------------------------------------	--------------------------------------------------------

- Xplore Technologies Corp. (Nasdaq: XPLR) raised \$10 million in October 2013 in a common stock public offering at \$5.00 per share which listed the company on Nasdaq (without warrants).
- In March 2015, the company raised another \$13 million in an underwritten common stock public offering (without warrants).
- In July 2018, the company was acquired by Zebra Technologies, a \$9 billion market cap company, for \$90 million or \$6 per share, a 20% premium to the initial offering price.

01 02 03 04 05 06 07 08 09 10 11 12 13 14

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Synergy Pharmaceuticals, Inc.

Nasdaq: SGYP, SGYPW
































\$51,800,000 Follow-On Offering May 4, 2012	\$17,250,000 Follow-On Offering December 1, 2011
---------------------------------------------------	--------------------------------------------------------

- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP, SGYPW) raised \$17 million in December 2011 in a common stock plus 50% tradable warrants public offering which listed the company on Nasdaq.
- Five months later in May 2012, Synergy raised another \$52 million in an underwritten common stock offering (without warrants).
- Eleven months later in April 2013, Synergy raised another \$90 million in an underwritten common stock offering (without warrants).
- Eleven months later in March 2014, Synergy put an at-the-market offering in place to raise up to \$50 million through offerings of common stock (without warrants).
- Eight months later in November 2014, Synergy raised over \$200 million through the issuance of Convertible Senior Notes.
- The Company received FDA approval for their drug TRULANCE® in January 2018.

50

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Past Nasdaq Up-Listing Offerings








Foremost Lithium Resource & Technology Ltd.  \$4,000,000 Follow-On Offering August 21, 2023	Alliance Entertainment Holding Corporation  \$4,000,000 Follow-On Offering June 29, 2023	Kwesst Micro Systems Inc.  \$14,100,000 Follow-On Offering December 6, 2022	Mobilicom Limited  \$11,800,000 U.S. Initial Public Offering August 24, 2022	Netcapital Inc.  \$5,000,000 Follow-On Offering July 12, 2022	SaverOne 2014 Ltd.  \$13,000,000 U.S. Initial Public Offering June 2, 2022	OKYO Pharma Ltd.  \$2,500,000 Follow-On Offering May 16, 2022	CEA Industries Inc.  \$24,000,000 Follow-On Offering February 10, 2022
authID.ai  \$11,500,000 Follow-On Offering August 23, 2021	PetVivo Holdings, Inc.  \$11,250,000 Follow-On Offering August 10, 2021	Draganfly Inc.  \$20,000,000 Follow-On Offering July 29, 2021	Save Foods, Inc.  \$12,000,000 Follow-On Offering May 13, 2021	Red Cat Holdings, Inc.  \$16,000,000 Follow-On Offering April 29, 2021	BriaCell Therapeutics Corp.  \$28,700,000 Follow-On Offering February 23, 2021	urban-gro, Inc.  \$62,000,000 Follow-On Offering February 11, 2021	BioVie Inc.  \$18,000,000 Secondary/Follow-On September 17, 2020
GreenPower Motor Company, Inc.  \$37,200,000 U.S. Initial Public Offering August 28, 2020	Duos Technologies Group, Inc.  \$9,300,000 Follow-On Offering February 12, 2020	ElectraMeccanica Vehicles Corp.  \$10,000,000 Follow-On Offering August 8, 2018	Blink Charging Co.  \$18,500,000 Follow-On Offering February 13, 2018	AYTU BioScience, Inc.  \$11,800,000 Private Placement August 15, 2017	Immuron  \$6,100,000 Initial Public Offering June 8, 2017	Ontrak, Inc. (fka Catasys, Inc.)  \$16,500,000 Follow-On Offering April 25, 2017	Meridian Waste Solutions  \$12,400,000 Follow-On Offering January 24, 2017
EyeGate Pharmaceuticals, Inc.  \$10,000,000 Secondary/Follow-On July 31, 2015	Cryoport, Inc.  \$6,500,000 Secondary/Follow-On July 23, 2015	Abocma Therapeutics, Inc. (fka PlasmaTech Biopharmaceuticals)  \$14,000,000 Secondary/Follow-On December 18, 2014	Collector Biosciences, Inc.  \$12,500,000 Secondary/Follow-On August 14, 2014	SMTP, Inc.  \$11,500,000 Secondary/Follow-On January 30, 2014	InterCloud Systems, Inc.  \$5,800,000 Secondary/Follow-On October 30, 2013	Sorrento Therapeutics, Inc.  \$34,600,000 Secondary/Follow-On October 24, 2013	Advaxis, Inc.  \$26,500,000 Secondary/Follow-On October 16, 2013

01 02

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

51

Past Nasdaq Up-Listing Offerings

Cancer Genetics, Inc.  \$16,100,000 Secondary/Follow-On August 13, 2013	Micronet Enertec Technologies, Inc.  \$9,300,000 Secondary/Follow-On April 23, 2013	Northwest Biotherapeutics, Inc.  \$13,800,000 Secondary/Follow-On December 7, 2012	Xplore Technologies Corp.  \$10,000,000 Secondary/Follow-On October 25, 2012	Trovagene, Inc.  \$10,600,000 Secondary/Follow-On May 29, 2012	Galectin Therapeutics, Inc.  \$12,000,000 Secondary/Follow-On March 23, 2012	Synergy Pharmaceuticals, Inc.  \$17,300,000 Follow-on Direct December 1, 2011
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

01 02

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

52

Past Foreign Financings

<p>Foremost Lithium Resource & Technology Ltd. FOREMOST LITHIUM</p> <p>\$4,000,000 Follow-On Offering August 21, 2023</p>	<p>KWESST Micro Systems Inc. KWESST</p> <p>\$14,100,000 Follow-On Offering December 6, 2022</p>	<p>TECO 2030 TECO 2030</p> <p>\$10,000,000 Joint Placement Agent November 14, 2022</p>	<p>Mobilicom Limited MOBILICOM Limited</p> <p>\$13,300,000 U.S. Initial Public Offering August 24, 2022</p>	<p>Save Foods, Inc. SAVE FOODS PROCESSED FRESH FRUITS</p> <p>\$4,800,000 Follow-On Offering August 15, 2022</p>	<p>EZRaider EZRaider</p> <p>\$880,000 Debt Financing June 10, 2022</p>	<p>SaverOne 2014 Ltd. SAVERONE</p> <p>\$13,000,000 U.S. Initial Public Offering June 2, 2022</p>	<p>OKYO Pharma Ltd. OKYO PHARMA</p> <p>\$2,500,000 Follow-On Offering May 16, 2022</p>
<p>Snow Lake Resources Ltd. SNOW LAKE LITHIUM</p> <p>\$18,000,000 Follow-On Offering April 7, 2022</p>	<p>Permex Petroleum Corporation PERMEX</p> <p>\$7,500,000 Private Placement March 28, 2022</p>	<p>OMNIQ Corp. omniQ</p> <p>\$8,500,000 Debt Financing March 25, 2022</p>	<p>Piedmont Lithium Inc. PIEDMONT LITHIUM</p> <p>\$130,800,000 Follow-On Offering March 22, 2022</p>	<p>Snow Lake Resources Ltd. SNOW LAKE LITHIUM</p> <p>\$27,600,000 Initial Public Offering November 18, 2021</p>	<p>Siyata Mobile Inc. siyata mobile</p> <p>\$6,000,000 Debt Financing October 27, 2021</p>	<p>Draganfly Inc. DRAGANFLY</p> <p>\$20,000,000 Follow-On Offering July 29, 2021</p>	<p>Pyxis Tankers, Inc. PXS PYXIS TANKERS</p> <p>\$6,200,000 7.75% Series A Cumulative Convertible Preferred Stock July 14, 2021</p>
<p>OMNIQ Corp. omniQ</p> <p>\$13,800,000 Private Placement July 8, 2021</p>	<p>BriaCell Therapeutics Corp. BriaCell</p> <p>\$27,000,000 Private Placement June 3, 2021</p>	<p>Save Foods, Inc. SAVE FOODS PROCESSED FRESH FRUITS</p> <p>\$12,000,000 Follow-On Offering May 13, 2021</p>	<p>Piedmont Lithium Limited PIEDMONT LITHIUM</p> <p>\$122,500,000 Follow-On Offering March 23, 2021</p>	<p>BriaCell Therapeutics Corp. BriaCell</p> <p>\$28,700,000 Follow-On Offering February 23, 2021</p>	<p>Pyxis Tankers, Inc. PXS PYXIS TANKERS</p> <p>\$25,000,000 Private Placement February 17, 2021</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$500,000,000 Registered Direct February 15, 2021</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$332,500,000 Nano Dimension Ltd. January 13, 2021</p>
<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$250,000,000 Registered Direct December 27, 2020</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$180,000,000 Registered Direct December 6, 2020</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$60,000,000 Registered Direct November 29, 2020</p>	<p>Vision Marine Technologies Inc. VISION MARINE TECHNOLOGIES</p> <p>\$27,600,000 Initial Public Offering November 23, 2020</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$100,000,000 Registered Direct November 19, 2020</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$50,200,000 Registered Direct October 26, 2020</p>	<p>Piedmont Lithium Ltd. PIEDMONT LITHIUM</p> <p>\$57,500,000 Follow-On Offering October 21, 2020</p>	<p>Pyxis Tankers Inc. PXS PYXIS TANKERS</p> <p>\$5,000,000 7.75% Series A Cumulative Convertible Preferred Stock October 8, 2020</p>

01 02 03

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

53

Past Foreign Financings







<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$16,900,000 Registered Direct September 30, 2020</p>	<p>GreenPower Motor Company, Inc. GreenPower MOTOR SOLUTIONS</p> <p>\$37,200,000 U.S. Initial Public Offering August 28, 2020</p>	<p>Tiziana Life Sciences plc tiziana LIFE SCIENCES</p> <p>\$57,300,000 Registered Direct August 3, 2020</p>	<p>Piedmont Lithium Ltd. PIEDMONT LITHIUM</p> <p>\$20,500,000 Follow-On Offering June 8, 2020</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$35,900,000 Registered Direct May 20, 2020</p>	<p>Medigus</p> <p>\$5,000,000 Follow-On Offering May 19, 2020</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$13,300,000 Follow-On Offering April 22, 2020</p>	<p>Tiziana Life Sciences plc tiziana LIFE SCIENCES</p> <p>\$200,000 ATM Offering April 10, 2020</p>
<p>Tiziana Life Sciences plc tiziana LIFE SCIENCES</p> <p>\$10,000,000 Follow-On Offering March 12, 2020</p>	<p>Nano Dimension Ltd. NANO DIMENSION LITHIUM</p> <p>\$3,900,000 Follow-On Offering February 5, 2020</p>	<p>Immuron Limited immuron</p> <p>\$2,000,000 Follow-On Offering May 23, 2019</p>	<p>GreenPower Motor Company ep GreenPower</p> <p>\$4,000,000 Private Placement May 3, 2019</p>	<p>OMNIQ Corp. omniQ</p> <p>\$5,000,000 Private Placement April 4, 2019</p>	<p>ElectraMeccanica Vehicles Corp. MECCANICA</p> <p>\$8,500,000 Registered Direct November 7, 2018</p>	<p>ReWalk ReWalk Lower Limb Robotics</p> <p>\$13,300,000 Follow-On Offering November 16, 2018</p>	<p>Collect Biotechnology Ltd. COLLECT</p> <p>\$8,400,000 Initial Public Offering July 29, 2016</p>
<p>Wize Pharma, Inc. WP Wize Pharma</p> <p>\$4,500,000 Private Placement October 23, 2018</p>	<p>OMNIQ Corp. omniQ</p> <p>\$6,300,000 Merger Consultant October 11, 2018</p>	<p>ElectraMeccanica Vehicles Corp. MECCANICA</p> <p>\$10,000,000 Follow-On Offering August 8, 2018</p>	<p>Immuron Limited immuron</p> <p>\$5,100,000 Private Placement March 14, 2018</p>	<p>BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.</p> <p>\$10,000,000 Follow-On Offering September 14, 2017</p>	<p>ElectraMeccanica Vehicles Corp. MECCANICA</p> <p>\$8,500,000 Registered Direct March 26, 2019</p>	<p>Immuron Limited immuron</p> <p>\$6,100,000 Initial Public Offering June 8, 2017</p>	<p>BioBlast Pharma Ltd. BioBlast Pharma</p> <p>\$4,800,000 Private Placement February 6, 2014</p>
<p>Kitov Pharmaceuticals Holdings Ltd. kitov</p> <p>\$12,000,000 Secondary/Follow-On June 29, 2016</p>	<p>DarioHealth Corp. DARIO</p> <p>\$8,500,000 Secondary/Follow-On March 4, 2016</p>	<p>Kitov Pharmaceuticals Holdings Ltd. kitov</p> <p>\$13,000,000 Initial Public Offering November 20, 2015</p>	<p>Oasmia Pharmaceuticals AB oasmia</p> <p>\$10,400,000 Initial Public Offering October 23, 2015</p>	<p>One Horizon Group, Inc. horizon</p> <p>\$3,000,000 Secondary/Follow-On August 5, 2015</p>	<p>BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.</p> <p>\$9,600,000 Initial Public Offering May 11, 2015</p>	<p>Top Ships, Inc. TOP SHIPS INC</p> <p>\$21,300,000 Secondary/Follow-On June 6, 2014</p>	<p>Immuron Limited immuron</p> <p>\$6,100,000 Initial Public Offering June 8, 2017</p>

01 02 03

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

54

Past Foreign Financings





 <p>Oramed Pharmaceuticals, Inc. \$15,800,000 Registered Direct December 24, 2013</p>	 <p>SuperCom Ltd. \$13,800,000 Secondary/Follow-On December 19, 2013</p>	 <p>RIT Technologies, Inc. \$6,000,000 Secondary/Follow-On November 21, 2013</p>	 <p>Alcobra Ltd. \$38,000,000 Secondary/Follow-On October 24, 2013</p>	 <p>Oramed Pharmaceuticals, Inc. \$4,600,000 Registered Direct July 10, 2013</p>	 <p>DarioHealth Corp. \$10,000,000 Private Placement May 10, 2013</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

01 02 03

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

55

Selected M&A Experience

		<p>\$98,000,000 <i>Business Combination</i> August 2023</p>	<p>\$80,500,000 <i>Initial Public Offering</i> February 2022</p>
		<p>\$480,000,000 <i>Business Combination</i> February 2023</p>	<p>\$115,000,000 <i>Initial Public Offering</i> February 2021</p>

- In February 2022, FG Financial Acquisition Corp. (Nasdaq: FGMC) raised \$80.5 million in a common stock public offering which listed the Company onto the Nasdaq. ThinkEquity acted as sole book-running manager for the offering.
- The Company priced the initial public offering of 11,500,000 equity units at a public offering price of \$10.00 per unit, including the full exercise of the underwriter's over-allotment option.
- In February 2023, Alliance Entertainment LLC and Adara Acquisition Corp. announced the merger agreement for Alliance Entertainment LLC to become a publicly traded company. The transaction values Alliance Entertainment LLC at a pro forma enterprise value of \$480 million.
- The business combination closed on February 10, 2023, and the common stock and warrants began trading on the OTC under the ticker symbols "ADRA" and "ADRA WS," respectively.
- Alliance Entertainment LLC (OTC: ADRA) distributes music, movies, and consumer electronics to independent music and video resellers and retailers in the United States and internationally. The company offers a range of compact discs, vinyl LP records, DVDs, Blu-rays, and video games, as well as an array of related apparel, accessories, toys, and collectibles.
- ThinkEquity served as a financial advisor to Adara Acquisition Corp. in connection with the business combination.

01 02 03 04 05

Includes a sample of transactions and may not be an all-inclusive list.

- In April 2021, Adara Acquisition Corp. (NYSE: ADRA) raised \$115 million in a common stock public offering which listed the Company onto the NYSE. ThinkEquity acted as sole book-running manager for the offering.
- The Company priced the initial public offering of 11,500,000 equity units at a public offering price of \$10.00 per unit, including the full exercise of the underwriter's over-allotment option.
- In February 2023, Alliance Entertainment LLC and Adara Acquisition Corp. announced the merger agreement for Alliance Entertainment LLC to become a publicly traded company. The transaction values Alliance Entertainment LLC at a pro forma enterprise value of \$480 million.
- The business combination closed on February 10, 2023, and the common stock and warrants began trading on the OTC under the ticker symbols "ADRA" and "ADRA WS," respectively.
- Alliance Entertainment LLC (OTC: ADRA) distributes music, movies, and consumer electronics to independent music and video resellers and retailers in the United States and internationally. The company offers a range of compact discs, vinyl LP records, DVDs, Blu-rays, and video games, as well as an array of related apparel, accessories, toys, and collectibles.
- ThinkEquity served as a financial advisor to Adara Acquisition Corp. in connection with the business combination.

56

Selected M&A Experience



SECOND SIGHT nanoprecision medical **\$57,500,000** **\$27,900,000** **\$7,500,000**
Business Combination **Follow-On Offering** **Private Placement** **Follow-On Offering**
August 2022 **June 2021** **March 2021** **April 2020**

- Second Sight Medical Products Inc. (Nasdaq: EYES) raised \$7.5 million April 2020 in a follow-on offering of common stock.
- In March 2021, the Company raised an additional \$27.9 million in a private placement of common stock.
- In June 2021, Second Sight raised an additional \$7.5 million in a follow-on offering of common stock priced at \$5.00 per share.
- In August 2022, Second Sight Medical Products announced the successful completion of its merger with Nano Precision Medical.
- Nano Precision Medical's lead program, NPM-119, is a near clinical stage GLP-1 receptor agonist which is being developed to treat patients with Type 2 diabetes for up to 6 months with a single, tiny subdermal implant.
- ThinkEquity acted as the financial advisor to Second Sight in connection with the merger.
- In connection with the merger, Second Sight changed its name to Vivani Medical, Inc., the Company's common stock will trade on The Nasdaq Capital Market under the symbol "VANI".

01 02 03 04 05

Includes a sample of transactions and may not be an all-inclusive list.



\$3.13 Billion **\$115,000,000**
Business Combination **Initial Public Offering**
December 2021 **April 2021**

- In April 2021, Aldel Financial, Inc. (NYSE: ADF) raised \$115 million in a common stock public offering which listed the Company onto the NYSE. ThinkEquity acted as sole book-running manager for the offering.
- The Company priced the initial public offering of 11,500,000 equity units at a public offering price of \$10.00 per unit, including the full exercise of the underwriter's over-allotment option.
- In August 2021, Hagerty and Aldel Financial announced the merger agreement for Hagerty to become a publicly traded company. The transaction values Hagerty at a pro forma enterprise value of \$3.13 billion.
- The business combination closed on December 2, 2021, and the common stock and warrants began trading on the NYSE under the ticker symbols "HGTY" and "HGTY.WS," respectively.
- Hagerty (NYSE: HGTY) is a leading specialty insurance provider focused on the global automotive enthusiast market with a scalable, innovative membership model and robust offerings, including immersive events, media content and valuation tools.
- ThinkEquity served as a financial advisor to Aldel in connection with the business combination.

Selected M&A Experience



\$14,600,000
Acquisition
August 2021

- In August 2021, ProPhase Labs, Inc. (Nasdaq: PRPH), announced the acquisition of Nebula Genomics, a privately-owned personal genomics company.
- The Company's recently formed subsidiary, ProPhase Precision Medicine, Inc., completed the acquisition for approximately \$14.6 million in a combination of ProPhase Labs common stock and cash.
- The Company intends to integrate Nebula's whole genome sequencing services with the robust clinical diagnostic testing services already offered at ProPhase's CLIA-certified molecular testing laboratories.
- ThinkEquity acted as advisor to ProPhase in the acquisition.

01 02 03 04 05

Includes a sample of transactions and may not be an all-inclusive list.



\$800,000,000 **\$238,000,000**
Business Combination **Initial Public Offering**
July 2021 **September 2020**

- In September 2020, FG New America Acquisition Corp (NYSE: FGNA) raised \$238 million in a public offering which listed the Company onto the NYSE. ThinkEquity acted as a book-running manager for the offering.
- The Company priced the initial public offering of 23,775,000 equity units at a public offering price of \$10.00 per unit, including the full exercise of the underwriter's over-allotment option.
- In July 2021, Opportunity Financial ("OppFi") and FG New America Acquisition Corp. announced the merger agreement for OppFi to become a publicly traded company. The transaction values OppFi at a pro forma enterprise value of \$800 million.
- The business combination closed on July 20, 2021, and the common stock and warrants began trading on the NYSE under the ticker symbols "OPFI" and "OPFI WS," respectively.
- OppFi (NYSE: OPFI) is a leading financial technology platform that powers banks to offer accessible products and a top-rated experience to everyday consumers.
- ThinkEquity served as a capital markets advisor to FG New America Acquisition Corp.

Selected M&A Experience



\$2,840,000
Acquisition
June 2021

- In June 2021, Altamira Therapeutics Ltd (Nasdaq: CYTO) (f/k/a Auris Medical Holding) announced the acquisition of Trasir Therapeutics, Inc., an RNA Therapeutics Company.
- The consideration comprises 0.77 million common shares of Auris Medical Holding Ltd., the assumption of certain selling shareholders' cash outlays as well as a future share-based payment contingent on reaching a specific development milestone.
- The Company acquired Trasir's innovative peptide-based OligoPhore™ platform designed to enable extrahepatic delivery of oligonucleotides.
- Trasir's founder, Dr. Samuel Wickline, joined the leadership team as Chief Scientific Officer.
- ThinkEquity acted as advisor to Altamira in the acquisition.

01 02 03 04 05

Includes a sample of transactions and may not be an all-inclusive list.



\$70,000,000
Debt Financing
June 2021

\$209,500,000
Follow-On Offering
May 2021

\$5,000,000
Bridge Loan
March 2021

\$10,000,000
Initial Public Offering
July 2020

- 1847 Goedecker Inc. (NYSE American: GOED) raised \$10.0 million in July 2020 in an initial public offering of common stock which listed the Company on the NYSE American.
- In March 2021, the Company announced the closing of two 10% OID senior secured promissory notes for an aggregate of \$5 million in gross proceeds.
- In May and June 2021, Goedecker simultaneously closed a follow-on offering, debt financing, and an acquisition. In May 2021, Goedecker raised \$209.5 million in the follow-on offering of common stock and warrants. One month later, the Company raised \$70.0 million in debt financing and closed its acquisition of Appliances Connection, creating one of the largest pure-play online retailer of household appliances in the US.
- In July 2022, 1847 Goedecker Inc. changed its corporate name to Polished.com Inc., the Company's common stock and warrants now trade under the symbols "POL" and "POL WS", respectively.

Selected M&A Experience



\$78,000,000
Business Combination
December 2019

- In December 2019, Drone Aviation and ComSovereign Holdings Corp. (Nasdaq: COMS) announced a business combination valued at \$78 million.
- The combined organization will focus on the penetration of 5G-Systems to new and existing global carrier customer base for fixed infrastructure and aerial mobile communications platforms.
- ThinkEquity acted as financial advisor to ComSovereign Corp.

01 02 03 04 05
















Includes a sample of transactions and may not be an all-inclusive list.



\$46,900,000
Acquisition
December 2019

- In December 2019, Better Choice Company Inc. (NYSE: BTTR) announced the acquisition of Halo. Purely for Pets valued at \$47 million, of which \$23.5 million was paid in cash, \$15 million in junior subordinated purchaser notes, and \$8.5 million in common equity.
- ThinkEquity acted as financial advisor to Better Choice Company.

Past Transactions – Lead & Co-Managed

SMTP, Inc.  \$3,800,000 Secondary/Follow-On August 6, 2015	One Horizon Group, Inc.  \$3,000,000 Secondary/Follow-On August 5, 2015	EyeGate Pharmaceuticals, Inc.  \$10,000,000 Secondary/Follow-On July 31, 2015	Cryoport, Inc.  \$6,500,000 Secondary/Follow-On July 23, 2015	CytRx Corporation  \$28,800,000 Secondary/Follow-On July 21, 2015	Caladrius Biosciences, Inc. (fka NeoStem)  \$28,800,000 Secondary/Follow-On May 27, 2015
Manhattan Bridge Capital, Inc.  \$4,500,000 Secondary/Follow-On May 22, 2015	Jaguar Animal Health, Inc.  \$20,000,000 Initial Public Offering May 13, 2015	BiondVax Pharmaceuticals Ltd.  \$9,600,000 Initial Public Offering May 11, 2015	Professional Diversity Network, Inc.  \$5,000,000 Secondary/Follow-On April 16, 2015	Matinas Biopharma  \$10,000,000 Private Placement April 10, 2015	CVSL, Inc.  \$20,000,000 Secondary/Follow-On February 26, 2015
CollabRx, Inc.  \$3,500,000 Secondary/Follow-On February 25, 2015	CollabRx, Inc.  \$5,500,000 Secondary/Follow-On February 19, 2015	Dance Biopharm Inc.  \$9,500,000 Private Placement February 18, 2015	Signal Genetics, Inc.  \$10,400,000 Secondary/Follow-On February 17, 2015	Snap Interactive, Inc.  \$3,000,000 Private Placement February 17, 2015	Intellicheck Mobilisa, Inc.  \$8,500,000 Secondary/Follow-On January 9, 2015
Stemline Therapeutics, Inc.  \$58,900,000 Secondary/Follow-On January 7, 2015	Abeona Therapeutics, Inc. (fka PlasmaTech Biopharmaceuticals) \$14,000,000 Secondary/Follow-On December 18, 2014	AtheroNova, Inc.  \$3,000,000 Secondary/Follow-On October 28, 2014	InterCloud Systems, Inc.  \$44,300,000 M&A October 10, 2014	DT Asia Investments Limited \$60,000,000 Initial Public Offering September 30, 2014	Manhattan Bridge Capital, Inc.  \$5,000,000 Secondary/Follow-On July 31, 2014

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.




























Past Transactions – Lead & Co-Managed

Medical Transcription Billing, Corp.  \$20,400,000 Initial Public Offering July 23, 2014	1347 Capital Corp.  \$40,000,000 Initial Public Offering July 16, 2014	Professional Diversity Network, Inc.  \$40,000,000 M&A July 14, 2014	GlobeImmune, Inc.  \$15,000,000 Initial Public Offering July 1, 2014	Garnero Group Acquisition Company \$125,000,000 Initial Public Offering June 25, 2014	China Biologic Products, Inc.  \$58,900,000 Secondary/Follow-On June 19, 2014	Signal Genetics, Inc.  \$8,500,000 Initial Public Offering June 17, 2014
1347 Property Insurance Holdings, Inc.  \$23,000,000 Secondary/Follow-On June 10, 2014	Top Ships, Inc.  \$21,300,000 Secondary/Follow-On June 6, 2014	Corbus Pharmaceuticals Holdings, Inc  \$10,300,000 Private Placement June 3, 2014	Sorrento Therapeutics, Inc.  \$28,800,000 Secondary/Follow-On May 14, 2014	InVivo Therapeutics Holdings Corp.  \$16,100,000 Secondary/Follow-On May 6, 2014	San Luis Facility Development Corporation \$26,100,000 New Issue May 1, 2014	1347 Property Insurance Holdings, Inc.  \$17,400,000 Initial Public Offering March 31, 2014
Advaxis, Inc.  \$14,100,000 Secondary/Follow-On March 26, 2014	Reero Pharma, Inc.  \$34,500,000 Initial Public Offering March 6, 2014	Ceres, Inc.  \$23,000,000 Secondary/Follow-On March 4, 2014	Semler Scientific, Inc.  \$10,000,000 Initial Public Offering February 20, 2014	GlobeImmune, Inc.  \$7,500,000 Private Placement February 13, 2014	NephroGenex, Inc.  \$37,200,000 Initial Public Offering February 10, 2014	Biocept, Inc.  \$19,000,000 Initial Public Offering February 4, 2014
SMTP, Inc.  \$11,500,000 Secondary/Follow-On January 30, 2014	CytRx Corporation  \$86,300,000 Secondary/Follow-On January 30, 2014	Kips Bay Medical, Inc.  \$4,200,000 Secondary/Follow-On January 23, 2014	Akers Biosciences, Inc.  \$15,000,000 Initial Public Offering January 23, 2014	Intellicheck Mobilisa, Inc.  \$6,100,000 Secondary/Follow-On January 8, 2014	Fusion Telecommunications Intl, Inc.  \$44,000,000 Private Placement December 31, 2013	Sorrento Therapeutics, Inc.  \$177,000,000 Block Trade December 19, 2013
					Oramed Pharmaceuticals, Inc.  \$15,800,000 Registered Direct December 24, 2013	

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Past Transactions – Lead & Co-Managed

SuperCom Ltd.  \$13,800,000 Secondary/Follow-On December 19, 2013	Cambridge Capital Acquisition Corporation  \$80,500,000 Initial Public Offering December 17, 2013	Opexa Therapeutics, Inc.  \$8,100,000 Secondary/Follow-On December 17, 2013	Synthetic Biologies, Inc.  \$13,200,000 Secondary/Follow-On December 11, 2013	RiT Technologies, Inc.  \$6,000,000 Secondary/Follow-On November 21, 2013	xG Technologies, Inc.  \$10,000,000 Secondary/Follow-On November 13, 2013	InterCloud Systems, Inc.  \$11,600,000 Private Placement December 13, 2013	InterCloud Systems, Inc.  \$5,800,000 Secondary/Follow-On October 30, 2013
Quartet Merger Corp. \$96,600,000 Initial Public Offering October 28, 2013	Sorrento Therapeutics, Inc.  \$34,600,000 Secondary/Follow-On October 24, 2013	Alcobra Ltd.  \$38,000,000 Secondary/Follow-On October 24, 2013	Advaxis, Inc.  \$26,500,000 Secondary/Follow-On October 16, 2013	CyRx Corporation  \$25,900,000 Secondary/Follow-On October 8, 2013	Caladrius Biosciences, Inc. (fka NeoStem)  \$40,300,000 Secondary/Follow-On October 3, 2013	Evoke Pharma, Inc.  \$29,000,000 Initial Public Offering September 25, 2013	
Timberline Resources Corp.  \$2,200,000 Secondary/Follow-On September 4, 2013	Cancer Genetics, Inc.  \$16,100,000 Secondary/Follow-On August 13, 2013	Astrom Biosciences, Inc.  \$9,000,000 Secondary/Follow-On August 13, 2013	Opexa Therapeutics, Inc.  \$19,400,000 Secondary/Follow-On August 7, 2013	Vuzix Corporation  \$8,100,000 Secondary/Follow-On July 30, 2013	Box Ships, Inc.  \$13,400,000 Secondary/Follow-On July 24, 2013	Heat Biologics, Inc.  \$27,000,000 Initial Public Offering July 23, 2013	
xG Technologies, Inc.  \$8,500,000 Initial Public Offering July 18, 2013	Oramed Pharmaceuticals, Inc.  \$4,600,000 Registered Direct July 10, 2013	Miller Energy Resources, Inc.  \$7,200,000 Secondary/Follow-On July 3, 2013	Echo Therapeutics, Inc.  \$12,500,000 Secondary/Follow-On June 19, 2013	RCS Capital Corporation  \$50,000,000 Initial Public Offering June 5, 2013	The Industrial Development Authority Of the County of La Paz, Arizona \$91,200,000 New Issue May 29, 2013	Virtual Piggy, Inc.  \$6,400,000 Private Placement May 28, 2013	

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.





























Past Transactions – Lead & Co-Managed

Willacy County Public Facility Corporation \$20,500,000 New Issue May 28, 2013	Alcobra Ltd.  \$25,000,000 Initial Public Offering May 22, 2013	Stemline Therapeutics, Inc.  \$69,000,000 Secondary/Follow-On May 16, 2013	Caladrius Biosciences, Inc. (fka NeoStem)  \$11,500,000 Secondary/Follow-On April 29, 2013	Micronet Enertec Technologies, Inc.  \$9,300,000 Secondary/Follow-On April 23, 2013	Selway Capital Acquisition Corp. and Healthcare Corp of America  \$60,000,000 Business Combination April 11, 2013	Cancer Genetics, Inc.  \$6,900,000 Initial Public Offering April 4, 2013
Rosetta Genomics Ltd.  \$5,900,000 Advisor March 22, 2013	Five Oaks Investment Corp.  \$60,500,000 Initial Public Offering March 21, 2013	Hercules Technology Growth Capital  \$98,800,000 Secondary/Follow-On March 7, 2013	Professional Diversity Network, Inc.  \$21,000,000 Initial Public Offering March 5, 2013	Imprimis Pharmaceuticals, Inc.  \$11,100,000 Secondary/Follow-On February 7, 2013	Echo Therapeutics, Inc.  \$11,800,000 Secondary/Follow-On January 31, 2013	Stemline Therapeutics, Inc.  \$38,200,000 Initial Public Offering January 19, 2013
Kips Bay Medical, Inc.  \$6,500,000 Secondary/Follow-On December 21, 2012	Echo Therapeutics, Inc.  \$3,500,000 Secondary/Follow-On December 20, 2012	Northwest Biotherapeutics, Inc.  \$13,800,000 Secondary/Follow-On December 7, 2012	Superconductor Technologies Inc.  \$3,200,000 Secondary/Follow-On November 20, 2012	AspenBio Pharmaceuticals, Inc.  \$4,100,000 Secondary/Follow-On November 15, 2012	Comstock Mining  \$8,100,000 Secondary/Follow-On November 13, 2012	Xplore Technologies Corp.  \$10,000,000 Secondary/Follow-On October 25, 2012
CyRx Corporation  \$23,000,000 Secondary/Follow-On October 18, 2012	Net Element International Inc. merger with Cazador Acquisition Corporation  \$350,000,000 M&A October 2, 2012	Ascent Solar Technologies, Inc.  \$11,000,000 Secondary/Follow-On September 19, 2012	PURE Bioscience, Inc.  \$4,200,000 Secondary/Follow-On September 11, 2012	IZEA Inc.  \$2,200,000 Secondary/Follow-On September 5, 2012	Neuralstem, Inc.  \$2,800,000 Secondary/Follow-On August 14, 2012	Rosetta Genomics Ltd.  \$31,600,000 Secondary/Follow-On August 2, 2012

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.




























Past Transactions – Lead & Co-Managed

Ampio Pharmaceuticals, Inc.  \$17,800,000 Secondary/Follow-On July 12, 2012	New York Mortgage Trust, Inc.  \$30,200,000 Secondary/Follow-On July 11, 2012	AspenBio Pharmaceuticals, Inc.  \$12,200,000 Secondary/Follow-On June 19, 2012	Trovogene, Inc.  \$10,600,000 Secondary/Follow-On May 23, 2012	New York Mortgage Trust, Inc.  \$18,300,000 Secondary/Follow-On May 25, 2012	Rosetta Genomics Ltd.  \$6,600,000 Registered Direct May 16, 2012	IZEA Inc.  \$1,400,000 Private Placement May 15, 2012
Synergy Pharmaceuticals  \$51,800,000 Secondary/Follow-On May 4, 2012	Firsthand Technology Value Fund  \$118,800,000 Secondary/Follow-On April 19, 2012	Rosetta Genomics Ltd.  \$3,100,000 Registered Direct April 12, 2012	TCP Capital Corp.  \$84,800,000 Initial Public Offering April 4, 2012	Gaza County Public Facility Corporation  \$35,900,000 New Issue March 28, 2012	Arlington Asset Investment Corp.  \$41,900,000 Secondary/Follow-On March 22, 2012	BGS Acquisition Corp.  \$40,000,000 Initial Public Offering March 21, 2012
NetSol Technologies, Inc.  \$6,700,000 Secondary/Follow-On March 1, 2012	In Vivo Therapeutics Holdings, Inc.  \$20,000,000 Secondary/Follow-On February 16, 2012	GSV Capital Corp.  \$90,000,000 Secondary/Follow-On February 10, 2012	Comstock Mining  \$17,300,000 Secondary/Follow-On February 9, 2012	Chromadex Corporation  \$11,200,000 Registered Direct January 31, 2012	Selway Capital Acquisition Corp.  \$20,000,000 Initial Public Offering November 8, 2011	American Realty Capital Properties, Inc.  \$15,800,000 Secondary/Follow-On October 28, 2011
TowerStream Corporation  \$41,400,000 Secondary/Follow-On July 15, 2011	China Growth Equity Investment Ltd.  \$50,000,000 Initial Public Offering May 26, 2011	IZEA Holdings Inc.  \$3,300,000 Private Placement May 24, 2011	NetSol Technologies, Inc.  M&A May 19, 2011	Universal Business Payment Solutions Acquisition Corporation  \$72,000,000 Initial Public Offering May 9, 2011	Mission NewEnergy Limited  \$25,100,000 Initial Public Offering April 20, 2011	Hyperdynamics Corporation  \$143,800,000 Secondary/Follow-On March 25, 2011

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.
































Past Transactions – Lead & Co-Managed

Prime Acquisition Corp.  \$36,000,000 Initial Public Offering March 24, 2011	Gulfport Energy Corporation  \$153,600,000 Secondary/Follow-On March 24, 2011	Endavour International Corporation  \$110,000,000 Secondary/Follow-On March 24, 2011	Kips Bay Medical, Inc.  \$16,500,000 Initial Public Offering February 11, 2011	On Track Innovation, Ltd.  \$18,000,000 Secondary/Follow-On February 3, 2011	Kingold Jewelry, Inc.  \$23,000,000 Secondary/Follow-On January 14, 2011	Sino Clean Energy, Inc.  \$33,000,000 Secondary/Follow-On December 22, 2010
Magic Software Enterprises Ltd.  \$21,200,000 Private Placement December 20, 2010	Ventrus Biosciences, Inc.  \$17,400,000 Initial Public Offering December 16, 2010	YM Biosciences Inc.  \$40,000,000 Secondary/Follow-On December 14, 2010	FlatWorld Acquisition Corp.  \$22,000,000 Initial Public Offering December 10, 2010	SKY-mobi Limited  \$58,000,000 Initial Public Offering December 10, 2010	Lizhan Environmental Corp.  \$10,000,000 Initial Public Offering November 19, 2010	Ascent Solar Technologies, Inc.  \$21,800,000 Secondary/Follow-On November 12, 2010
Triangle Petroleum Corporation  \$59,400,000 Secondary/Follow-On November 5, 2010	China Linen Textile Industry, Ltd.  \$7,000,000 Private Placement November 4, 2010	Exact Sciences Corporation  \$69,000,000 Secondary/Follow-On November 4, 2010	JinkoSolar Holding Co., Ltd.  \$126,000,000 Secondary/Follow-On November 4, 2010	China Dredging Group Company Ltd.  \$50,100,000 Private Placement October 29, 2010	Cavico Corp.  \$2,100,000 Secondary/Follow-On October 27, 2010	Funtank China Holdings Limited  \$49,000,000 Secondary/Follow-On October 26, 2010
Comstock Mining Inc  \$35,800,000 Private Placement October 21, 2010	Yuhe International, Inc.  \$25,200,000 Secondary/Follow-On October 20, 2010	OncoGenex Pharmaceuticals  \$50,000,000 Secondary/Follow-On October 19, 2010	Golden Minerals Company  \$75,000,000 Secondary/Follow-On October 7, 2010	Net Element  \$46,000,000 Initial Public Offering October 7, 2010	D Medical Industries Ltd  \$10,500,000 Initial Public Offering August 5, 2010	China Intelligent Lighting and Electronics, Inc.  \$101,000,000 Initial Public Offering June 17, 2010

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

































Past Transactions – Lead & Co-Managed

Universal Travel Group  \$20,000,000 Secondary/Follow-On June 16, 2010	57th Street General Acquisition Corp.  \$54,600,000 Initial Public Offering May 20, 2010	China Agritech, Inc.  \$23,000,000 Secondary/Follow-On April 29, 2010	China Jo-Jo Drugstores, Inc.  \$17,500,000 Secondary/Follow-On April 22, 2010	NIVS IntelliMedia Technology Group, Inc.  \$24,000,000 Secondary/Follow-On April 20, 2010	Lihua International Inc.  \$34,500,000 Secondary/Follow-On April 9, 2010	Southern China Livestock International, Inc.  \$7,600,000 Private Placement March 31, 2010	Golden Minerals Company  \$34,000,000 Secondary/Follow-On March 18, 2010
G. Willi-Food International Ltd.  \$20,000,000 Secondary/Follow-On March 11, 2010	Sincoking Coal and Coke Chemical Industries, Inc.  \$44,000,000 Private Placement March 11, 2010	Duoyuan Global Water, Inc.  \$104,600,000 Secondary/Follow-On February 27, 2010	China Redstone Group  \$4,600,000 Private Placement February 22, 2010	Derma Sciences, Inc.  \$5,600,000 Secondary/Follow-On February 16, 2010	Fushi Cooperweld, Inc.  \$59,800,000 Secondary/Follow-On January 26, 2010	Andatee China Marine Fuel Services Corp.  \$22,700,000 Initial Public Offering January 26, 2010	Seanergy Maritime Holdings Corp.  \$30,000,000 Secondary/Follow-On January 26, 2010
Rex Energy Corp.  \$84,500,000 Secondary/Follow-On January 14, 2010	DJSP Enterprises, Inc.  M&A January 11, 2010	Puntalk China Holdings Limited  \$21,700,000 Secondary/Follow-On December 17, 2009	Crimson Exploration  \$100,000,000 Secondary/Follow-On December 16, 2009	Energy XXI (Bermuda) Limited  \$171,000,000 Secondary/Follow-On December 8, 2009	AuthentiDate Corp  \$3,400,000 Private Placement December 8, 2009	ZIOPHARM Oncology Inc.  \$48,000,000 Secondary/Follow-On December 4, 2009	GeoResources, Inc.  \$30,600,000 Secondary/Follow-On November 24, 2009
China Cord Blood Corporation  \$20,000,000 Secondary/Follow-On November 19, 2009	GSME Acquisition Partners I  \$36,000,000 Initial Public Offering November 19, 2009	American Lorain Corporation  \$12,000,000 Private Placement October 29, 2009	Shandong LongKang Juice Co.  \$15,100,000 Private Placement October 26, 2009	China Agritech, Inc.  \$15,000,000 Private Placement October 20, 2009	ZST Digital Networks, Inc.  \$25,000,000 Secondary/Follow-On October 20, 2009	China Education Alliance, Inc.  \$19,800,000 Secondary/Follow-On September 30, 2009	ATP Oil & Gas Corporation  \$98,100,000 Secondary/Follow-On September 23, 2009

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

































Past Transactions – Lead & Co-Managed

WaveWave Communications  \$9,000,000 Debt Replacement Facility September 6, 2009	Lihua International Inc.  \$10,400,000 Initial Public Offering September 4, 2009	MannKind Corporation  \$54,400,000 Secondary/Follow-On August 5, 2009	FreeSeas, Inc.  \$18,100,000 Secondary/Follow-On July 22, 2009	Cell Therapeutics, Inc.  \$43,700,000 Secondary/Follow-On July 22, 2009	Skystar Bio-Pharmaceuticals Co.  \$20,900,000 Secondary/Follow-On June 30, 2009	Cyalume Light Technology  December 29, 2008	Pantheon China Acquisition Corp. Merger with China Corp Blood Corp  \$28,000,000 Bridge Loan December 10, 2008
Seanergy Maritime Holdings Corp.  \$395,300,000 M&A August 27, 2008	SmartHeat, Inc.  \$5,700,000 Private Placement July 8, 2008	Sequenom, Inc.  \$85,300,000 Secondary/Follow-On June 25, 2008	NeSol Technologies, Inc.  Dual Listing June 16, 2008	China Fundamental Acquisition Corp.  \$30,000,000 Initial Public Offering May 15, 2008	BPW Acquisition Corp.  \$350,000,000 Initial Public Offering February 26, 2008	Overture Acquisition Corp.  \$150,000,000 Initial Public Offering January 30, 2008	Triam Acquisition I Corp.  \$800,000,000 Initial Public Offering January 23, 2008
Asia Special Situation Acquisition  \$100,000,000 Initial Public Offering January 16, 2008	United Refining Energy Corp.  \$450,000,000 Initial Public Offering December 11, 2007	Global Consumer Acquisition Corp.  \$300,000,000 Initial Public Offering November 21, 2007	2020 ChinaCap Acquiror, Inc.  \$60,000,000 Initial Public Offering November 9, 2007	Secure America Acquisition Corp.  \$80,000,000 Initial Public Offering October 23, 2007	TM Entertainment and Media, Inc.  \$72,000,000 Initial Public Offering October 17, 2007	Stone Tan China Acquisition Corp.  \$240,000,000 Initial Public Offering October 15, 2007	FMG Acquisition Corp.  \$36,000,000 Initial Public Offering October 4, 2007
Seanergy Maritime Holdings Corp.  \$220,000,000 Initial Public Offering September 24, 2007	InterAmerican Acquisition Group  \$40,000,000 Initial Public Offering September 5, 2007	ImaRx Therapeutics Inc.  \$15,000,000 Initial Public Offering July 25, 2007	Alyst Acquisition Corp.  \$56,000,000 Initial Public Offering June 29, 2007	Response Genetics, Inc.  \$21,000,000 Initial Public Offering June 4, 2007	TransTech Services Partners  \$36,000,000 Initial Public Offering May 23, 2007	Arcade Acquisition Corporation  \$60,000,000 Initial Public Offering May 21, 2007	China Healthcare Acquisition Corp  \$51,000,000 Initial Public Offering April 19, 2007

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Past Transactions – Lead & Co-Managed

PinPoint Advance Corp  \$36,000,000 Initial Public Offering April 19, 2007	Alpha Security Group Corporation  \$60,000,000 Initial Public Offering March 23, 2007	Oceanaut, Inc.  \$150,000,000 Initial Public Offering March 1, 2007	Dekania Corp.  \$97,000,000 Initial Public Offering February 1, 2007	Oculus Innovative Sciences, Inc.  \$24,200,000 Initial Public Offering January 26, 2007	Fuwei Films (Holdings) Co.  \$31,000,000 Initial Public Offering December 18, 2006	SORL Auto Parts, Inc  \$31,100,000 Secondary/Follow-On November 27, 2006	Thermage, Inc.  \$42,000,000 Initial Public Offering November 9, 2006
RRSAT Global Communication  \$47,500,000 Initial Public Offering November 1, 2006	Ivivi Technology, Inc.  \$15,000,000 Initial Public Offering October 18, 2006	Millennium India Acquisition Company  \$58,000,000 Initial Public Offering July 20, 2006	Energy Infrastructure Acquisition Corp.  \$202,500,000 Initial Public Offering July 18, 2006	Affinity Media International Corp.  \$16,500,000 Initial Public Offering June 5, 2006	Community Bankers Acquisition Corp.  \$60,000,000 Initial Public Offering June 5, 2006	Minrad International, Inc.  \$32,500,000 Secondary/Follow-On May 23, 2006	Compass Diversified Trust  \$202,500,000 Initial Public Offering May 10, 2006
JK Acquisition Corp.  \$69,000,000 Initial Public Offering April 11, 2006	Incredimail, Ltd.  \$21,500,000 Initial Public Offering January 30, 2006	Star Maritime Acquisition Corp.  \$188,700,000 Initial Public Offering December 15, 2005	Key Hospitality Acquisition Corp.  \$48,000,000 Initial Public Offering October 20, 2005	BioDelivery Sciences Int'l  \$8,800,000 Secondary/Follow-On September 29, 2005	AD Venture Partners  \$54,000,000 Initial Public Offering August 26, 2005	Healthcare Acquisition Corp.  \$72,000,000 Initial Public Offering July 28, 2005	Contech Group  \$40,400,000 Secondary/Follow-On July 15, 2005
Gentium S.p.A  \$24,800,000 Initial Public Offering June 16, 2005	Coffee Holding Co., Inc.  \$9,200,000 Initial Public Offering May 2, 2005	Interchange Inc.  \$22,000,000 Initial Public Offering October 19, 2004	GuruNet Corp.  \$11,800,000 Initial Public Offering October 13, 2004	Newtek Business Services, Inc.  \$25,000,000 Secondary/Follow-On June 28, 2004	Manhattan Pharmaceuticals  \$10,000,000 Private Placement Sole Placement Agent	Acacia Combinatrix Corp.  \$4,900,000 Private Placement Sole Placement Agent	TeamStaff, Inc.  \$4,300,000 Private Placement Sole Placement Agent

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Past Transactions – Lead & Co-Managed

ADM/Tronics Unlimited  \$6,100,000 Private Placement Sole Placement Agent	Starfire Systems, Inc.  \$3,000,000 Private Placement Co-Placement Agent	psivida LTD  \$15,000,000 Private Placement Co-Placement Agent	Velocity Express Corporation  \$45,000,000 Private Placement Co-Placement Agent	Xstream Network, Inc.  \$17,500,000 Private Placement Sole Placement Agent	Drugmax, Inc.  \$17,000,000 Private Placement Co-Placement Agent	Association of Volleyball Professionals  \$5,000,000 Private Placement Sole Placement Agent	Altaitt Nanotechnologies  \$202,50,000 Shelf Offering Sole Placement Agent
PacificNet Inc.  \$8,000,000 Convertible Debt Private Placement Co-Placement Agent	Gentium S.p.A.  \$10,900,000 Private Placement Co-Placement Agent	Diguang Electronics  \$12,000,000 Private Placement Co-Placement Agent	PRB Gas Transportation  \$22,000,000 Private Placement Co-Placement Agent	ImaRx Therapeutics  \$14,200,000 Private Placement Co-Placement Agent	Jed Oil Inc.  \$34,300,000 Private Placement Co-Placement Agent	NetsoI Technologies, Inc.  \$5,500,000 Private Placement Sole Placement Agent	Debt Resolve, Inc.  \$2,600,000 Bridge Financing Co-Placement Agent
Pipeline Data, Inc.  \$37,000,000 Convertible Debt Private Placement Sole Placement Agent	Cel-Sci Corporation  \$8,300,000 Private Placement Sole Placement Agent	IXI Mobile  \$20,000,000 Bridge Financing Co-Placement Agent	Hyperspace Communications, Inc.  \$9,500,000 Private Placement Sole Placement Agent	Asiamart, Inc.  \$3,100,000 Private Placement Co-Placement Agent	Signalife, Inc.  \$2,900,000 Private Placement Sole Placement Agent	Universal Guardian Holdings, Inc.  \$6,000,000 Private Placement Sole Placement Agent	Commed Healthcare Management, Inc.  \$15,000,000 Private Placement Sole Placement Agent
Telesone Technologies Corp.  \$6,000,000 Private Placement Sole Placement Agent	Velcera, Inc.  \$9,900,000 Private Placement Sole Placement Agent	IsoRay, Inc.  \$16,500,000 Private Placement Co-Placement Agent	Oncovista, Inc.  \$6,800,000 Private Placement Sole Placement Agent	DigitalFX International, Inc.  \$7,000,000 Private Placement Sole Placement Agent	Manhattan Pharmaceuticals  \$10,000,000 Private Placement Sole Placement Agent	Acacia Combinatrix Corp.  \$4,900,000 Private Placement Sole Placement Agent	TeamStaff, Inc.  \$4,300,000 Private Placement Sole Placement Agent

01 02 03 04 05 06 07 08 09 10

Transactions occurring before April 1, 2018 were executed by the team as lead or co-manager prior to joining ThinkEquity LLC. Includes a sample of transactions and may not be an all-inclusive list.

Disclaimer

Investment products are made available through ThinkEquity, member NYSE, FINRA (www.finra.org) & SIPC (www.sipc.org).

These documents are for informational purposes only. The information does not constitute a solicitation or an offer to buy or sell any security.

Transactions occurring before April 1, 2018, were executed by the team prior to joining ThinkEquity LLC and selected transactions may not be an all-inclusive list.

This information is confidential and intended solely for the use of ThinkEquity and the client or prospective client to whom it has been delivered. It is not to be reproduced or distributed to any person except to the client's professional advisor.

Before making an investment decision, you should carefully read the applicable offering memorandum or prospectus which contains important disclosures regarding risks, fees, and expenses. Any third party information used in this document has been obtained from various published and unpublished sources considered to be reliable. However, ThinkEquity cannot guarantee its accuracy or completeness and thus, does not accept liability for any direct or consequential losses arising from its use.

Past performance is no guarantee of future results. The investment return and principal value of an investment can fluctuate with changes in market conditions.

Contact Us



ThinkEquity

Member NYSE, FINRA, SIPC



Address

17 State Street, 41st Floor
New York, NY 10004



Phone

646-968-9355



Email

info@think-equity.com

Centri

CentriConsulting.com

EXPERTISE ON DEMAND

At **Centri**, our team of experts leverage their **multilayered skill sets** to provide you with **tailored solutions** for **any business challenge**.

Our Services

**Financial Reporting | Capital Markets Readiness | Technical Accounting
Audit Support | Accounting Transformation | Tax Advisory | Valuation
Risk Advisory | Outsourced Accounting | M&A Advisory | HR Advisory**

Contact Us

info@CentriConsulting.com

 NELSON MULLINS

Committed

to excellence in client service and our profession

Tireless advocacy, business sense, and working side by side with clients toward the same goals – that is the character of who we are. A full-service law firm with a national footprint, we provide corporate, litigation, intellectual property, and government relations services to clients, including Fortune 500 companies, private equity and venture funds, portfolio companies, and emerging growth companies and start-ups. Nelson Mullins is a leader within the profession, and we are committed to serving the public welfare.



David Mannheim

Partner

Raleigh, NC

david.mannheim@nelsonmullins.com

T: 919.329.3804



Mike Bradshaw

Partner

Washington, D.C.

mike.bradshaw@nelsonmullins.com

T: 202.689.2808

33 


Offices located in 17 states
and Washington, D.C.



Practice Areas



Strong commitment
to leadership & service

 1,000+

Attorneys and Government
Relations Professionals

Nelson Mullins Riley & Scarborough LLP
Attorneys and Counselors at Law
nelsonmullins.com

Meridian | 17th Floor
1320 Main Street | Columbia, SC 29201
803.799.2000



THE EXCHANGE FOR THE WORLD STAGESM

Company IPOs & ETF Listings
◆ Uplistings ◆ Intralistsings

More liquidity.

More support.

More connectivity.

Get **MORE** with Cboe Global Listings

Visit cboe.com/listings



Lucosky Brookman is a boutique corporate and securities law firm directly serving the micro-cap and small-cap markets, specializing in sophisticated corporate and capital markets transactions, mergers and acquisitions, secured and unsecured lending deals and commercial and securities litigation. The Firm was established out of a desire to dedicate more time and effort to directly serve a select clientele in the small and middle markets.

**RELATIONSHIP FOCUSED.
RESULTS DRIVEN.**

www.lucbro.com

Practice Areas

Corporate & Securities

Uplisting/Cross-Listing/IPOs

Mergers & Acquisitions

SPACs

Banking & Finance

Litigation

Insurance Coverage & Defense

Corporate Tax

Real Estate

Regulatory Investigations

Intellectual Property

Israeli Practice Group

More Information



Explore Our Comprehensive and In-Depth Market Data and Analytics Reports



Discover Our Latest Presentation: "The Bell Isn't Going to Ring Itself" Download the Digital Booklet Now

EQUISOLVE



DIGITAL

IR & CORPORATE WEBSITES



ADA/ACCESSIBILITY

ACCESSIBILITY AS A SERVICE (AaaS)



STUDIO

VIDEO PRODUCTION • ANIMATION



SERVICES

WEBCASTING & TELECONFERENCING

equisolve.com



We're Part of the Solution

Solutions for life sciences companies that help you transform, innovate, build, connect.



Learn more at EisnerAmper.com/LS

 | **EISNERAMPER**

H | T | F | L

HUNTER TAUBMAN FISCHER & LI LLC

NEW YORK WASHINGTON, D.C. MIAMI

Competent Counsel for a Complex World.

Strategically located in New York, Washington D.C., and Miami, Hunter Taubman Fischer & Li LLC (“HTFL”) brings a truly global perspective to the practice of law.

HTFL is a noted boutique corporate and securities law firm with core strengths in providing transactional and litigation services to small and medium sized companies, institutional investors and broker-dealers.

We regularly provide advice and counsel with regard to a wide range of securities transactions, including Reg. A+ offerings, ‘33&’34 Act compliance, mergers and acquisitions, corporate immigration, regulatory enforcement defense and commercial litigation. We also have a highly recognized Asia practice, handling IPOs for Asian based companies to be listed on U.S. exchanges and OTC Markets, representing issuers or underwriters. We are committed to providing straight forward, cost effective solutions to even the most complicated problems.

In a complex world, HTFL’s superior legal team is there to help our clients manage the unique intricacies of a global marketplace.

NEW YORK

950 Third Avenue, 19th
Fl New York, NY 10022
212.530.2210

WASHINGTON, D.C.

1050 Connecticut Avenue,
NW, Suite 690,
Washington, D.C. 20036
202.347.9090

MIAMI

848 Brickell Avenue
Suite 200
Miami, FL 33131
786.391.3849

CORAL GABLES

2 Alhambra Plaza
Suite 650
Coral Gables, FL 33134
305.629.8810

www.htflawyers.com | info@htflawyers.com

“Ask Us About Zero Down Time”



PARTNERING IN YOUR SUCCESS

The 1st to Provide ThinkEquity with Zero Down Time



1-888-947-1515

Serving New York City & Surrounding Areas

www.apextechservices.com

Ascent Investor Relations



Our Objective Is to Help Clients Better Connect with U.S. Capital Market and Realize Highest Market Value

We are a leading investor relations agency specializing in investor relations strategic planning, capital market advisory and corporate communication services for companies listed on U.S. stock exchanges with seasoned senior communication experts and Wall Street professionals. Headquartered in New York, we have explored our presence in strategic Asia markets such as China, Singapore, Malaysia and Japan, tailoring to support clients with personalized services on a global scale.



Client Base

- Pre-IPO Companies at various stages of development
- Small & mid-cap companies listed on NYSE, Nasdaq, and OTC
- Across varies industries, particularly in TMT, Fintech, Bio-tech, Healthcare, Financial, Education, and Consumer



Access to 3000+ buy-side and sell-side institutions in North America and Asia



2000+ domestic and international media outlet resources



200+ equity research analysts recommendations



Executives have 50+ years of combined experience across industries

INVESTOR RELATIONS

- Strategic Investor Relations Planning
- Corporate Communication Strategy
- Investor Presentations & Briefings
- Information Disclosure

CAPITAL MARKET ADVISORY

- Capital Market Intelligence
- Investors Targeting
- Research Coverage Recommendations
- Peer Metrics Analysis

MEDIA RELATIONS

- Marketing Strategy Planning
- Media Resource Expansion
- Interview with Reporters
- Social Media Operation

CUSTOMIZED SERVICES

- Roadshow Deck
- Bell Ringing Arrangement
- IPO Consulting
- Crisis Management

733 3rd Ave., 16th FL, New York, NY 10017 | investors@ascent-ir.com | <http://www.ascent-ir.com>

Keeping You Ahead of the Curve

Our outsourced accounting, tax, and audit experts have in-depth knowledge and cutting-edge solutions to help your organization navigate the complex terrain of the life science and technology industries.

With CBIZ by your side, you can focus on what you do best: pushing the boundaries of innovation and scientific discovery.

CBIZ | MHM
TAX | ACCOUNTING | ADVISORY

CBIZ.COM

MHMCPA.COM

MHM (Mayer Hoffman McCann P.C.) is an independent CPA firm that provides audit, review and other attest services, and works closely with CBIZ, a business consulting, tax and financial services provider.

UNLIMITED EDGAR & iXBRL

M2
COMPLIANCE

UNPARALLELED SERVICES

\$6,995

Annually



EDGAR & iXBRL

Unlimited processing for Quarterly and Annual reports (10-Q's and 10-k), Prospectuses (424B3, 424B4, 424B5), 8-K's, Alterations, Amendments and Proxy Statements (PRE 14A, PRE 14C, DEF 14). No limitation on the number of pages to be converted



Faster Service

We will provide you a more dedicated, faster turnaround time for EDGAR & XBRL processing while maintaining quality and accuracy throughout the process



Registration Statements

Unlimited processing for Registration Statements (S-1, S-3, S-4, S-8, F-1, F-3, F-4)



Exceptional Service

Our account managers are available 24/7 to help you with all your compliance requirements



Ownership Documents & Section 16

Unlimited processing for ownership documents (SC 13D, SC 13G, Forms 3, 4 and 5)



Overnight and Weekend Processing

No additional charges for overnight or weekend processing, it is all included in your Unlimited program



Experienced, Efficient and Knowledgeable

With extensive industry experience, we are able to deliver unparalleled customer support, expedited processing and accurate service



Competitive Rates

We are the only provider of the Unlimited EDGAR & iXBRL Program, guaranteeing to save you up to 40%

754.243.5120 | info@M2compliance.com | M2compliance.com

AMERICA'S LARGEST COMMUNITY OF FAMILY OFFICES

Force brings Family Offices together to share intellectual capital and best practices across all areas of their operations. We provide a platform to help spread the word about their philanthropic work. We also introduce them to best-in-class service providers and coinvestment opportunities investment by sharing exceptional deal flow in what we believe are innovative public and private companies with bright futures ahead. Learn more at: www.forcefamilyoffice.com



Elevating Legal Excellence

Ruberry Stalmack & Garvey, LLC is a law firm with a proven track record of delivering exceptional results. Clients turn to us when they need litigators with actual and in-depth trial experience who are prepared to vigorously fight for their interests and, if necessary, take cases to trial for resolution.

We serve a diverse clientele, including entrepreneurs, startups, corporate leaders, directors and officers, and policyholders. Our nationwide caseload ranges from complex commercial disputes and SEC matters to class actions, contentious M&A transactions, SPAC litigation, and employment covenant issues.

Beyond our litigation practice, we provide strategic counsel to numerous boards of directors and C-suite officers, assisting them in navigating complex matters, such as fiduciary duties and competition covenants in executive and director agreements. No matter the challenge, we are dedicated to crafting innovative legal theories and strategies to secure exceptional outcomes for our clients.

RUBERRY

RUBERRY STALMACK & GARVEY, LLC
300 South Wacker Drive, Suite 3250
Chicago, Illinois 60606
Main (312) 466-8050 | Fax (312) 466-8055
www.ruberry-law.com

CONTINENTAL

STOCK TRANSFER & TRUST

TAILORED SOLUTIONS FOR YOUR SHAREHOLDERS



Our Services:

- Transfer Agent Solutions
- Tailored IPO & SPAC Services
- Escrow & Corporate Action Services
- Proxy & Virtual Meeting Services
- Dividend Disbursement & Paying Agency
- Direct Purchase & Dividend Reinvestment Programs
- Dedicated Account Management Team
- Domestic Shareholder Call Center

View our website with the QR code below to learn more



1 State Street, 30th Floor
New York, NY 10004

www.continentalstock.com



Every business needs a finance, accounting, and, if publicly-traded, SEC compliance department, but only the largest corporations can truly afford them.

Enter Eventus: A proven team of seasoned professionals ready to provide the complete slate of specialized finance, accounting, and technical reporting expertise your business requires without the expense of building an in-house staff.

For more information about our full-service and on-demand finance, accounting, and SEC compliance services contact:

Neil Reithinger
Managing Director
nreithinger@eventusag.com

Aaron Spool
Managing Director
aspool@eventusag.com


Mark Stoller
Head of New Business
mstoller@eventusag.com

www.eventusag.com

SEASONED PROFESSIONALS WITH DECADES OF PUBLIC MARKET EXPERIENCE AND A PASSION FOR DELIVERING RESULTS



The IRTH Communications Team, Delivers Expert Implementation and Execution



COMMITTED TO CLIENTS & COMMUNITY

Helping clients meet their legal and business challenges throughout the world, McGuireWoods serves public, private, government and nonprofit clients from countless industries in all areas of law.

We are proud to support the **ThinkEquity Conference.**

McGuireWoods

1,100 lawyers | 21 offices | www.mcguirewoods.com




ELEV8 NEW MEDIA IS AN AWARD-WINNING PUBLIC AND MEDIA RELATIONS FIRM

- Earned Media Placements
- Op-Eds & Thought Leadership
- Positioning & Messaging
- Media Coverage Monitoring
- Press Release Support
- Media Training & Coaching
- Social Media Management
- Trade Show Support
- Influencer Relations
- Crisis Management



EdgarAgents

FILE WITH CONFIDENCE™



Our Mission is to simplify and expedite the SEC filing and financial printing process, delivering speed, precision, value, and exemplary customer service.



EdgarAgents makes YOUR LIFE EASIER by working natively in Word. This avails the entire working group to use track changes and benefit from the industry's highest quality and service. Receive document proofs 3x faster and realize efficiencies throughout the filing process!



Don't pay more for less! Know what you're paying for with our transparent pricing. Our proprietary technology enabled workflows reduce the need for premium rush charges while accelerating your path to market.



As a top 3 filing agent (#1 SPAC+deSPAC, #1 IPOs), EA employs 500+ full-time employees with deep understanding of SEC filing requirements. You can depend on our knowledgeable customer service team, available to you 24/7/365.

www.edgaragents.com | info@edgaragents.com



SOCIALSUITE

SHARE YOUR IMPACT WITH THE WORLD

Fast, simple, and affordable ESG & impact measurement software

Trusted by over 100 public companies, Socialsuite provides value by helping organizations raise capital, enhance their reputation, and prepare for upcoming regulations.



Seth Forman
President of ESG
seth@socialsuitehq.com

socialsuitehq.com



Assurtrak Insurance Brokers
www.assurtrak.com

Charlotte, NC | Atlanta, GA | Chicago, IL
info@assurtrak.com

as·sur·trak

/ə'SHŏor, trak/

noun

1. Focused Insurance Strategies.

We are a specialty insurance brokerage, built to advocate for public companies and to be your D&O liability insurance experts.

Assurtrak was founded on the belief that starting with a great plan is the only way to finish with the best result. We are experts in specialty commercial insurance and we focus 100% of our training, resources, and knowledge into providing the best products, pricing, and service in the business.

Take the first step toward better risk management; we've got your back.



INSTITUTIONAL QUALITY EQUITY RESEARCH

Are You Being Awarded A Fair Valuation and Attracting Sufficient Liquidity?

Research Coverage Brings Visibility

- ✓ Attract Liquidity
- ✓ Lower Cost of Capital
- ✓ Achieve a Fair Valuation

Why Choose Diamond Equity Research

- ✓ Strong Track Record
- ✓ Institutional Quality Reports
- ✓ Extensive Investor Distribution

For More Information Contact

research@diamondequityresearch.com or (646) 300-5723

CLARK WILSON IS PLEASED TO SUPPORT THE THINKEQUITY CONFERENCE 2023

Seamless U.S. and Canadian Cross-border Legal Services

for companies raising capital in the United States and/or Canada, including IPOs on Nasdaq, NYSE or the Toronto Stock Exchange.

CWILSON.COM

SCAN HERE TO
LEARN MORE



CLARK WILSON

COREIR

Experience The Difference

INVESTOR / PUBLIC RELATIONS & CAPITAL MARKETS ADVISORY

Who We Are

Founded in 2009, CORE IR (formerly Cor Prominence) provides Investor Relations, Capital Markets Advisory, Corporate Communications, Public Relations, Media, and Marketing Communications services for small to mid-sized companies. Our team of 23 has more than 350+ years of combined buy-side, sell-side, investment banking/services, IR consulting, and strategic communications experience. We execute a process tailored to the unique circumstances and requirements of each of our clients.

Our Approach

Clients are managed by our expert team through a multi-disciplinary approach in which we leverage our proprietary, deeply-established, and long-term relationships, providing strong introductions across the buy-side and sell-side of the capital markets.

Measurable Results



Our Services

- Message Development and Review
- Non-Deal Roadshows
- Integrated Shareholder and corporate communications
- Institutional & Retail Shareholder Development
- Capital Markets Advisory
- Public Relations, Media (Traditional, Digital, Social), and marketing communications
- Securing Select Investment Conference Invitations
- Strategy Evaluation, Analysis, and Reporting
- Editorial Calendar Development and Management
- Investment Banking Networking
- Research Analyst Network Development
- Investor Relations Website Consulting

Integrated Shareholder And Corporate Communications

- Editorial Calendar Development & Management
- Effective Presentations
- Investment Thesis Development
- Professional Press Release Drafting/Editing
- Earnings Call Script and Call Management
- Media Strategy and Management
- Review Corporate Website Content to Ensure Message Continuity
- Development of Professional IR Website
- Crisis Communications

Strategic Advisory Services

CORE IR provides a wealth of strategic advisory services that address a wide array of both public and private company objectives. Our strategic advisory services facilitate introductions to our incomparable relationships with Investment Bankers, Institutional Investors, Portfolio Managers, Family Offices, and Registered Investment Advisors in service to the unique objectives of each client across the expanse of capital formation, strategic growth, and corporate structure. Our strategic advisory team represents decades of "in-the-trenches" expertise in banking, syndicate, and all manner of capital formation.



VISIT US AT COREIR.COM
CALL US AT (212) 655-0924 OR EMAIL US AT INFO@COREIR.COM
FOR MORE INFORMATION

COREIR

COREIR

Experience The Difference

At Barton LLP, we're more than just a law firm – we're your partner in navigating the complex world of finance and securities.

Thinking of going public? Explore opportunities with IPOs or the alternative route with APOs. For businesses seeking diverse financing avenues, we specialize in both private and public offerings, from debt and equity solutions to follow-on offerings, PIPEs, Registered Directs, CMPOs, and Rights Offerings. Strengthen your financial foundation with our expertise in revolving credit lines and asset-based lending.

As you evolve, rely on us for unmatched public company representation, uplisting, and listing transitions. Navigate block trades and 10b5-1 plans seamlessly with our guidance.

With Barton LLP, you receive full-service corporate and securities representation. And for those unique scenarios, we're on standby as special counsel for securities offerings or to advise board committees. Partner with Barton LLP, where your vision meets our experience.

BARTON

Discover Better Law

Los Angeles | New York | Nashville | bartonesq.com



SKYLINE CORPORATE COMMUNICATIONS GROUP, LLC

Your leading experts in strategic corporate communications and investor relations

Offices in New York City & Boston



MORE THAN JUST ANOTHER TRANSFER AGENT

Online cap tables and transfer agent expertise since 1987. We manage your disclosure reporting requirements to the SEC and states, capital raises from start to finish, shareholder meeting and proxy voting, employee plans and more.

www.colonialstock.com



TRANSFER AGENT SERVICES

Colonial is an SEC registered transfer agent, providing full stock transfer and registrar services for companies of varying sizes, public and private, domiciled both nationally and internationally.



ANNUAL MEETING SERVICES

When it comes to planning or implementing a proxy meeting, we can manage the process from start to finish including date planning, printing and mailing, coordination with brokers, online voting, tabulation and more.



EMPLOYEE PLAN SERVICES

Colonial provides Employee Stock Purchase Plan services and a fully secured web-based solution for managing and accounting for stock awards such as options, RSUs, and more. You can find information about the system overview, benefits, administration on our website.



BLUE SKY COMPLIANCE SERVICES

As a leading provider of Blue Sky Compliance Services, we provide clients with one of the most reliable and cost-efficient alternatives to law firm filings.



CAPITAL RAISING SOLUTIONS

Through our proprietary Cloudraise® platform and invest now button you can raise money for your Reg A+ and Reg D 506 offerings directly on your website. We manage the entire process including investor questionnaire, subscription, escrow, payment processing and



EDGAR & XBRL FILING SERVICES

Colonial is an SEC filing agent that provides EDGAR and XBRL filing services to SEC reporting entities such as public corporations and mutual funds.



Nasdaq is a Proud Sponsor of
the ThinkEquity Conference
2023



Nasdaq.com



Quantum

PUBLIC RELATIONS
INVESTOR RELATIONS
EQUITY RESEARCH

Ari Zoldan, CEO, Quantum Media Group, LLC | Quantum Research Group, LLC

ari@quantum-corp.com



www.quantum-corp.com



Data, technology
and expertise that
**connect you
to opportunity**

Blank Rome is proud to sponsor the **2023 ThinkEquity Conference**

Blank Rome and ThinkEquity have collaborated on numerous capital markets and securities transactions. We look forward to our continued partnership and to helping ThinkEquity meet and exceed its business goals.

Blank Rome is an Am Law 100 firm with 15 offices and more than 680 attorneys and principals who provide a full range of legal and advocacy services to clients operating in the United States and around the world.

For more information, please contact:

Leslie Marlow

Partner, Corporate
212.885.5358

leslie.marlow@blankrome.com

Brad L. Shiffman

Partner, Corporate
212.885.5442

brad.shiffman@blankrome.com

BLANKROME
blankrome.com

Chicago • Cincinnati • Dallas • Fort Lauderdale • Houston • Los Angeles • New York • Orange County
Philadelphia • Pittsburgh • Princeton • Shanghai • Tampa • Washington • Wilmington

Attorney advertising. © 2023 Blank Rome LLP. All rights reserved.

nyse.com

NYSE
AN ICE EXCHANGE

[This page intentionally left blank]

[This page intentionally left blank]

We're all connected.



At Loeb & Loeb, we connect deep industry insight with cutting-edge transactional experience to represent domestic and foreign companies, both public and private, in a range of legal and business matters.

As pioneers in counseling on regulations related to the use of new technologies and developing media channels, we have a unique depth of experience advising companies in

the digital and information services sectors as they access the capital markets. We also have decades of experience representing innovators in the life sciences industries and energy companies, along with their financial intermediaries, in the full spectrum of capital raising and corporate finance transactions.

Connect with us and experience the difference.



LOS ANGELES
NEW YORK
CHICAGO
NASHVILLE

WASHINGTON, DC
SAN FRANCISCO
BEIJING
HONG KONG

loeb.com



Security, Speed and Accuracy for Capital Markets Transactions

Industry leading solutions delivered with peace of mind.

- IPO / SPAC / de-SPAC Transactions
- Equity & Debt Offerings
- Mergers & Acquisitions
- Annual Meeting & Proxy Statements
- SEC EDGAR and iXBRL Filings

For more information on Toppan Merrill services and solutions contact Michael Frohlich at **201.410.6500** or **MichaelFrohlich@ToppanMerrill.com**.

55+
years of successfully navigating complex SEC requirements

1M+
SEC filings

99.98%
EDGAR filing accuracy rate

1.7M+
XBRL tags applied

Advancing business. Expanding possible.

TOPPAN
TOPPAN MERRILL

